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CHAPTER I 
INTRODUCTION 
7 

Epidemiology. 
In urologie oncology metastatic renal cell carcinoma (RCC) provides an intriguing 
challenge to urologists, oncologists and biologists in understanding this so far 
unpredictable tumor. Because RCC, also called 'Grawitz' tumor, commonly shows no 
early pathognomonic clinical signs or symptoms, patients often enter the clinic in a 
late stage of the disease. Already 30% of the patients show metastases at first 
presentation^ and this increases with an additional 30% after radical nephrectomy 
because of a high late-relapse rate2. 
RCC or adenocarcinoma is the most common malignancy involving the kidney and 
comprises approximately 80-90% of all renal tumors^. Nephroblastoma, also called 
'Wilm's tumor' is the most common solid tumor in childhood'' and accounts for 6% 
of the kidney tumors5. Renal oncocytomas^7 are classified in about 4-5% of the 
renal tumors and sporadically tumors are classified in the group of connective 
tissue tumors, adenomas and small cell carcinoma of the kidney^. 
The incidence of RCC is about 5 cases per 100,000 and is similar in men and 
women up to about the age of 50. Thereafter the incidence in men is about 2-3 
times higher as in women' . The median age of patients with RCC is 55 years , 
but RCC may occur at any age . In childhood the common symptoms are 
heamaturia, fever, weight loss, abdominal pain and gradual abdominal 
enlargement^7 . In adults the most common symptoms are haematuria, pain in the 
flank and a palpable mass. It is notable, however, that all three features of this so 
called 'classical triad' occurs only in 5-9% of all cases^*. 
The natural history. 
The consensus view at this moment is that RCC originates from the proximal 
tubular epithelium of the nephron^"2^. 
The diversity of RCC at presentation is a well documented phenomenon and solid, 
cystic, papillary and multifocal tumors may be seen. The tumor itself usually has a 
yellow to grey colour and frequently shows necrotic and or haemorrhagic areas. It 
often forms a pseudocapsule by condensation of fibrous tissue around the borders. 
This structure has been said to be intact in 87% of all non-metastatic RCC with a 
diameter of less than 7 cm22. Because the tumors usually are in the cortex of the 
kidney, spread outside the pseudocapsule will be by direct extension into the 
perinephric fat and then into surrounding tissues as colon, pancreas, liver, spleen, 
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diaphragm and adrenal. Extension into the calices and renal pelvis may occur 
providing a means of haematuna. Spread may also be via the lymphatics and by 
invasion of intrarenal capillaries and veins2*. 
Cell and tumor types. 
Based on cytoplasmic properties, three basic cell types can be recognised in 
RCC24·25. 
1) Clear cells, with optically 'empty' cytoplasm containing large amounts of glycogen 
and often also lipids. 
2) Granular cells, poor in glycogen, with granular cytoplasm as a result of abundant, 
mostly abnormal, mitochondria and cellular organelles. 
3) Spindle cells, spindle-shaped pleomorphic cells. 
On basis of these cellular characteristics, four different histologic tumors can be 
classified: 
1) clear cell tumors (30%) 
2) granular cell tumors (15%) 
3) spindle cell tumors (10%) 
4) mixed type tumors (45%), containing predominantly clear cells and granular cells. 
Because the spindle cells represent the highest grade of dedifferentiation, spindle 
cell tumors have the worst prognosis and the overall 5-year survival is only 23% 2 0, 
whereas the overall 5-year survival for the other tumor types is reported to be 
50%2 7. The most important factor influencing survival, however, is the presence or 
absence of metastatic disease. The 5-year survival of patients with distant metastases 
is less than 3%, with a median survival of 8-10 months after the time of first 
diagnosis^2β'л,. 
Metastatic disease. 
One of the characteristics of RCC is the long dormancy of metastatic disease which 
accounts for the occasional late recurrences of the disease . Metastatic lesions have 
been recorded in a variety of sites, appearing up to 31 years after nephrectomy^ 
and this unpredictable behavior makes lifelong followup necessary^ . Common sites 
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for metastases are lungs, lymph nodes, bone, adrenal, liver, opposite kidney and 
brain. Odd sites in which metastases have been found are: urinary bladder, urethra, 
corpus cavernosum, epididymis, gall bladder, iris and thyroid^·^. 
As indicated shortly, RCC may spread through haematogenic and lymphogenic 
pathways. The incidence of regional lymph node metastases varies between 9 and 
25% in reported series^35"-**. The process of spread of lymph node metastases, 
however, does not necessarily occur in a logic stepwise fashion because distant 
nodes such as axillary or inguinal nodes may contain tumor without involvement of 
regional nodes59'''0. This means that once the tumor has reached the regional nodes, 
extensive lymphatic spread may have taken place2-*. Venous ingrowth, although also 
often associated with the presence of metastases^, does not, as in the case of 
lymph node mvolvement, adversely affect survival which is comparable to patients 
with disease confined to the kidney^ . The implications of these findings point 
directly to evidence of host resistance which is further evidenced by the occasional 
idiopathic regressions of RCC primary tumors and or their metastases^. 
Spontaneous regressions, mainly concerning lung metastases, however, are rare and 
is noticed in less than 1% of the patients with metastatic disease. Regression of 
metastases, unfortunately, is not synonymous with cure because new metastases may 
arise during and after regression^. 
Treatment modalities. 
At present, surgical excision of the primary tumor and sometimes of solitary 
metastases is the only effective treatment of RCC7 ' . Systemic therapy, 
nevertheless remains necessary for those patients with proven progression to 
metastatic disease^47. Chemotherapy has limited value and due to this lack of 
effective systemic treatment, new methods have been pursued and various forms of 
hormone therapy'** or immunological treatment, whether or not combined with 
chemo- or radiotherapy have been tested in clinical trials and or in animal 
model systems during the last decades. 
- Radiotherapy has proven to be ineffective against RCC and there are no 
documented improvements of survival of irradiated patients. Relieve of pain is 
case of bone metastases is the greatest advantage of this treatment. 
- Hormonal therapy of RCC found its basis on the demonstrated hormonal 
(androgen) dependence of estrogen induced renal carcinoma in the male Syrian 
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golden hamster . Also the fact that RCC is predominant in men, together with 
reported regressions of metastatic cancer during administration of progesterone or 
androgen""55 provided rational support for the hypothesis of hormonal dependency 
in humans. Response rates in different studies, however, are very low and range 
from l-6%56. 
- Chemotherapy results in response rates of approximately 9% and vinblastine is 
apparently the most active agent with reported objective response rates up to 
20% . The reason for the low response rates to most chemotherapeutic agents is 
not quite clear but may be due to a rapid development of acquired resistance to 
drugs due to the development of protective mechanisms as the expression of the p-
glycoprotein encoded by the MDR-1 gene, and the glutathione redox cycle57'59. 
Also, the heterogeneity of the RCC's60 may contribute to the chemoresistance. 
Although continuous infusions may reduce side effects of chemotherapy6^, treatment 
of RCC with cytostatic drugs is not widely used because of the considerable toxicity 
and the generally poor response. 
- Immunotherapy of RCC, both active and passive, as well as specific and non-
specific ^ , resulted in substantial differences in response rates. Nonspecific 
immunostimulation of patients with Bacillus Calmette-Guérin (BCG) for instance 
resulted in 5% response64, whereas nonspecific immunostimulation with Interferon 
(IFN) (cytokine therapy) may result in 30% response65,66 (partial + complete 
responses). 
Numerous clinical trials with different doses and treatment schedules of alpha-, 
beta-, gamma-IFN or their combinations show response rates between 13 and 
30%67"72. Therapy with Interleukin-2 (IL-2) results in 0-20% response75'75 and 
combinations of moderate doses IL-2 + beta-IFN result in maximal 27% response76. 
Treatment of patients with IL-2 and autologous lymphokine (IL-2)- activated killer 
(LAK) cells77 or IL-2 stimulated tumor infiltrating lymphocytes (TIL)7e in the so 
called adoptive therapy79 results in response rates of 9-30Ψο80'83. 
Phase-I clinical trials with Tumor Necrosis Factor (TNF) so far have indicated only 
minor response rates involving considerable toxicities**"*6. 
Combination therapies of the cytokines with other treatment modalities have also 
been tested in phase-I and -II studies. A general review about the antineoplastic 
activity of combinations of IFN and cytostatic agents is given by Wadler and 
Schwartz87 and especially the combination of alpha-IFN and 5-fluorouracil seems 
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very promising. For RCC, however, most reports describe the combination of alpha-
IFN with vinblastine and response rates vary between 22 and 40%ss"s>0. The 
contribution of vinblastine to the noticed antitumor effects, however, is doubtful and 
toxicity of this treatment modality is high . 
Response rate in a phase-II study with a combination of alpha-IFN and 
prednisone was 20%. The contribution of prednisone was concluded to be 
doubtful, but led to significantly reduced toxicity. 
Cytokines used in these studies. 
The cytokines used in these studies were recombinant human (ree. hu.) Interferon-
alpha, ree. hu. Interferon-gamma and ree. hu. Tumor Necrosis Factor-alpha. The 
specifications of these cytokines are given in Materials and Methods of the next 
chapters in this thesis. 
The interferons are a group of naturally occuring proteins/glycoproteins with 
molecular masses ranging between 15 and 21 Kd. They were first discovered in 1957 
by Isaacs and Lindenmann and their name was given after the finding that the 
substance interfered with the viral replication of virus infected cells. 
Based on various biologic, antigenic and physico-chemical properties, the human 
IFN's are classified in three major classes; alpha-IFN, beta-IFN and gamma-IFN. 
About 20 different subtypes of alpha-IFN are characterized, two subtypes of beta-
IFN and only one gamma-IFN. Alpha-IFN's are produced by lymphocytes and 
lymphoblastic cells, beta-IFN by fibroblasts and gamma-IFN by T-cells. 
The alpha-IFN's are composed of approximately 166 amino-acids and they show 
>75% homology. The cloned and commercially available recombinant alpha-IFN's 
2a, 2b and 2c for example differ from each other by only one or two amino acids. 
The alpha- and beta-IFN's (type-I IFN's) have approximately 40% homology. 
Gamma-IFN (type-II or immune-IFN) differs significantly from alpha- and beta-IFN 
and homology is only 12%!>6. 
Theoretically, interferons may exert their antitumor effects in three ways; 1) via the 
host immune system, 2) by a direct action on the tumor cells and or 3) by altering 
some non-immune/tumor cell interactions. Biologic action is initiated after binding to 
specific membrane receptors on the cell surface ^ . Following receptor binding 
(one class for alpha- and beta-IFN, another class for gamma-IFN), the IFN-receptor 
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complex is internalized ' triggering as yet undefined second messages which 
transmit regulatory signals to the nucleus. Ultimately the pattern of cellular RNA 
and protein synthesis is affected, with some proteins being switched off and others 
strongly induced. In all, approximately 100 of the more than 10,000 cellular proteins 
are changed, resulting in altered cellular function. These processes result in the 
suppression of cell proliferation and enhancement of the phagocytic activity in 
macrophages and augmentation of the specific cytotoxicity in lymphocytes^. Since 
most, if not all, cells in the body have IFN receptors, however, it is not surprising 
that the mechanism of anticancer activity of interferons is still not clearly 
understood. 
IFN's antiproliferative action could be explained, in part, by their induction of 
various enzymes, such as phosphodiesterase, protein kinase and 2'5' oligo-adenylate-
synthetase, which reduce protein synthesis and thereby provoking quiescence of 
cel l s ' 0 ^ 0 5 . 
IFN may also control cell proliferation by inhibiting the expression of cellular 
oncogenes as c-myc, c-Ha-ras and C-STC106'108. 
Furthermore, the IFN's may stimulate the expression of HLA class-I and -II 
antigens and Fc receptors which play an important role in the immunologic 
surveillance of the body. 
Interferons are an important part of the cytokine cascade in which tumor cells, 
leucocytes, macrophages, NK-cells and T- and B-cells all take part and in which also 
TNF, Interleukins and Colony Stimulating Factors play an important role. During an 
immune response, these factors are produced in combinations, but their mechanisms 
of control are not yet understood. Three levels of interaction between these four 
groups of the so called cytokine concept^0 can be identified; 1) each acts as an 
inducing signal for the other cytokines, 2) they often have synergistic actions in 
combinations and 3) each individual cytokine can control response to another by 
specific down- or upregulation of its receptor. 
Tumor Necrosis Factor-alpha was first described in 1975 by Carswell et а\.1П. They 
investigated a factor in the serum of mice induced by spaced intravenous injection 
of BCG and lipopolysaccharide (LPS). This serum caused haemorrhagic necrosis of 
a subcutaneously transplanted mouse tumor, the Meth-A sarcoma. 
TNF, also called cachectin^2 is secreted as an unglycosylated 157 amino acid 
polypeptide with relative molecular mass of 17 Kd and in its active form the protein 
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is thought to be trimeric^. 
TNF (or TNF-alpha) which properties are reviewed by Вагга^ 4 and Semanzatoíí,y 
is predominantly derived from macrophages^0, whereas another TNF (TNF-beta of 
lymphotoxin)"' is derived predominantly from activated T-cells. Although TNF-
alpha and TNF-beta have only approximately 30% homology in their amino acid 
sequences, they bind to the same receptor^* and share many biological activities^9" 
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How TNF causes tumor cell death is not yet clear, but TNF mediated killing begins 
at binding to its receptor. After binding, the TNF-receptor complex is internalized 
by receptor mediated endocytosis^22. It is assumed that after internalization, the 
complex transduces signals across the plasma membrane that result in the 
accumulation of second messengers which activate an intracellular suicide program 
(programmed cell death), that ultimately results in cytotoxicity72·^26. 
Experimental models used in these studies 
In vitro studies 
To date, many methods for the in vitro evaluation of the antiproliferative efficacy of 
new drugs are described. 
The various assays are based on: 
1) short-term cultures of cell suspensions (e.g. Volm et al.727). 
2) cell monolayer cultures (e.g. Wilson and Neal72e). 
3) clonogenic cell survival (e.g. Hamburger and Salmon729). 
These methods can be applied by various techniques which estimate the 
surviving/dying fraction of cells; i.e. 
- dye exclusion tests, based on the fact that undamaged cells will exclude a dye, e.g. 
trypan blue7 30. 
- dye reduction tests; based on the fact that undamaged cells will be able to reduce 
uncolored tetrazolium salts into coloured products, staining the cells and therefore 
directly indicating their viability7-*7"7-*-*. 
- tests measuring the incorporation of radioactive RNA or DNA precursors by 
undamaged cells7^'7^. 
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- tests measuring the colony forming capacity of cells after treatment. The most 
widely used assay is the test of Hamburger and Salmon , in which cells are 
cultured in a double layer soft agar medium in culture dishes. This time and 
material consuming test have been modified in numerous ways, e.g. using 
methylcellulose or collagen instead of agar* ^* , or using glass capillaries instead of 
culture dishes*35. 
A model considered to be an intermediate between in vitro and in vivo models are 
the multicellular tumor spheroids, multicellular structures grown from single cells in 
liquid media over an agar base. Spheroids exhibit a structure with some 
characteristics of a solid tumor. These include: intimate cell-cell contacts, chronically 
hypoxic cell populations and the distribution of vital and necrotic areas*39. 
Numerous studies have been published comparing the responses of spheroids and 
monolayer cultures to cytotoxic drugs. Most of these studies have shown that in 
general spheroids are more drug resistant than monolayers*^0'*4*. Inadequate drug 
exposure is one of the explanations for the relative resistance of spheroids as 
compared to that of monolayers*42. 
A critical review of the use of in vitro methods as a means for preclinical drug 
screening has been written by Phillips et al. . The predictive value of the 
clonogenic assay as used in our studies (chapter 2) is about the same as that in 
most of the nonclonogenic assays, in which drug resistance is predicted with greater 
accuracy than drug sensitivity (90% and 60% respectively). 
When we started our studies, some reports about the chemosensitivity testing of 
RCC cells in the clonogenic soft agar assay had been published*44"*47. The highly 
different results reported in these papers were disencouraging but may have been a 
result of the well known chemoresistancy of renal tumors, as well as, the 
heterogeneity within the individual tumors. Only few authors had reported 
antiproliferative effects of IFN's against RCC cell lines in the clonogenic 
assay*4*'*49. Results showed significant antiproliferative effects, which indicated that 
further investigation of the action of cytokines on the clonogenic capacity of RCC 
cells was worth while, providing a means of getting some insight into the direct 
effects of these molecules on the proliferative capacity of renal tumor cells. 
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In vivo model systems 
As indicated in the preceding section, in vitro studies in general have only limited 
value with respect to the clinical applications of cytokines. The main contribution is 
the insight it provides into the direct antiproliferative effects of drugs under optimal 
conditions. In case of cytokines, however, it completely abolishes the indirect 
immune system mediated effects which play a very important role in the antitumor 
activity of these molecules. To be able to get some insight into the role and effects 
of some cytokines on the activity of tumor killing cells, some authors have 
stimulated these cells with cytokines and analyzed the effects on autologous tumor 
cells in experimental in vitro LAK cell systems150'152. Significant tumor cell lysis 
may be the result, but the disadvantages of the in vitro tests will also influence 
results of these tests. 
Optimally, studying the effects of cytokines in neoplastic development should be 
performed in a syngeneic model. Only few syngeneic animal tumors models 
concerning renal tumors have been described, and the most important are the 
Renca tumor model, a murine renal adenocarcinoma model of spontaneous 
origin ' and a renal adenocarcinoma model in the rat, also of spontaneous 
origin755. Studying the syngeneic tumors in these immunocompetent systems 
circumvents the problem of all immunological aspects, but these tumors differ from 
human tumors in a number of aspects of their biological characteristics75^57 and 
therefore probably will not be finely representative for the human situation. 
Nevertheless, these model systems provide a means of getting insight into the 
antineoplastic effects of cytokines in syngeneic renal tumor systems. Therefore, we 
choose to test the antineoplastic effects of recombinant rat gamma-IFN (species 
specific activity) and ree. hu TNF-alpha (low species specific activity) in the rat 
renal tumor model. 
Experimental research on human tissue in an in vivo situation is possible only in 
artificial non-syngeneic animal models. In the experimental setting, small pieces of 
human tissues are transplanted (grafted) orthotopically or heterotopically into the 
animal and because these tissues are non- or xeno-geneic to the host, these tissues 
often are referred to as xenografts. 
Basically, there are three systems available for growing human tumor xenografts. 
1) Tumor tissue can be introduced into an immunologically privileged site, such as 
the hamster cheek pouch or the anterior chamber of the eye, where it remains free 
from attack by the host immunological defenses. These methods appeared to be 
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inconvenient and tumor take was only about 10% and therefore are not applied 
anymore158'160. Another technique is the implantation of xenografts under the renal 
capsule of normal immunocompetent mice or rais161'164. Short experiments of 6 
days are possible with this technique since the humoral response to a primary 
antigenic stimulus in the normal animal generally evolves in 7-10 days and cell-
mediated responses become evident in 9-12 days. 
2) The hosts can be rendered immunologically incompetent so that they are unable 
to reject xenografts. These animals are prepared by procedures designed to ablate 
mainly the T-lymphocytes that are responsible for the graft rejection reaction. 
3) Xenografts can also be grown in 'nude' mice or rats which are genetically athymic 
and unable to reject foreign tissue gvaîXs165'167. 
The nude mouse is a hairless mutant first described in 1962 . This mouse is 
homozygous for an autosomal recessive gene, the so called 'nu' gene169. The 
animals are genetically immunodeficient because they lack a normal thymus. Despite 
this nominal athymic state, however, nude mice have some residual T-cell activity 
and therefore can elicit some immune reactions^70^7^. The number of B-cells, NK 
cells and macrophages are similar or even higher than in euthymic mice of the same 
strain and because of these characteristics, tissue rejection may also impair with 
transplantation experiments in the nude mouse. 
Nude mouse mutants having low levels of NK cells, the so called Beige nude 
mouse173, or mutants being deprived of the humoral responses as well, the so called 
severe combined immunodeficiency mutants or SCID mice174·175 have also been 
described. Use of these mice, however, demands expensive experimental precautions 
and therefore are not yet widely used. 
The site of implantation of tissue pieces most frequently used in the nude mouse is 
the flank. Easy evaluation of tissue growth or rejection is possible at this place and 
inconvenience for the animal is as low as possible. The limitation of this technique, 
however, is that metastases formation seldom takes place from the subcutis and 
therefore, studying aspects of metastases formation needs orthotopic implantation of 
the tissues. Metastases formation from orthotopic sites is frequently reported^76^50. 
Because in our studies we were primarily interested in the direct effects of the 
cytokines on the growth of human renal tumor tissue, we have chosen BalbC nu/nu 
mice for our experiments in which the xenografts were implanted subcutaneously in 
the right flank of the mice. 
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Predictive markers for response to cytokine therapy. 
The differential response rates found in the numerous clinical trials with the 
different cytokines indicates that probably no consensus therapy can be designed 
that will be beneficial for all patients. Consequently, therapy needs individualization 
and this is possible only when individual parameters can be related to the effect of 
the therapy. Two different categories of markers may prove to be of clinical 
importance; 1) serum markers i.e. factors released into the serum as a response to 
the therapy and 2) cellular markers, i.e. markers on the tumor cells. These markers 
do not necessarily need to be tumor associated or tumor specific. A third category 
of markers eventually may be formed by the cells playing a role in immunological 
responses. Very little, however, is known about their predictive value so far, and in 
a study on the functional and immunophenotypic modifications induced by IL-2, 
Favrot et al. could not relate these modifications in the peripheral blood 
lymphocytes to response to therapy in patients with RCC. 
Serum markers which can be related to response to cytokine therapy are: neopterin 
and ß2-microglobulin (ß2-M). Neopterin, a guanosine triphosphate (GTP) 
degradation product^ is released by monocytes/macrophages specifically upon 
stimulation with gamma-IFN and to a much lesser extent by alpha- and beta-IFN 
and TNF . This serum marker reflects functional activation of the 
monocyte/macrophage system^** and has been related to the response to IFN 
therapy in metastatic RCC0 . It has also been shown to be a prognostic marker for 
disease progression in carcinoma of the cervix^*4 and ovarian cancer7 . 
Beta2-microglobulin is expressed in non-covalent association with the HLA class-I 
glycoprotein heavy chain on the surface of most nucleated cells. It is released upon 
internalization of the HLA heavy chain but may also be shed into the serum by 
direct cellular secretion. Serum ß2-M levels have been shown to be of prognostic 
value in leukaemic disease^56 and, as neopterin, it also has been related to response 
to IFN therapy in metastatic RCC6·*. The tumor itself seems to be implicated as the 
source of increasing serum ß2-M, but since elevated levels are also observed in 
inflammatory and viral conditions, it is conceivable that increased levels may in part 
also be due to cellular mechanisms in the immunological response to the 
malignancjr . 
The ß2-M is also expressed in association with HLA class-I molecules on most renal 
tumor cells, hence the HLA class-I antigens may function as cellular marker in the 
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response to cytokine therapy. HLA class-I molecules have been shown to act as 
restriction elements for the lysis by cytotoxic T-lymphocytesiS*. The HLA class-I 
antigens function as presentation site of the intracellular protein synthesis and 
therefore provide a means of control of the cellular processes by the cytotoxic T-
lymphocytes (CTL). In a murine system, it was demonstrated that loss or reduction 
of class-I antigens on tumor cells decreased their susceptibility to lysis by CTL·189. 
The HLA class-I antigens also play a role in the activation of natural killer cells 
(NK) cells, which are specifically activated by cells with reduced class-I 
expression . 
HLA class-II molecules, another class of membrane bound markers functioning in 
the immunological surveillance of the body, may also function as cellular marker for 
response. These antigens are known to function as restriction molecules for the 
presentation of antigen fragments to helper T-cellsw and have a function in the 
activation of macrophages and B-cells. 
In immunocompetent syngeneic systems, expression of both classes of HLA antigens 
is related to the immune response of the host and especially in renal cell cancer, 
the degree of expression of HLA class-I on the tumor cells has been found to be 
related to the host immune response792. 
Because expression of both antigens is known to be influenced by Interferons and 
TNF, they may provide a good means of following the cellular response to the 
therapy. 
Outline of this thesis. 
In order to get insight into the direct effect of alpha-IFN, gamma-IFN, TNF and 
their combinations on the proliferative capacity of renal tumor cells in experimental 
situations, we established five renal t,umor xenografts from fresh primary tumor 
samples. The experimental value of these tumors was determined by evaluating 
various tumor characteristics during their establishment (chapter 2). The direct in 
vitro effects of the cytokines on the clonogenic potential of the tumor cells was 
tested in a soft agar colony forming assay and this gave an indication of the 
differential sensitivity of the tumors for the cytokines, and revealed the in vitro 
effective anti-tumor doses (chapter 3). We next tested the in vitro effective doses in 
the nude mouse model system in which subcutaneously implanted tumors were 
treated peritumorally. These experiments learned us that the direct in vitro and in 
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vivo antiproliferative effects of the cytokines are not related to each other and that 
response to the treatments differed widely amongst the xenografts. The in vivo 
antitumor effects further indicated that other factors than just the direct anti-tumor 
effects play a role in the in vivo situation (chapter 4). This indicated the importance 
of testing the anti-tumor effects of the cytokines in a syngeneic tumor model. We 
therefore tested the effects of gamma-IFN and TNF in a syngeneic rat renal tumor 
model which gave us an idea of the combined direct and indirect anti-tumor effect 
of different doses and combinations of these cytokines (chapter S). 
The differential responses of the xenografts in the nude mouse model indicated that 
therapy probably needs individualization and this urged the need for markers 
indicating response. We tested for the HLA class-I and class-II antigen expression 
on the differentially treated tumors and this gave us an impression of the direct 
effects of the treatment on the cells, indicating that the modulatory capacity of both 
HLA class-I and class-II antigens eventually may function as markers for response. 
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SUMMARY 
Ten different human renal cell carcinoma (RCC) primary tumors were xenografted 
into BalbC nu/nu mice. Five of the tumors (NU-10, NU-12, NU-20, NU-22 and NU-
28) gave rise to serially transplantable tumors which were further characterized. 
Histology, DNA index, immunohistochemical characteristics, growth rate and 
clonogenic potential were followed from primary tumor to the fifth to fifteenth 
transplant passage. Only one of the tumors (NU-20) showed remarkable instability 
for all tested parameters in the first five transplant passages. Histology of the other 
tumors was essentially the same to the histology of the primary tumors although 
differences between human and host derived vessels were apparent. DNA index 
values in general showed a trend towards an aneuploid character of the xenografts. 
Immunohistochemical analyses showed a loss of intensity of staining but a 
concomitant rise in the fraction of positively staining cells with antibodies against 
cytokeratins, vimentin, tumor associated antigens and HLA class-I antigens. HLA 
class-II antigen expression showed a loss of intensity as well as a decrease in the 
fraction of positive cells. Tumor doubling time was lowest in transplant passage 
number 0 and stable growth was noticed in transplant passage 1-4. Clonogenic 
potential of four of the lines was higher for the xenografts than for the primary 
tumors. We conclude that upon xenografting, histologic characteristics of the primary 
tumor are essentially conserved. Progression in the first transplant passages, 
however, results in tumors with a more aggressive character. 
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INTRODUCTION 
Human renal cell carcinoma (RCC) rarely responds to conventional therapy with 
cytostatic drugs or hormones and, clinically this tumor seems to have a unique 
immunobiology as evidenced by the occasional spontaneous regressions of its 
metastases/*2 which suggests that host factors may be capable of modifying the 
course of RCC/ Therefore, studying antineoplastic effects against human RCC in a 
model system will never be able to mimic the human situation in all its aspects 
because in in vitro systems only direct effects can be measured and in in vivo 
systems host factors, to some extent, will always impair with histologic and or 
immunologic aspects of the tumor. Studying syngeneic tumors in rodent systems4,5 
circumvents the problem of the immunological aspects but these tumors can differ 
from human tumors in their biological characteristics and so will not be highly 
representative for the human situation.^7 
Since the first report on cultivation of RCC cell lines by Richter and Akin,* many 
reports described the establishment and characterization of new RCC cell lines. 
In vitro cultivation, however, usually is associated with progression to a more 
aggressive status due to the intrinsic genetic instability of the tumor. Transplantation 
of human tumors in vivo became possible after initial observations that athymic 
nude mice could support progressive growth of human t u m o r s ^ 5 and nude mice 
have since also been used to establish human RCC xenografts. 2 i Not all tumors 
thereby readily form transplantable tumors and immunological reactions by the nude 
mouse against the human tumors2^2^ may be responsible for at least part of the 
xenotransplantation failures, which is evidenced by the fact that immunosuppression 
of nude hosts enhances the xenotransplantability of human tumors.2''"20 
In this report we describe the characterization of five new transplantable human 
RCC xenografts which we used in our studies to the direct in vitro and in vivo 
sensitivity to human recombinant Interferon-alpha, Interferon -gamma and human 
recombinant Tumor Necrosis Factor.27"29 
Tumor pieces from ten tumors obtained after nephrectomy were transplanted 
subcutaneously into the right flank of nude mice (Pimm and Morris, 1990). We 
screened for short term establishment of tumors ( < 5 passages) and serially 
transplantable tumors ( > 5 passages). Furthermore, we compared the tumor lines 
with their primary tumors and evaluated their establishment, not only by means of 
37 
histology and or DNA index, but also by means of various other parameters such as 
immunohistochemical characteristics, tumor doubling times and clonogenic potential. 
MATERIAL AND METHODS 
Tumors 
Ten different primary human renal tumors were tested for their xenotransplantability 
in the nude mouse. Five tumors (NU-10, NU-12, NU-20, NU-22 and NU-28) gave 
rise to serially transplantable tumors ( > 5 passages), one tumor did not give rise to 
a growing tumor at all and the other four tumors stopped growing in the first to 
third transplant passage. A description of the tumor history is given only for the 
serially transplantable tumors. 
NU-10: 
This tumor originates from a 78-year-old male patient with long term complaints of 
pain in the right flank and haematurie. Diagnosis revealed a T3 tumor with 
diameter of 9.5 cm in the right kidney and multiple lung metastases. Lung 
metastases showed spontaneous regression after nephrectomy but one year later the 
patient showed to have multiple brain metastases. Material for xenotransplantation 
was taken from the primary tumor. 
NU-12: 
This tumor originates from a 53-year-old male patient with short term complaints of 
pain in the left flank. Diagnosis revealed a yellow coloured T3 tumor with max. 
diameter of 7 cm and multiple white to brown coloured satellite tumors with max. 
diameter of 1 cm. in the left kidney. Tumor growth was also localized in a hilar 
lymphnode and two metastases were apparent in the left lung. Four months after 
nephrectomy the lung metastases in the left lung had disappeared completely 
without any therapy but a 7 mm diameter metastases had formed in the right lung. 
Four months later also this metastasis had disappeared completely. One year after 
nephrectomy, however, two local recurrences of 4 and 2 cm and two new lung 
metastases had formed. Material for xenotransplantation was taken from the 7 cm 
diameter primary tumor. 
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NU-20: 
This tumor originates from a 41-year-old male patient with short term pain 
complaints in his right flank. Diagnosis revealed a T2 tumor with max. diameter of 
8.5 cm in the right kidney and 2 lung metastases in the right lung. Three months 
after nephrectomy a slight progression of these metastases could be measured. One 
year after nephrectomy the lung metastases were clearly progressed. No new lung 
metastases had formed, but multiple liver metastases were present at that time. 
Material for xenotransplantation was taken from the primary tumor. 
NU-22: 
This tumor originates from a 46 -year-old male patient with short term complaints 
of coughing and cachexia. Diagnosis revealed a cystous T3 tumor with max diameter 
of 9 cm in the right kidney. Metastases already existed in the retroperitoneal lymph 
nodes, adrenal and both lungs. Possible small metastases also existed in the liver. 
Three months after nephrectomy this patient also showed to have brain metastases. 
Material for xenotransplantation was taken from the primary tumor. 
NU-28: 
Material for xenotransplantation was taken from a lung metastasis of 6 cm in 
diameter grown after Interferon-alpha/gamma therapy in a patient with a long 
history of a tumor in the right kidney. This 16-year-old male patient entered the 
clinic after complaints about erythrocytury, and diagnosis revealed a T2 tumor with 
max. diameter of 5 cm in the right kidney, with retroperitoneal lymph node 
metastases as well as metastases in both lungs. Lung metastases grew progressively 
after radical nephrectomy and removal of retroperitoneal lymph nodes. Positive intra 
thoracal lymph nodes (mediastinum) were removed from the right lung five months 
after nephrectomy and again four months later positive mediastinal lymphnodes 
were removed. Six months later no macroscopically visible tumor mass was visible 
anymore. Ten months after the last removal of positive nodes, however, small 
metastases were visible again in abdomen and mediastinum. The patient then 
received a combination of alpha- and gamma-Interferon and eight weeks after start 
of the therapy, dimensions of the 'intrapulmonale' metastases had stabilized whereas 
the retroperitoneal tumor mass had clearly regressed. Nine months after therapy the 
retroperitoneal tumor mass had completely disappeared but the intrapulmonale 
metastases showed a minor progression. Three months after the therapy had 
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stopped there was a clear progression of this lesion in the left lung again and this 
lesion with max diameter of 6 cm was removed chirurgically. Material for 
xenotransplantation was taken from this metastasis. Ten months after this chirurgical 
removement the patient was still free of any macroscopically visible metastases. 
Mice 
Six weeks old male BalbC nu/nu mice (Bomholtgârd, Ry, Denmark) were used for 
the xenotransplantations. The animals were allowed to adjust to the experimental 
environment for two weeks before being used for the transplantations. Groups of 
five mice were kept in PAG type 2 cages covered with an iso cap (Iffa Credo, 
France) for sterile conditions. Sterilized sawdust (Iffa Credo, Broekman bv., The 
Netherlands) was used as bedding material inside the cages. The mice were fed ad 
libitum with gamma irradiated (0.9 MR) SRM-A MM food (Hope Farms, Woerden, 
The Netherlands) and drinking water was acidified with 0.7 ml concentrated HC1/1. 
Day-night rhythm was 12 hours light, 12 hours dark and the temperature was 220C. 
Humidity in the experimental environment was unregulated. 
Xenotransplantation 
Tumor material was taken as soon as possible after nephrectomy. Tumor pieces 
were transported in unsupplemented RPMI-1640 medium (Gibco, Paisly, U.K.) and 
after removal under sterile conditions of necrotic and haemorrhagic fragments and 
connective tissue, vital tumor pieces of about 3 mm·' were cut from the tumor mass. 
One tumor piece was transplanted subcutaneously into the right flank of each ether 
anaesthetized mouse after making a S mm dorsal incision into the skin. After 
transplantation, the incision was closed with a metal clip (agrave Michel, Instruvet, 
Amerongen, The Netherlands ). Five mice were used for each transplantation. 
Transplant generations were performed under the same conditions as for the 
primary tumors after the transplanted tumor pieces reached dimensions of about 1 
cm. Corresponding fragments of primary tumors and all serial passages were either 
fixed in formalin or frozen directly in liquid nitrogen for further histological analyses. 
For analyses of DNA index and testing of the clonogenic potential, fresh tumor 
material was used. 
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Histopatholopical examination 
For histopathological evaluation of the tumors, surgical specimens and fragments of 
the different passages in the nude mice were fixed in 4% formaldehyde and 
embedded in paraffin. Sections (5 μιη) were stained with haematoxylin and eosin by 
standard techniques and evaluated by light microscopy. 
Preparation of single cell suspensions 
When tumors reached sizes of about 1 cnr' the mice were sacrificed by cervical 
dislocation and tumor material was suspended in unsupplemented RPMI-1640 
medium. After careful removal of central necrosis, blood clots and connective tissue, 
the tumors were cut into pieces of about 3 to 4 mm*. The tumor pieces were then 
minced with scissors into a 300 μπι metal sieve and continuously washed with RPMI-
1640 medium in a petri dish. The minced tumor tissue was then passed twice 
through a 40-70 nylon filter (Ortho Diagnostics, Beerse, Belgium) to obtain a single 
cell suspension. The cells were centrifuged at room temperature at 400g for five 
minutes after which the supernatant was discarded. After resuspension of the cell 
pellet, cell density and viability were determined using the trypan blue exclusion test 
and simultaneously counting coloured and not coloured cells using a Biirker Turk 
haemocytometer. 
Flowcytometric analysis of cellular DNA content 
Suspensions of mechanically disaggregated tumor tissues were centrifuged at 400g 
for 5 minutes. The supernatant was discarded and under constant shaking, 70% 
ethanol (-2(PC) was added rapidly to the cell pellet. The final concentration was 
about 3.10o cells/ml. Approximately 1.10o cells in 70% ethanol were centrifuged at 
400g for 5 minutes and the cell pellet was resuspended in 1 ml of a propidium 
iodide (PI) solution (20 mg/1 A-grade Calbiochem-Boehringer, La Yolla Ca in 150 
mM sodium phosphate buffer, pH 7.4). 0.1 ml of a 1% RNase solution (RNase type 
A, Sigma, St. Louis, MO; in 150 mM sodium phosphate buffer pH 7.4) was added 
to 1 ml of this cell suspension and subsequently incubated for 10 min. at 370C. 
Finally, the cell suspension was filtered through a 49 μπι filter and the cells were 
kept in the dark at room temperature prior to FCM analysis. 
A cytofluorograph 50H (Ortho, Westwood, MA) equipped with an argon ion laser 
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(Spectra Physics, Mountain View, CA) was used for the DNA measurements. The 
fluorochrome PI was excited at 488 nm and fluorescence was measured using a 630 
nm longpass filter. Data were recorded as 2048 channel histograms and stored in a 
PDP 11/34 computer (Digital, Marlboro, MA) for subsequent data analyses. For 
ploidy measurements, chicken red blood cells (CRBC) were added to the samples as 
internal standard, and a mixture of human lymphocytes and CRBC served as 
external standard. The DNA content was expressed as a DNA index (DI) with 
human lymphocytes equivalent to 1.00. The coefficient of variation for the G0/G1 
peak of malignant and non-malignant cells ranged from 3% to 6%. 
Human tumor colony forming assay 
For the detection of the growth potential of tumor cells in soft agar a modified two 
layer soft agar culture method as originally described by Hamburger and Salmon50 
was used.^ In short: tumor cell suspensions were plated at a concentration of 5.10* 
tumor cells per dish for primary tumor cell suspensions or l.lCr for xenograft cell 
suspensions in the upper layer of the two-layer agar culture method. The cells were 
cultured immediately after preparation of the single cell suspension and growth 
potential was quantified using an Omnicon Fas II automated colony counter (Milton 
Roy Inc. Rochester, New York, USA).52 For dynamic colony growth development 
we used the 'temporal growth pattern' method giving an estimation of growth over a 
certain period of time.33 
Immunohistochemistry 
2 Micron (immunofluorescence) or 4 micron (immunoperoxidase) thick frozen 
sections of tumor tissue which was stored in liquid nitrogen were dried in the air 
during the night and next fixed in aceton (10 minutes, room temperature). The 
indirect immunofluorescence technique was performed as described by Ramaekers et 
al. (1983). In short: after being washed in phosphate-buffered saline (PBS) for 10 
min., the tissue sections were incubated with 10% normal goat serum (NGS) in PBS 
at room temperature (30 min.) and subsequently with the primary antiserum for 1 
hour. After repeated washings in PBS (3 times, 10 min.) the fluorescein 
isothiocyanate (FITC) conjugated goat antimouse IgG and goat antirabbit IgG (1:25 
in 10% NGS, Nordic, Tilburg, The Netherlands) were applied to the monoclonal 
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and polyclonal antibodies conjugated sections respectively. After incubation for 30 
min. and extensive washing in PBS (3 times, 10 min.), the tissue was mounted in 
Gelvatol (Monsanto, St. Louis, M.O.) containing 100 mg/ml 1.4-diazobicyclo-(2.2.2)-
octane (DABCO, Janssen Pharmaceutica, Beerse, Belgium). In control experiments, 
10% NGS was used instead of the primary antiserum. 
The direct immunoperoxidase technique was performed as follows: the aceton fixed 
slides were incubated during one hour at room temperature with direct peroxidase 
(HRPO) labelled MoAb. After repeated washings in PBS (3 times, 10 minutes), 3-
3'diaminobeiizidine (DAB; 6 mg/10ml, 0.65% imidazole in PBS) and hydrogen 
peroxide to a final concentration of 0.01% was applied. After incubation for 5 min. 
and extensive washing with tap water, the slides were counterstained with 
hematoxylin, and mounted with permount (Fisher Scientific, New Yersey, USA). 
The following antibodies directed against human intermediate filament proteins, 
HLA class-I and -II antigens and tumor specific antigens were used in this study. 
1) pKER. An affinity purified rabbit antiserum to human skin keratins which reacts 
with virtually all epithelial tissues, but not with non-epithelial tissues. This broadly 
cross-reacting polyclonal antibody was used for the detection of the epithelial nature 
of the tumors. It was also used for comparison of the staining with the monoclonal 
antibodies against cytokeratins, to ascertain the distinction between human tumor 
and mouse stromal cells. 
2) pVim. An affinity purified rabbit antiserum to bovine lens vimentin. This 
broadly cross-reacting polyclonal antibody was used for the detection of the 
intermediate filament protein present in mesenchymal cells. It was also used for 
comparison of the staining with the RV 202 monoclonal antibody, to ascertain the 
distinction between the human tumor and mouse stromal cells. 
3) RCK 102 (IgGl). A cytokeratin antibody which recognizes cytokeratins 5 and 8 
(nomenclature according to Moll et al.) and as a result stains virtually all epithelial 
tissues. 
4) RCK 105 (IgGl). A monoclonal antibody reacting with cytokeratin 7, staining a 
subgroup of glandular epithelia and their tumors, next to transitional bladder 
epithelium and bladder carcinomas. This antibody does not react with renal cell 
carcinoma (Grawitz tumors). 
5) RCK 106 (IgGl). A monoclonal antibody reacting with cytokeratin 18. In general, 
this antibody recognizes columnar epithelial cells from digestive, respiratory, and 
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urogenital tracts, endocrine and exocrine tissues and mesothelial cells, as well as 
their tumors. Generally no reaction is found in squamous epithelia. 
6) RV 202 (IgGl). A monoclonal antibody reacting with vimentin, specific for 
mesenchymal cells.^ 
7) W6.32 (IgG2a). A monoclonal antibody directed against the human 
histocompatibility leucocyte antigens (HLA) of class-I (Α,Β,Ο)/* 
8) B8.11.2 (IgG2b). A monoclonal antibody directed against the human 
histocompatibility leucocyte class-II antigen (HLA-DR).^9 
9) RC-38 (IgG2a). A monoclonal antibody directed against a heat-labile antigen 
expressed on cell membranes of primary and metastatic renal cell carcinoma 
cells.40·« 
10) G 250 (IgG2a). A tumor-associated antigen that does not react with normal 
proximal tubular epithelium but recognizes an antigen preferentially expressed on 
cell membranes of primary and metastatic renal cell carcinoma cells.40, 
The direct labelled antibodies W6.32 and B8.11.2 were kindly provided by dr. G.N.P. 
van Muyen, department of Pathology, University Hospital Nijmegen, The 
Netherlands and the RC-38 and G250 MoAb were kindly provided by dr. S.O. 
Wamaar, University of Leiden, The Netherlands. 
Mvcoplasm test 
Possible contamination of the xenografts by mycoplasm was routinely checked with 
Hoechst stain no 33258 three days after attachment of single cell suspensions of the 
xenografts to glass slides in RPMI-1640 medium supplemented with 10% fetal calf 
serum. Attached cells were fixed in Camoy's ñxativ (methanol/acetic acid 3:1) and 
next stained with Hoechst stain solution in phosphate citric acid buffer. Cells were 
analyzed by means of immunofluorescence microscopy. 
RESULTS 
Histology of the primary tumors and their xenografts 
We reviewed the histology of the primary tumors and their xenografts up to the 
fifth to fifteenth transplant generation using histopathological criteria as described by 
Thoenes et al.42 
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NU-10: 
The primary tumor (Figure 1) showed a solid, both trabecular and acinar pattern of 
predominantly clear cells, admixed with some granular cells. Areas of both Gl 
nuclei (small, round nuclei with inconspicious nucleoli) and G2 nuclei (enlarged, 
moderately polymorphic nuclei with prominent nucleoli) were present. Mitotic 
figures were rare (< 1/10 high power fields (HPF)(40x)). Only focal necrosis and 
fibrosis were present. The capillaries were, inconspicious. 
The transplant passages in the nude mouse, up to passage no. 15 showed 
consistently the features of the primary tumor of a solid pattern with both clear and 
granular cells with G2 nuclei and a similar low mitotic index. Only the small 
thinwalled bloodvessels were frequently severely dilatated as compared to the 
primary tumor. 
NU-12: 
The primary tumor (Figure 1) consisted of large solid trabecular fields of large clear 
cells with rather small, polymorphic nuclei (G2) which were frequently 
multinucleated. Nucleoli were small and mitotic figures were rare (< 1/10 HPF). 
The thinwalled vessels in the septa were moderately dilatated. Extensive necrosis 
was found. 
The transplant passages up to no 10 showed consistent features similar to the 
primary tumor, except for the multinucleated cells which were scarce in the 
xenografts. 
NU-20: 
The primary tumor (Figure 1) was solid with a trabecular pattern. The cells were 
predominantly granular and the nucleoli were moderately pleomorphic with 
inconspicious nucleoli and dispersed multinucleated forms (G2). Mitoses were rare 
(< 1/10 HPF). The thin walled vessels were dilatated and some fibrosis and necrosis 
was present. 
The transplant passages up to no 10 showed increasing cell polymorphism up to G3 
with multinucleated cells, increasing numbers of mitoses (up to 10-12/10 HPF) and 
necrosis with leucocytic infiltrates. 
45 
NU-22: 
The primary tumor (Figure 1) showed a solid, both acinar and trabecular pattern of 
predominantly granular cells admixed with clear cells. The nuclei were enlarged, 
polymorphic with prominent nucleoli (G2). Mitoses were observed up to 5/10 HPF. 
The small vessels were inconspicious. Necrosis and fibrosis were not extensive. 
The transplant passages up to no 10 resembled consistently the primary tumor very 
well. Mitoses were found up to 3/10 HPF. 
NU-28: 
The primary tumor (Figure 1) and the retroperitoneal lymph node metastasis 
showed similar features of a solid tubular pattern with extensive necrosis and 
cellular leucocytic infiltrates. The tumor cells were predominantly granular cells 
admixed with some clear cells. The nuclei were large, polymorphic, irregular and 
frequently multinucleated (G3) and the nucleoli were prominent. Mitosis were rare 
(< 1/10 HPF). The lung metastasis excised two years later and which gave rise to 
the xenograft was more solid with less extensive necrosis. More clear cells were 
encountered. Nuclear atypia was less severe (G2) and in the septa many leucocytes 
were present. Mitoses were also frequent. 
The xenografts up to passage no 5 showed less nuclear polymorphism and 
multinucleated cells were not present (G2). Also no leucocytic infiltrates were 
encountered. Mitotic index was also low as found in the lung metastasis. The 
thinwalled vessels were dilatated and the first three passages showed an increase in 
vessel diameter. 
This slow growing tumor gives rise to many intravascular localizations of small nests 
of solid tumor with large granular cells with G2 nuclei and only rare mitosis in the 
lungs of the mice three to four months after subcutaneous transplantation of small 
tumor fragments. 
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Figure 1: 
Histology of primary tumors and their xenograft transplant passages no. 0 and 5-15. The slides (S 
micron) were stained with haematoxylin- eosin by standard techniques and observed at 40x 
magnification under a Zeiss Axioskop microscope. 
1= transplant passage 0. 11= transplant passage 5 of NU-10, NU-12, NU-20, NU-22; transplant 
passage 3 of NU-28. 111= transplant passage IS of NU-10 and NU-12; transplant passage 10 of NU-
20 and NU-22; transplant passage 5 of NU-28 
Flow cytometric analyses of cellular DNA content 
Data about DNA index (DI) values of the primary tumors and their xenografts are 
summarized in Table 1. 
NU-10: 
The primary tumor, as well as, the xenografts show to be aneuploid. In both the 
primary tumor and in the different xenografts passages two cell populations are 
present; one with a diploid and one with an aneuploid DNA content. (This pattern 
is seen in all other primary tumors and their xenografts except for the NU-22 
tumor). The xenograft with passage number 0, i.e. the xenograft directly grown from 
the primary tumor tissue transplant, has a DI value of 1.5 and even in the 15th 
transplant generation this DI value still has a value of about 1.5. 
NU-12: 
The primary tumor has a predominant diploid character. However, a small triploid 
tumor peak can be identified in the histogram (data not shown). The xenografts 
from passage number 0 up to number 15 have an aneuploid character with DI 
values of about 1.6. 
NU-20: 
The primary tumor has a diploid DNA index. The DI value is 1.00. In transplant 
passage 0 an aneuploid peak is seen (DI value of 1.5). Transplant generation no 10 
has a DNA index value of 2.06, hence this transplant passage has a tetraploid DNA 
content. No signs of any tetraploidy could be found in the histogram of transplant 
number 0. 
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TABLE 1 
Tumor transplant generation aneuploidy D.I. Gl 
diploid 
D.I. G2 
tumor 
NU-10 
NU-12 
NU-20 
NU-22 
NU-28 
primary tumor 
passage no. 0 
passage no. 15 
primary tumor 
passage no. 0 
passage no. 15 
primary tumor 
passage no. 0 
passage no. 10 
primary tumor 
passage no. 0 
passage no. 10 
primary renal tumor 
retroperitoneal lung metastasis 
primary lung metastasis 
passage no. 0 
passage no. 5 
Y 
Y 
Y 
S 
Y 
Y 
N 
Y 
Y 
N 
-
N 
N 
Y 
Y 
Y 
Y 
1.08 
0.96 
0.97 
0.97 
0.89 
0.93 
0.92 
0.88 
0.90 
0.96 
-
0.93 
0.92 
0.93 
0.95 
0.89 
0.89 
1.54 
1.50 
1.53 
0.97 
1.68 
1.57 
1.00 
1.50 
2.06 
1.00 
-
1.05 
. 
1.80 
1.60 
1.63 
1.60 
Table 1: 
Flowcytometric analyses of the primary tumors and their xenografts. 
DI+ DNA index: Y= yes, N= no, S= suspect. 
NU-22: 
Like the NU-20 tumor the primary tumor is diploid with a DI value of 1.00. All 
transplant generations also show to have a DI value of 1.00 for the tumor fraction, 
so this tumor remains its diploid nature in all transplant generations tested so far. 
Due to shortage of tumor material, flowcytometric analysis of transplant generation 
no 0 was not possible. 
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NU-28: 
In the primary tumor we could not measure an aneuploid tumor peak (G2) because 
100% of the cells were found in the Gl diploid peak, however, the intrathoracal 
lymph node removed from the right lung five months after nephrectomy had a DI 
value of 1.80 for the tumor fraction. The lung metastasis removed two years after 
nephrectomy and which gave rise to the xenograft is clearly aneuploid with a DI 
value of about 1.6. The subsequent xenografts from passage 0 to 5 show to maintain 
this DI value so the xenografts have a near triploid DNA content. 
Colony forming capacity in soft apar 
Data about the colony forming capacity of the primary tumors and their xenografts 
are summarized in Table 2. As appears from this table the cells from all xenografts 
have gained anchorage independent growth potential in this culturing assay. The 
primary tumors of the NU-20 and NU-22 did not give rise to colony formation but, 
because their xenografts did, sensitivity of the system will probably have been to low 
to detect the colony forming capacity of the cells isolated from the primary tumors. 
Plating efficiency (PE) of the xenografts NU-10, -12, -20 and -22 was at least 20 fold 
higher than their primary tumors. Plating efficiency of the NU-28 xenograft, 
however, was the same as the PE of the corresponding tumor (lung metastasis), the 
primary tumor and the retroperitoneal lymph node metastasis, which all showed to 
have a PE of 0.1%. 
Tumor doubling times 
Tumor doubling times were constant after the first (NU-22), third (NU-20) or fourth 
transplant generation (NU-10, -12, -28). Table 3 summarizes the doubling times for 
the first five transplant generations of the different tumors. This Table shows that 
doubling time is longest for the primary tumor pieces (transplant generation no. 0). 
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TABLEZ 
Tumor material no. of cells no. of colonies plating efficiency 
per dish χ 1000 after 4 weeks (%) 
NU-10 
NU-12 
NU-20 
NU-22 
NU-28 
primary tumor 
xenograft p.S 
xenograft p. 15 
primary tumor 
xenograft p.S 
xenograft p.l 
primary tumor 
xenograft p.S 
xenograft p. 10 
primary tumor 
xenograft p.5 
xenograft p. 10 
primary tumor 
lymph node met. 
lung met. 
xenograft p.5 
500 
100 
100 
500 
100 
100 
500 
100 
100 
500 
100 
100 
500 
500 
500 
100 
134 
695 
740 
160 
275 
240 
0 
150 
130 
0 
268 
280 
70 
463 
154 
31 
0.1 
2.0 
2.0 
0.1 
1.0 
1.0 
0.0 
1.0 
1.0 
0.0 
1.0 
1.0 
0.1 
0.1 
0.1 
0.1 
Table 2: 
Clonogenic potential of cells of the primary tumors and their xenografts in a double layer soft agar 
cultunng system. Colonies were counted by an Omnicon Fas-II automated colony counter and 
plating efficiency was calculated as percentage of viable cells (i.e. not staining cells with trypan blue) 
giving rise to a colony (colony diameter > 60 micron) after 4 weeks of incubation at 370C and 6% 
CO,. 
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TABLE 3 
Tumor 
NU-10 
NU-12 
NU-20 
NU-22 
NU-28 
transplant 
generation 
0 
1 
2 
3 
4 
5 
0 
1 
2 
3 
4 
5 
0 
1 
2 
3 
4 
5 
0 
1 
2 
3 
4 
5 
0 
1 
2 
3 
4 
5 
tumor doubling time 
(days) 
9 
8 
6 
6 
4 
4 
11 
9 
6 
5 
4 
4 
6 
5 
5 
3 
3 
3 
7 
6 
6 
6 
6 
6 
11 
10 
10 
9 
8 
8 
Table 3: 
Tumor doubling times of the xenografts in BalbC nu/nu mice. Tumor pieces of 2 mm cubes were 
implanted subcutaneous into the right flank of the mice and tumor dimensions were measured with 
calipers twice a week. 
Intervals between two passages are reflected by the tumor doubling times although 
there are remarkable differences in tumor growth when tumor dimensions pass 
about 1.0 cm. NU-10 tumor grows till about 1.3 cm but stops growing thereafter. 
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The tumor can stay in the mice for about one month beyond this point before 
forming elaborate necrosis. The NU-12 tumor will grow with a tumor doubling time 
of 4 days till its dimensions reach about l.S cm. Thereafter, due to the formation of 
a cyst, tumor dimensions change much faster until maximum dimensions of about 2 
cm are reached. Extensive necrosis then forms most part of the tumor. The NU-20 
tumor is not limited in its growth as the NU-10 and NU-12 tumors are. This tumor 
grows till the mouse dies because of cachexia. Tumor dimensions will be about 2.5 
cm at this point of its development and extensive necrotic fields form most part of 
the tumor at that point. The NU-22 tumor already stops growing at dimensions of 
about 1 cm. Like the NU-10 tumor, this tumor can remain in a dormant state for 
about one month before becoming extensively necrotic. The NU-28 tumor which is 
the slowest growing tumor is, like the NU-20 tumor, not restricted in its growth by 
the dimensions of the tumor ( > 2.5 cm). The mice do not show any signs of 
cachexia despite the intravascular colonies and micro metastases that are found in 
the lungs at that time of the development. 
Metastatic capacity 
Lungs, liver and lymph nodes were checked for metastases by means of histological 
analyses of paraffin embedded material. Four of the tumors (NU-10, -12, -20, -22) 
do not form any metastases. The NU-28 tumor gives rise to multiple tumor colony 
formation in the lungs of the mice. Sporadic outgrowth of these colonies into the 
surrounding lung tissues giving rise to micro metastases of about 300- 700 μιη is also 
noticed in all transplant generations. 
Immunohistochemical analyses 
Data about the immunohistochemical analyses of the primary tumors and their 
xenografts are summarized in Table 4. This table shows that all tumors stain with 
RCK 102. The expression on the NU-10 tumor remains the same from primary 
tumor to xenogran passage no 15. In the NU-12 tumor however, there is a selection 
for the positive cells between passage no 1 and no 5. In the NU-20 tumor the 
intensity of the staining is going down from primary tumor to xenograft passage 0 (3 
and 1 resp.). Also between the first and S1* passage there is a selection for the 
positive cells. Loss of intensity but selection for the positive cells is also seen in the 
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NU-22 and NU-28 tumors. Intensity of the staining appears to be higher on the lung 
metastases than on the primary kidney tumor of the NU-28 xenograft. 
Except of sporadically staining cells, none of the tumors shows staining with RCK 
105. 
Loss of intensity of staining in the first five passages of the tumors is not as evident 
for RCK 106, except for the NU-28 tumor. The NU-20 tumor even shows 
enhancement of RCK 106 expression between the first and fifth passage. All tumors, 
however, show a positive selection for RCK 106 expressing cells in the first five 
passages. 
A loss of intensity of staining with RV 202 is seen in the NU-10, NU-22 and NU-28 
tumors. The NU-20 tumor shows a rise in intensity of staining with RV 202, 
concomitantly with a rise in percentage of cells staining with this antibody. Also, the 
NU-12 shows a positive selection for RV 202 positive cells. 
Staining with the polyclonal antibodies pKer and pVim shows the same patterns as 
seen with the monoclonal antibodies. 
HLA class-I expression remains present on all cells of the different passages. 
Intensity, however, is diminished in all tumors from passage 0 to passage 1, except 
for the NU-28 tumor on which the intensity of the Class-I staining remains the same 
in the succeeding passages. 
Staining with the HLA class-II antibody is rapidly lost in most tumor cells except for 
the NU-12 tumor. The low intensity of staining is already partly lost in passage 0 of 
the NU-10 tumor and, in passage 1 almost all cells have lost any detectable antigen 
expression. Staining in the NU-12 tumor remains constant in the different passages 
but staining is completely lost in passage no 1 of the NU-20 tumor. Like the NU-10 
tumor, HLA class-II expression is also almost completely lost between passage 1 and 
5 of the NU-22 tumor. The NU-28 tumor shows only a loss in intensity of the 
staining and not of percentage of positive cells. 
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TABLE 4 
Tumor 
NU-10 
NU.12 
NU-20 
NU-22 
NU-28 
transplant 
generation 
primary tumor 
passage 0 
passage 1 
passage S 
passage IS 
primary tumor 
passage 0 
passage 1 
passage 5 
passage IS 
primary tumor 
passage 0 
passage 1 
passage S 
passage 10 
primary tumor 
passage 0 
passage 1 
passage S 
passage 10 
primary tumor 
retroper. l.n. 
lung met. 
passage 0 
passage 1 
passage 5 
RCK 102 
Int. % 
1 0 
1 0 
1 0 
1 0 
1 0 
1 3 
1 3 
1 3 
1 4 
1 4 
3 2 
1 2 
1 2 
1 3 
1 3 
RCK 105 
Int. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
% 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
RCK 106 
Int. 
2 
2 
2 
3 
3 
2 
2 
2 
2 
2 
2 
2 
3 
1 
1 
1 
% 
0 
0 
1 
1 
1 
3 
3 
4 
4 
4 
1 
1 
2 
4 
4 
1 
3 
3 
4 
4 
1 
1 
1 
3 
3 
3 
RV202 
Int. 
3 
3 
2 
2 
2 
1 
1 
1 
1 
1 
3 
1 
2 
3 
3 
3 
2 
2 
2 
2 
3 
3 
3 
2 
2 
2 
% 
4 
4 
4 
4 
4 
3 
3 
4 
4 
4 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
3 
3 
pKer 
Int. 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
3 
1 
1 
2 
2 
3 
1 
1 
1 
1 
1 
2 
2 
1 
1 
1 
% 
1 
1 
1 
1 
1 
3 
3 
3 
3 
3 
1 
1 
2 
4 
4 
2 
3 
3 
4 
4 
1 
1 
0 
2 
2 
2 
pVim 
Int. 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
3 
1 
1 
2 
2 
1 
1 
1 
1 
1 
2 
2 
3 
1 
1 
1 
% 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
2 
3 
4 
4 
4 
3 
3 
3 
3 
3 
1 
2 
2 
2 
2 
2 
W6.32 
Int. 
3 
3 
2 
2 
2 
3 
3 
2 
2 
2 
2 
2 
1 
1 
1 
3 
3 
2 
2 
2 
3 
3 
2 
2 
2 
2 
% 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
B8.11.2 
Int. 
0 
0 
0 
1 
1 
1 
1 
1 
2 
2 
2 
1 
1 
1 
% 
3 
2 
0 
0 
0 
4 
4 
4 
4 
4 
2 
1 
0 
0 
0 
3 
2 
1 
0 
0 
3 
3 
3 
3 
3 
3 
G 250 
Int. 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
2 
3 
3 
3 
3 
2 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
% 
3 
4 
4 
4 
4 
2 
3 
3 
3 
3 
2 
4 
4 
4 
4 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
RC-38 
Int. 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
% 
4 
4 
4 
4 
4 
2 
4 
4 
4 
4 
2 
4 
4 
4 
4 
2 
4 
4 
4 
4 
2 
2 
2 
4 
4 
4 
Table 4: 
Immunohistochemical analyses of the pnmaiy tumors and their xenografts. 
Staining with the antikeratin monoclonal antibodies RCK 102, RCK 105, RCK 106, the antivimentin 
monoclonal antibody RV 202 and the polyclonal antibodies against cytokeratin and vimentin (K40 
and K36 resp.) was analyzed by means of indirect fluorescence microscopy. Staining with the W6.32 
(anti HLA class-I), B8.11.2 (anti HLA class-II), G250 and RC-38 monoclonal antibodies (both tumor 
associated) was followed by means of direct immunoperoridase staining (DAB staining). 
Intensity of staining was graded according to the following scale: 0= no visible staining present, 1= 
just visible staining, 2= clear visible staining and 3= strong staining (Int, left figures). The 
percentage of tumor cells expressing the particular antigen (%, right figures) was estimated within 
the following ranges: 0« 0%, 1= 1-25%, 2= 26-50%, 3= 51-75% and 4= 76-100% positive tumor 
cells. 
Except for the G250 staining of the NU-22 tumor, a selection for G 250 and RC-38 
positive cells is shown by all tumors in their early passages in the nude mouse. A 
loss of intensity for both G250 and RC-38 is shown by the NU-22 tumor only, and 
as for the staining with the anticytokeratin and antivimentin antibodies, intensity of 
staining with the G250 and RC-38 antibodies is also enhanced in the transplant 
passages of the NU-20 tumor as compared to the primary tumor. 
Tumor characteristics of the non serially transplantable tumors 
Tumor characteristics od the primary tumors as described for the serially 
transplantable tumors were performed also for the non serially transplantable 
tumors, in order to see whether a relation could be found between histologic and 
molecular characteristics of a tumor and its capacity to form a serially transplantable 
tumor. A lower HLA class-I expression on the primary tumors of the non serially 
transplantable tumors was the only obvious difference between the two groups. One 
of the tumors (NU-24), showed that not only intensity of staining with the HLA 
class-I antibody was low, but that also the percentage of staining cells diminished 
from 100% in the primary tumor to about 50% in transplant passage number 1, 
which is opposed to the ñndings from the serially transplantable tumors in which the 
HLA class-I antigen was found in about 100% of the primary tumors and all 
succeeding transplant passages. 
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Mycoplasm screening 
None of the cultures showed any signs of contamination with mycoplasm. 
DISCUSSION 
A disadvantage of studying human cancer in models is, that none of the models will 
be representative in all aspects. In vitro models do not enable us to study the 
histological and many of the physiological aspects of the tumor and in the in vivo 
models, the syngeneic rodent tumors for instance have the disadvantage of the 
different physiological and metabolic aspects between human and rodent tumors. A 
model enabling in vivo studies on human tumors, the nude mouse model system, has 
a disadvantage that the intrinsic Τ cell deficiency may impair with many aspects of 
the transplanted tumors. However, since the first description of the nude mouse in 
1966 by Flanagan** and the demonstration of the congenital defect of the thymus by 
Pantelouris, many reports described the use of this model for the transplantation 
of human tumors. Use of this model was stimulated by the report of the first 
International Workshop on Nude Mice in 1974 which recognized and confirmed 
that original tumor structures and functions are maintained through the 
transplantation of human cancers in the nude mouse. Conservation of tumor 
histology during transplantation has since been described by many authors/* * ' 
We tested whether this important observation could be confirmed for the 
xenotransplantation of human RCC. We found that, except for the vasculature, 
tumor histology is essentially conserved during xenografting. At a molecular level, 
however, we found that characteristics as DNA index, cytokeratin and vimentin 
expression and HLA class-I and -II expression may change considerably during the 
first transplant generations. 
Histology and tumor doubling time 
Tumor histology remained essentially the same in the different transplant passages, 
however, some histologic and cytologic changes occurred during transplantation. The 
NU-20 tumor showed most apparent changes in cell morphology. In this tumor 
there was an increasing nuclear polymorphism during succeeding transplant passages 
and an increase of the numbers of mitoses and multinucleated cells which was 
opposite to the findings in the NU-12 and NU-28 tumors which showed less 
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multinucleated cells and also less nuclear polymorphism (NU-28) in the succeeding 
transplant passages. Differences in vascular structure, were most pronounced 
between the primary tumors and their xenografts. Blood vessels appeared to be very 
thin and dilatated in the xenografts (NU-10, NU-28). A remarkable increase in 
vessel diameter in the first three transplant passages was shown by the NU-28 
tumor. Changes in vessel structure were noticed by other authors as weil48·49 and 
may be explained by the fact that blood flow and vessel structure are host related 
because the vascular system and stroma in xenograft tumors are known to be host 
derived (Giovanella and Fogh, 1978). The differences in vessel structure may also 
explain part of the differences in growth characteristics between the primary tumor 
transplants (passage no. 0) and the succeeding xenografts). Table 3 shows that 
tumor doubling time is highest in transplant passage number 0 and decreases 
thereafter until constant growth is reached. The tumor transplants taken directly 
from the primary tumor will contain human endothelial cells and stromal parts 
which will be replaced by host cells. So, before newly formed host derived capillaries 
will be functional in the tumor, blood supply and oxygenation will be insufficient for 
normal tumor growth. As seen in the NU-28 transplant passages, diameter of the 
newly formed vessels may increase further in the first transplant passages. Such 
tumor-induced vessels are known to have a different structure and hence possess 
different haemodynamic properties. Furthermore, the vascular density in the 
primary tumor in humans and in xenografts is likely to be strongly influenced by the 
dissociation curve for oxygen from haemoglobin. The рОз 50 values for mouse and 
human haemoglobin are 41 and 25 mm Hg respectively.^ This suggests that 
anatomically identical vascular networks would result in a less effective tissue 
oxygenation in mice. Because a change in vessel diameter was not noticed as clear 
in the other tumors, intrinsic factors will also play a role in tumor vascularization, 
which is in accordance with the conclusions drawn by Solesvik et al.5 2 in a study to 
the vascular anatomy of five different human melanoma xenografts. 
Molecular characteristics 
Flowcytometric analyses reveal that DNA index (DI) values can show considerable 
change in the subsequent transplant passages, which is not in accordance with 
findings by other authors'** who found preservation of DNA characteristics after 
passage in nude mice. 
Interpretation of FCM data regarding primary RCC, however, need careful 
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consideration. Recently, it became evident that a wide spread in DNA index can 
exist within an individual tumor. The consensus at the moment is that for a valid 
DNA index determination of a primary renal tumor, at least 6 samples need to be 
evaluated. At the start of this studies (three years ago), the DNA index was 
established from single specimens. Hence it is conceivable that the xenografts arose 
from sub populations not abundantly present in the primary tumor. It is interesting 
to see that in the samples analyzed for FCM one of the tumors remains diploid 
(NU-22) whereas others progress to aneuploidy or tetraploidy. Recent studies 
suggest that aneuploidy may arise from several mechanisms. Either by acquisition of 
DNA abnormalities resulting in peridiploid tumors or by a gain of chromosome 
numbers and subsequent chromosomal loss resulting in near triploid tumors. In this 
aspect the NU-10 and NU-28 tumors arose from near triploid tumors and retain the 
same DNA content during the subsequent transplant passages. The NU-22 tumor 
resulted from a diploid primary tumor piece and this tumor shows to retain its 
diploid character during xenotransplantation. The NU-12 and NU-20 tumors are 
interesting since they developed from apparently diploid primary tumors, whereas 
during xenotransplantation they gave rise to aneuploid tumors. The NU-12 shows to 
be hypertriploid in passage number 0 and appears to remain its triploid character in 
passage no 15. The NU-20 tumor, however, has a triploid DNA content in passage 
number 0 but appears to be tetraploid in passage number 10. Most probably, the 
triploid and tetraploid tumors evolved from minor different tumor fractions not 
apparent in the preceding transplant passages, although, a tetraploid peak for 
instance could not be detected in the histogram of transplant passage number 0. 
Staining with the cytokeratin antibodies RCK 102, RCK 105 and RCK 106 fulfills 
the characteristics of RCC tumors.^-*7 Also, most of the tumor cells stain with the 
vimentin antibody RV 202 and this too is a characteristic of RCC cells.55,56 Because 
we did not perform double labeling studies we cannot exclude the possibility that 
some cells of the NU-10 tumor stain only with anti-cytokeratin (RCK 106) or only 
with anti-vimentin. The concomitant keratin and vimentin expression of most of the 
cells of the other tumors is obvious from the staining patterns with both types of 
antibodies. Staining with the polyclonal antibodies against keratin and vimentin are 
comparable with the staining with the monoclonal antibodies. Due to the lower 
intensity of staining by the polyclonal antibodies, however, some low keratin and or 
vimentin expressing cells may have been overlooked. 
The cytokeratin and vimentin staining patterns show that, except for the NU-20 
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tumor, some particular changes occur during the first passages of the tumors. In 
most tumors there is a loss of intensity of staining in passage number 0, but 
concomitantly there is a selection of the keratin and or vimentin expressing cells 
which may even continue in the following passages (e.g. NU-22). Again, this pattern 
is also seen with the polyclonal antibodies. The NU-20 tumor, however, instead of a 
loss of intensity, shows an increase in staining intensity with both cytokeratin (RCK 
106) and vimentin antibodies, together with a positive selection of staining cells, 
which shows that also as regard to the cytoskeletal filaments this tumor is very 
instable. 
HLA class-I and class-II expression is down modulated in all transplant passages, 
except for the NU-12 tumor which only looses some intensity of class-I expression. 
Class-I remains present on almost all cells in the different passages, but class-II is 
lost on most of the cells of the NU-10 and NU-22 tumor and is even completely 
lost on cells of the NU-20 tumor. Downregulation or loss of HLA class-II expression 
upon xenografting is not uncommon and found for melanoma cells as well.57 
Staining with the antitumor antibodies G250 and RC-38 shows a pattern which is 
very much alike the staining with the mono- and polyclonal antibodies against 
cytokeratins and vimentin. An increase in positive cells is seen in almost all cases 
for both G250 and RC-38 upon xenotransplantation. A loss of intensity, however, is 
seen only in the NU-22 tumor. A gain of intensity of staining, however, is again 
shown by the NU-20 tumor which means that except for the HLA class-I and class-
II antigens this tumor shows an increase in intensity of staining of all other tested 
antigens upon xenotransplantation, whereas for the other tumors intensity of staining 
of these antigens is constant or diminished upon xenotransplantation. 
No essential differences between the histologic and molecular characteristics 
between the serially- and non serially transplantable tumors could be measured 
except for a lower HLA class-I expression in the non serially transplantable tumors. 
Nude mice possess high levels of NK cells and reduction of the NK activity in nude 
mice has been shown to enhance the growth of transplanted tumor growth in nude 
mice.5*'59 On the other hand, in autologous systems, NK cells are known to be 
activated by cells expressing low levels of HLA class-I antigens.60 The fact that the 
low HLA class-I expressing cells do not form serially transplantable RCC tumors in 
the nude mouse is therefore an interesting finding because to our present knowledge 
it is not known whether there is a functional relation between human HLA class-I 
expression and murine NK cell activity. 
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Colony forming capacity 
The colony forming capacity in soft agar of the xenograft passages is indicative for 
the increase in tumorigenic characteristics of the xenografts. The enrichment for 
viable tumor cells, as well as, the progression to a more aggressive character of the 
xenografts may explain the differences (up to 20 times) in PE between the primary 
tumors and their xenografts. 
We conclude that xenografting human renal tumor tissue into nude mice gives rise 
to tumors which in general give a good representation of the primary tumor, 
however, presenting the more aggressive character of the primary tumors. Histology 
of the primary tumors was essentially preserved during xenotransplantation in which 
host derived bloodvessels replaced the human vasculature. Molecular characteristics 
of the tumor cells, however, may change to a more or lesser extent during the first 
transplant passages in which there is a trend for a selection for cytokeratin, vimentin 
and tumor associated antigen expressing cells. The DNA index shows a trend 
towards aneuploidy which means that during transplantation a selection for the most 
tumorigenic cells is made. 
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SUMMARY 
The in vitro antitumor activity of recombinant alpha- and gamma-Interferon as well 
as recombinant Tumor Necrosis Factor alpha was tested on renal cell carcinoma 
xenografts using the double layer soft agar method. Using this assay, the effect of 
the drugs on the clonogenic potential of tumor cells in soft agar was determined 
and used as an indication for the antiproliferative capacity of these drugs. There 
appeared to be a differential response of the tested xenografts towards these drugs 
in a seemingly dose dependent way. However, when used in combination in most 
cases an additive or synergistic effect was observed. Even though again the 
response was differential, the combination of alpha-Interferon (10 ng/dish) and 
Tumor Necrosis Factor (100 ng/dish) resulted in a complete inhibition of colony 
formation in soft agar for all tumor lines. We conclude that there is a direct effect 
of alpha-Interferon, gamma-Interferon and Tumor Necrosis Factor on renal cell 
carcinoma xenografts. In combination drug tests the effect of alpha-Interferon and 
Tumor Necrosis Factor was strongly synergistic. The implication of these studies for 
in vivo use of these drugs remains to be established. 
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INTRODUCTION 
For patients with renal cell carcinoma (RCC) the 5-year survival rate has not 
significantly improved during the last two decades . New therapeutic regiments 
against RCC are difficult to obtain because patients present with the disease in a 
wide range of gradings and stagings. Transplantation of human renal cell carcinoma 
into athymic nude mice, however, provided experimental tumor models which make 
the development of new therapeutic approaches possible ' . Especially, 
therapeutic regiments using Biological Response Modifiers (BRM's) appear to be 
very promising as anticancer therapy in experimental animals and man. Interferons 
appear to have a dual mode of effect; directly on the cancer cell and indirectly 
through the immune system. Direct effects on tumor cells could be shown in a 
tumor model system of heterotransplantation in nude mice of breast tumors-', 
fibrosarcoma24 and bowel carcinoma2. Indirect effects were observed when murine 
Interferon (IFN) was used in the treatment of human tumor xenografts in the nude 
mouse host4,6, which indicates that murine IFN can mediate tumor inhibition via an 
immunological effect in the T-cell deficient host. 
The combined direct and indirect in vitro antiproliferative effects of rIFN-gamma to 
renal cells were tested by Saito et al.42 using a clonogenic assay with human 
adherent ascites cells which contained >80% macrophages as feeder cells in a 
separate agarose underlayer. When treated with human rIFN-gamma these cells 
became strongly inhibitory to tumor colony growth. Hence it seems that human 
tumor associated macrophages may become tumoricidal under the influence of 
rIFN-gamma producing a diffusible substance in agarose culture which caused the 
observed antiproliferative effects on tumor cells. 
Host mediated antitumor effects of Interferons were already suggested by Belardelli 
et al.5,7 and Pace et a\.38 and since the macrophage is the cellular source of Tumor 
Necrosis Factor (TNF)2 8, much attention has been payed to this antitumor 
agent"' . TNF has direct in vitro cytotoxic activity against tumor cells' ' 5 but TNF 
also induces a host mediated factor which contributes to the antitumor effects, 
especially in relation to T-cells ' ^ . The synergistic antitumor activity of IFN-gamma 
and TNF is now well documented for in у\ио14' '31'41'43' and in vivo systems5. 
Williamson et a\.49 also found a synergistic antitumor effect of IFN-alpha and TNF 
on human breast and colon cancer cells. 
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Since IFN-alpha appears to be a potential active antitumor agent in patients with 
renal cell carcinoma9·32·33·39 and TNF also shows in vitro cytostatic and cytolytic 
effects on human renal cell carcinoma cell lines2^ we decided to test the direct in 
vitro antiproliferative effects of human recombinant alpha- and gamma-IFN as well 
as human recombinant TNF on renal cell carcinoma tumor lines. 
In this study we show that alpha- and gamma-IFN as well as TNF have in vitro 
antiproliferative effects on RCC tumor cells. 
MATERIAL AND METHODS 
Renal cell carcinoma xenografts. 
After original subcutaneous transplantation of small tumor pieces (2 mm3) in both 
flanks of Balb-C nu/nu mice, the xenografts were passaged every four weeks. Tumor 
material for testing was harvested after four weeks. The NC-65 and RC-43 [23,26] 
tumors were kindly provided by Dr. J.C. Romijn, University Hospital Rotterdam, 
and the HAM-II and HAM-III lines were kindly provided by Dr. U. Otto, 
Eppendorf University Hospital, Hamburg, FRG. 
Biological Response Modifiers. 
Human IFN-alpha, IFN-gamma and TNF-alpha, obtained from Boehringer 
Ingelheim, were produced in E. coli by recombinant DNA technology. The specific 
activity of IFN-alpha and IFN-gamma was 3,2E8 units/mg protein and 2E7 units/mg 
protein respectively. It was measured by inhibition of encephalomyocarditis (EMC) 
virus replication in A549 cells with reference to the National Institute of Health 
(NIH) leucocyte IFN-alpha standard Go 23-901-527 and the NIH IFN-gamma 
standard Gg 23-901-530. The purity of both IFN's was > 98 percent as determined 
by SDS Polyacrylamide gel electrophoresis and the amount of endotoxin was less 
than 1,0 ng/mg protein for IFN-alpha and less or equal to 0.5 ng/mg protein for 
IFN-gamma as based on the limulus amoebocyte lysate assay. The specific activity 
of TNF-alpha determined in the presence of actinomycine-D was 6E7 units/mg 
protein as determined in the L·929 cytotoxicity assay. The purity was > 99 percent 
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as determined by SDS Polyacrylamide gel electrophoresis and it contained 1.0 ng or 
less endotoxin/mg protein based on the limulus amoebocyte lysate assay. The drugs 
were dissolved in the accessory dissolvent and diluted with double enriched (D.E.) 
CMRL 1066 medium (Gibco, Paisley, U.K.). 
Preparation of single cell suspensions. 
When tumors reached sizes of about 1,5x1,5 cm the mice were sacrificed and tumor 
material was suspended in McCoy's wash (Gibco, Paisley, U.K.). After careful 
removal of tumor necrosis, tumors were cut into pieces of about 3 to 4 m m . The 
tumor pieces were then minced with scissors into a 300μπι metal sieve and 
continuously washed with McCoy's wash into a petri dish. The minced tumor tissue 
was passed twice through a 40-70μπι nylon filter (Ortho Diagnostics, Beerse, 
Belgium) to obtain a single cell suspension. The cells were centrifuged at room 
temperature at 400g for 5 minutes after which the supernatant was discarded. Upon 
resuspension of the cell pellet in double enriched CMRL 1066, cell density and 
viability were determined by adding 15 μΐ trypan blue solution (25 mg in 5 ml 3% 
acetic acid) to 15 μΐ cell suspension and simultaneously counting colored and not 
colored cells using a Biirker Turk haemocytometer. 
Human Tumor Colony forming Assay fHTCSV 
For the detection of the growth potential of tumor cells in soft agar a modified two 
layer soft agar culture method as originally described by Hamburger and Salmon7* 
was used . Tumor cell suspensions were plated at a concentration of 10E5 tumor 
cells per dish in the upper layer of the two-layer agar culture system. The cells were 
cultured immediately after preparation of the single cell suspension and growth 
potential was quantified using an Omnicon Fas II automated colony counter (Milton 
Roy Inc., Rochester, New York, USA)22. For dynamic colony growth development 
we used the Temporal Growth Pattern' method giving an estimation of growth over 
a certain period of time11. 
Drug testing. 
Drug tests were performed as continuous exposure of the tumor cells to the drugs. 
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The drugs were layered over the top agar in a volume of 200 μΐ D.E. CMRL-1066 
medium. The dishes in the growth control were layered with 200 μΐ D.E. 
CMRL-1066 and as a cytotoxic growth control we used a 0,37mM HgC12 solution. 
RESULTS 
Effect of single doses of alpha-IFN. gamma-IFN and TNF on colony formation. 
Determination of optimal plating densities for analysis of colony formation according 
to the temporal growth curves revealed a concentration of 1.10E5 cells per dish for 
all tumor lines (data not shown). Single drug tests were performed using IFN-alpha, 
IFN-gamma and TNF at concentrations of 10, 100 and 1000 ng/dish (= ng/2ml). 
Figures 1, 2 and 3 give examples of the temporal growth patterns of three of the 
xenografts. 
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Figure 1. Effect of three different cytokines on colony formation of NC-65 renal tumor xenograft 
cells in soft agar after application of a single dose of the drugs. 
A.) IFN-alpha. Specific activity: 3.2.10E8 lU/mg. B.) IFN-gamma. Specific activity: 
2.0.10E7 lU/mg. C) TNF. Specific activity: б.О.ЮЕ? IU/mg. 
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Figure 1 shows that a dose dependent in vitro colony forming inhibition of alpha-
IFN and TNF was found for the NC-65 renal tumor cells (Fig. 2A and С resp.). 
Gamma-IFN, however, appeared to have only very little effect on the colony 
formation of these cells. After a delayed colony formation from about the second 
week of the experiment, final colony formation was completed at the growth control 
level. 
Figure 2: 
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Figure 2: Effect of three different cytokines on colony formation of HAM-II renal tumor xenograft 
cells in soft agar after application of a single dose of the drugs. A.) IFN-alpha. Specific activity: 
3.2.10E8 lU/mg. B.) IFN-gamma. Specific activity: 2,0.10E7 lU/mg. C.) TNF. Specific activity: 
6Д10Е7 lU/mg. 
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Figure 2 shows the temporal growth curves of the HAM-II xenograft. Inhibition of 
colony formation appears to be dose dependent for all three cytokines. As the NC-
65 tumor line, this line shows only limited sensitivity for alpha-IFN, gamma-IFN and 
TNF. Only the intermediate (100 ng/dish) and high (1000 ng/dish) concentrations of 
TNF show percentage survival fractions which are less than 50% of control level. 
Figure 3: 
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Figure 3: Effect of three different cytokines on colony formation of NU-12 renal tumor xenograft 
cells in soft agar after application of a single dose of the drugs. 
A.) IFN-alpha. Specific activity: 3.2.10E8 lU/mg. B.) IFN-gamma. Specific activity: 2,0.10E7 lU/mg. 
C.) TNF. Specific activity: 6,0.10E7 lU/mg. 
77 
Figure 3 shows that sensitivity of the NU-12 xenograft is dose dependent for all 
cytokines. Sensitivity for the lowest tested doses of alpha-IFN and TNF was the 
same, resulting in a percentage survival fraction of about 60% as compared to the 
growth control. The higher doses of alpha-IFN resulted in a 15% survival fraction, 
but there was no or hardly any difference in the survival fraction between the 
intermediate and highest doses of alpha-IFN. TNF and gamma-IFN both show the 
same pattern although the difference in activity between the lowest and intermediate 
concentrations of the cytokines is much less. NU-12 is most sensitive for gamma-IFN 
because a single dose of 10 ng/dish results in a percentage survival fraction of only 
30% of growth control level. 
Table 1 summarizes all percentage survival fractions of the different xenografts after 
incubation with single doses of the cytokines. The values denote the percentage 
survival fractions at the end of the experiments (around day 30). This Table clearly 
reveals the differences in sensitivities between the tumor lines. The NC-65 and 
HAM-II tumors are the least sensitive lines showing no or only moderate sensitivity 
for the cytokines. The RC-43, HAM-II, NU-10 and NU-12 all show moderate to 
considerable sensitivities, even for the lowest tested doses, with survival fractions 
ranging between 25 and 100% for the lowest doses. In this group only the HAM-III 
line is insensitive for gamma-IFN with less than 10% growth inhibition for the 
highest dose. The NU-20 tumor appears to be very sensitive for both IFN's and 
survival fractions are only 14 and 37% for the lowest doses of alpha- and gamma-
IFN respectively. Sensitivity for TNF, however, is very low and % survival is still 
90% after treatment with 1000 ng TNF/dish. 
Synergistic in vitro antiproliferative effects of combinations of alpha-IFN. gamma-
IFN and TNF. 
By using drugs in the lowest possible concentrations on the assumption that IFN 
and TNF can act synergistically*0'50, combination drug tests were performed with 
both IFN's and TNF. Interferon concentrations of 10 ng/dish were used because at 
this concentration inhibition of colony formation was shown for both alpha- and 
gamma-IFN, and the TNF concentration in these tests was 100 ng/dish because this 
concentration showed inhibition of colony formation in all lines. The end results of 
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Table 1: 
Treatment % survival % survival % survival % survival % survival % survival % survival 
NC-65 RC-43 HAM-II HAM-III NU-10 NU-12 NU-20 
control 100 100 100 100 100 100 100 
alpha-IFN 10 
alpha-IFN 100 
alpha-IFN 1000 
gamma-IFN 10 
gamma-IFN 100 
gamma-IFN 1000 
TNF 10 
TNF 100 
TNF 1000 
alpha-IFN 10, gamma-IFN 10 
alpha-IFN 10, TNF 100 
gamma-IFN 10, TNF 100 
alpha-IFN 10, gamma-IFN 10, TNF 100 
70 
59 
37 
90 
85 
100 
88 
75 
7 
65 
0 
2 
0 
25 
23 
8 
45 
14 
14 
100 
55 
13 
3 
0 
20 
1 
85 
73 
58 
90 
86 
69 
86 
35 
15 
70 
3 
3 
3 
35 
30 
18 
95 
93 
91 
25 
25 
15 
20 
0 
8 
0 
32 
23 
9 
39 
20 
17 
62 
60 
50 
11 
7 
9 
3 
55 
18 
11 
30 
14 
10 
57 
40 
39 
10 
3 
4 
4 
14 
5 
0 
37 
13 
0 
100 
95 
90 
4 
0 
0 
0 
Table l:Percenlage survival of renal tumor xenograft cells after growth in soft agar and application 
of a single dose of different combinations if IFN-alpha, IFN-gamma and TNF as compared to growth 
in the untreated control. Concentrations are given in ng/dish (ng/2ml). 
these combination tests are summarized, and given in Table 1. 
This Table shows that irrespective of the antiproliferative effect of the single 
cytokines, the combinations of alpha- or gamma-IFN with TNF result in highly 
synergistic in vitro antiproliferative effects. Only the combination of gamma-IFN and 
TNF on RC-43 tumor cells, resulting in 20% survival, proves to be less effective. 
However, calculated according to Valeriote and Lih^5, even here, synergistic 
antiproliferative effects are measured. The combination of the two IFN's results in 
less active antiproliferative mechanisms, although, except for the NC-65 tumor, this 
combination results in synergistic antitumor effects as well. This Table also 
summarizes the results of experiments in which a triple combination of alpha-IFN, 
gamma-IFN and TNF was tested on the lines. Except for the NU-10 tumor, this 
combination did not result in further measurable enhanced antiproliferative effects. 
DISCUSSION 
Experimental results presented in this paper show that the colony forming capacity 
of renal tumor cells in an in vitro clonogenic assay is inhibited in a dose dependent 
way when the cells are treated with single doses of alpha-IFN, gamma-IFN or TNF. 
In two of the tested lines, NC-65 and HAM-III, however, we could not measure this 
effect after treatment with different doses gamma-IFN, which may be explained by 
the fact that these lines are not or hardly sensitive for this cytokine. The same was 
found for the effect of TNF on the NU-20 tumor line. In general, the lines show 
widely different in vitro sensitivities for the direct antiproliferative effects of these 
cytokines. The effect of alpha-IFN is more or less dose dependent in all lines. The 
NC-65 and HAM-II lines show the lowest in vitro sensitivity with 70% and 85% 
survival respectively after treatment with 10 ng alpha-IFN/dish. The NU-20 is the 
most sensitive line with only 14% survival after treatment with the low dose alpha-
IFN. Comparing the percentage survival values in the groups treated with different 
doses, reveals that the relative efficacy of the treatments is highest in the low dose 
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treated groups, indicating that these low doses probably are able to trigger a main 
part of the in vitro antiproliferative effects in the cells. 
The antiproliferative effects of gamma-IFN are comparable with the effects of 
alpha-IFN. As already indicated, the NC-65 and HAM-III lines show no or hardly 
any sensitivity for this cytokine in the dose range tested. The HAM-II line is also 
insensitive. The highest tested dose still results in 70% survival as compared to the 
untreated control. The other lines show considerable sensitivity and the lowest tested 
dose (10 ng/dish) results in less than 50% survival for these lines. The NU-20 line 
appears to be the most sensitive line for gamma-IFN. As was found for alpha-IFN, 
the antiproliferative effect of gamma-IFN is dose dependent, although again, the 
differences in antiproliferative effects between the low and high dose tested are very 
small, indicating that also low doses of gamma-IFN are able to trigger a main part 
of the in vitro antiproliferative effects in the tumor cells. In general, sensitivity of 
the lines towards alpha-IFN is higher than for gamma-IFN. 
Also TNF shows a dose dependent inhibition of colony formation in the tumor lines 
and again, differences in antiproliferative effects between the low and high doses 
tested are small in most lines. Differences in effects, however, are much more 
pronounced in the NC-65, RC-43 and HAM-II lines than in the other lines. The 
NU-20 tumor which is sensitive for both alpha- and gamma-IFN appears to be 
insensitive for TNF which means that different effector mechanisms are responsible 
for the in vitro antiproliferative effects of IFN and TNF. 
Combinations of the low doses of alpha- and gamma-IFN result in synergistic 
antiproliferative effects, with exception of the NC-65 tumor on which the 
combination has a subadditive effect. This means that also these IFN's act 
differently on the proliferative capacity of the tumor cells, which may be partly 
explained by the fact that both alpha-IFN and gamma-IFN have their own specific 
receptor on the cell membrane. 
All combinations of the low doses of the IFN's with the intermediate dose TNF 
result in highly synergistic in vitro antiproliferative effects. Even the lines showing 
the least sensitivity for the single cytokines (NC-65, HAM-II) appear to be very 
sensitive for these combinations. Synergism in the NU-10 tumor, however, which is 
sensitive for the single IFN doses is less pronounced in the combination of these 
IFN's with TNF, as is the gamma-IFN/TNF combination in the RC-43 and HAM-III 
tumors. In general, however, sensitivity for the alpha-IFN^TNF combination is very 
high. Colony formation is completely inhibited in four of the lines. Sensitivity for the 
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gamma-IFNA'NF combination is less, and the colony formation of only one of the 
tumors (NU-20) is inhibited completely by this combination. 
Because the combinations of the IFN's with TNF have such pronounced effects, the 
combination of both IFN's + TNF cannot add very much to these effects and only 
minor effects are seen in the NU-10 tumor. 
Because vinblastine seemed to be a promising agent in the treatment of renal cell 
carcinoma'^7 and combinations of alpha· and gamma-IFN with vinblastine showed 
synergistic effects against renal cell carcinoma in vitro as well as in viver'"*'* ' , 
we tested combinations of alpha- and gamma-IFN with vinblastine-sulphate 
(concentration 100 ng/dish ). A synergistic in vitro antiproliferative effect was 
measured but none of these combinations inhibited colony formation completely 
(data not shown). 
In conclusion, the xenografts show different but distinct seemingly dose dependent 
sensitivities towards alpha-IFN, gamma-IFN and TNF. The most sensitive tumor is 
the NU-20 tumor in which colony formation may be inhibited completely by the 
high doses of both IFN's. The least sensitive tumor is HAM-II which was only 
moderately sensitive towards the three cytokines. Combinations of the cytokines 
resulted in synergistic antiproliferative effects of in vitro colony formation of all 
tumors. The combination of alpha-IFNATsiF resulted in the most pronounced 
antiproliferative effect, resulting in complete inhibition of colony formation in four 
of the seven lines. 
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SUMMARY 
Whereas cytokine therapy has proven efficacy in the treatment of metastatic renal 
cell carcinoma (RCC), many questions regarding the use of these drugs are 
unanswered. In this study we evaluate the antiproliferative effects of human 
recombinant alpha-Interferon (IFN), gamma-Interferon and Tumor Necrosis Factor-
alpha (TNF) on eight human RCC xenografts. Especially the importance of 
administration route, dosage scheme and tumor load was investigated. Response to 
the cytokines differed widely amongst the different tumors. Of three tested routes of 
administration; intravenous, intraperitoneal and subcutaneous peritumoral only the 
subcutaneous peritumoral route was effective against tumor growth. After six weeks 
of therapy in which 150 or 1500 U IFN/g were administered subcutaneously 
peritumoral three times a week or 30,000 U TNF/g five times a week, alpha-IFN 
therapy resulted in 2-100% growth inhibition, gamma-IFN in 7-80% and TNF in 35-
75% as compared to the untreated control. Growth of five of eight lines could be 
inhibited completely by combinations of IFN + TNF in which the tumor dimensions 
at start of therapy were decisive for the results of the treatment. In some cases 
IFN's had optimum doses. Antitumor effects of TNF, however, were always dose 
dependent. Our studies indicate that the doses at which optimal direct effects of the 
cytokines are measured are critically dependent on the tumor treated. Even though 
direct effects are only a part of the mode of action of cytokines, results indicate that 
dosage of cytokines may need individualization. 
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INTRODUCTION 
Renal Cell Carcinoma (RCC) is a relatively uncommon malignancy which accounts 
for 1-2% of all malignant human tumors*. When the tumor is localized, radical 
nephrectomy can be the effective method to cure the patient25,32. However, 
approximately 30 % of the patients with renal carcinoma have clinically manifest 
metastases at the time of diagnosis-72 and the prognosis for metastatic RCC is poor. 
The ñve-year survival rate for patients with advanced RCC is less than 15% and the 
mean survival time is 1-2 years. 
Clearly, systemic therapy is necessary in cases of advanced RCC. Chemotherapy, 
however, has proven to have limited efficacy and due to this lack of effective 
systemic treatments, new methods have been pursued and various forms of hormone 
therapy27 or immunological treatment, whether or not combined with chemo- or 
radiotherapy^'*'*™ have been tested in clinical trials and or in animal model 
systems during the last few decades^. 
The immunological defense mechanism can be stimulated by means of specific 
modulations of the immune system which can be divided into active, passive and 
adoptive methods ' . In the active method, the patient's own production of 
antibodies is stimulated, as well as, the cellular immunity. The immune defence 
hereby can be stimulated nonspecifically using e.g. Bacillus Calmene Guérin 
(BCG) , Coiynebacterium parvum or cytokines. In the passive method, 
antibodies are injected into the patient. In the adoptive method, immunocytes are 
specifically stimulated in vitro and reintroduced into the patient^5 '^ '2^5 ,50 . Specific 
and nonspecific methods can also be combined and used simultaneously52. 
Interest in biologic approaches to the treatment of RCC has been fostered by the 
identification of unique antigens on the surface of some RCCr and by observations 
of spontaneous regression of tumor metastases'-^. The observations suggest that 
host factors may be capable of modifying the course of RCCr*. 
Although the mechanisms of Biological Response Modifiers (BRM's) are not yet 
well understood, the possibility that cytokines such as Interferons (IFN's) and Tumor 
Necrosis Factor (TNF) might augment a host immune response against RCC, 
provided a rationale for early clinical trials. Even though the clinical responses vary 
considerably (10-50%)9'21,23,33,35,41,47,54
 i t j s e v j d e n t t j , a t cytokine therapy is effective 
in approximately 15% op the patients with metastasized RCC. 
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The importance of dosage, administration route and tumor load at start of therapy 
have not been evaluated extensively in a preclinical setting. Such insight might lead 
to more optimal treatment regimens. 
Transplantation of human RCC into athymic nude mice provides an experimental 
moder**** in which therapeutic regimens using BRM's may be tested^*'"'4. The T-
cell deficient nude mouse model system, however, does not allow us to study the 
indirect T-cell mediated antitumor effects. Nevertheless, direct effects of BRM's 
against tumor cells as well as macrophage and NK-cell mobilization can be studied 
in this in vivo model systeτπ,^I0'29. 
In this study we tested the effects of recombinant human IFN-alpha, recombinant 
human IFN-gamma, recombinant human TNF-alpha and their combinations on RCC 
xenografts growing in nude mice taking previous in vitro studies as a lead^7. 
Different treatment protocols were tested and the role of tumor volume at start of 
therapy was evaluated. 
MATERIAL AND METHODS 
Mice 
Six weeks old male and female BalbC nu/nu mice (Bomholtgârd, Ry, Denmark) 
were used for these experiments. The animals were adjusted to the experimental 
environment for two weeks before entering into the experiments. Groups of five 
male or female mice were kept in PAG type 2 cages covered with an iso cap (Iffa 
Credo, France) for sterile conditions. Sterilized sawdust (Iffa Credo Broekman b.v., 
The Netherlands) was used as bedding material inside the cages. The mice were fed 
ad libitum with gamma irradiated (0.9 MR) SRM-A MM food (Hope Farms, 
Woerden, The Netherlands) and drinking water was acidified with 0.7 ml 
concentrated HC1/I. Day-night rhythm was 12 hours light, 12 hours dark and the 
temperature was 220C. Humidity in the experimental environment was unregulated. 
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Renal Cell Carcinoma Xenografts 
Eight different renal tumor xenografts were used for these studies. NC-65 tumor*8 
was kindly provided by Dr. Romijn from the Department of Urology, Erasmus 
University, Rotterdam, The Netherlands. Seven NU tumors (NU-1, -3, -5, -10, -12, 
-20 and -22) were established from primary tumors by serial subcutaneous (s.c.) 
transplantation (Beniers et al., 1990; submitted for publication). Tumor stage of the 
primary tumors varied between T2 and T4 for the different lines. For the in vivo 
treatment protocols we used the third to tenth transplant generation for the NU-
10, -12, -20 and -22 lines and generations 20 to 30 for the NC-65 and NU-1, -3 
and -5 lines. Tumors were passaged at intervals of 6 weeks for the NU-10, NU-12, 
NU-20 and NU-22 lines and four weeks for the other lines. 
Biological Response Modifiers 
Human IFN-alpha, IFN-gamma and TNF-alpha, kindly supplied by Boehringer 
Ingelheim, Alkmaar, Netherlands, were produced in Escherichia coli by recombinant 
DNA technology. The specific activity of IFN-alpha and IFN-gamma was 3.2xl0E8 
units/mg protein and 2xl0E7 units/mg respectively. It was measured by inhibition of 
encephalomyocarditis (EMC) virus replication in A549 cells (human lung myeloma 
cell line) with reference to the National Institute of Health (NIH) leucocyte IFN-
alpha standard Go 23-901-527 and the NIH IFN-gamma standard Gg 23-901-530. 
The purity of both IFN's was > 98% as determined by SDS Polyacrylamide gel 
electrophoresis and the amount of endotoxin was less than 1.0 ng/mg protein for 
IFN-alpha and less or equal to 0.5 ng/mg protein for IFN-gamma as based on the 
limulus amoebocyte lysate assay. The specific activity of TNF-alpha determined in 
the presence of actinomycine-D was 6xlOE7 units/mg protein (the L-929 cytotoxicity 
assay). The purity was > 99% as determined by SDS Polyacrylamide gel 
electrophoresis and it contained 1.0 ng or less endotoxin/mg protein based on the 
limulus ameubocyte lysate assay. The drugs were dissolved in the accessory 
dissolvent and diluted with unsupplemented RPMI medium (Gibco, Paisley, UK). 
After dilution, the drugs were stored in 1.2 ml aliquotes at -SœC until use. 
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Τη vivo drug testing 
Each test group consisted of 5 mice. Male and female mice were used for these 
tests because experiments showed that growth characteristics in control and 
treatment groups were the same for male and female mice (data not shown). Six 
weeks old mice were implanted s.c. with tumor pieces of 1-2 mm cubes in the right 
flank. After careful removal of internal necrosis, tumor pieces were cut from s.c. 
growing tumors which were passaged every 4 to 6 weeks depending on tumor. 
Treatment groups were randomized before start of therapy and treatment started 
when tumors had grown to a volume of about 65 cubic mm (10-14 days after 
implantation), or 24-48 hours after implantation of the tumor pieces. The animals 
were treated intrapentoneally, intravenously (tail vein) or subcutaneously pentumoral 
three to five times a week during six weeks. Each application was in a total volume 
of 200 μΐ. Interferons were applied three times a week and TNF was applied three 
or five times a week. When the animals received both IFN's or IFN + TNF, this 
combination was given in a single injection. Control mice were treated with 
unsupplemented RPMI medium three times a week. Treatment protocols and doses 
of each BRM were determined from the results of preceding experiments and 
starting point was a combination of alpha-IFN 5ng/g body weight + TNF 50ng/g 
body weight which gave complete inhibition of colony formation in a soft agar 
colony forming assay of the different xenograft lines and which was one of the 
results of preceding in vitro studies with these tumor lines67. For determination of 
this starting point we presumed that 1 ml in the in vitro studies equalled lg body 
weight in the animal model system. 
Each tumor was measured twice a week with a sliding caliper in three dimensions: 
maximum diameter (L), diameter at right angles to the length (W) and thickness 
(H). The volume of the tumors expressed as the Tumor Size Index (T.S.I.) was 
calculated by the following equation: 
T.S.I. = LxWxH/2 
Each experiment was performed in duplo. 
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Statistical analyses 
T.S.I. values on the fourtieth day of the experiments were estimated for each 
individual mouse by linear regression on the cube roots of all T.S.I. measurements 
in the first 40 days of the treatment period. Since these results showed strong non-
normality, the (non-parametric) test of Kruskal-Wallis was applied to these values 
for statistical analysis. Ρ values less than 0.05 were considered to denote significancy. 
Additivity and synergism are defined as follows: 
A combination treatment is considered additive if the result of the combination is 
significantly better than each of the single treatments. A combination treatment is 
considered synergistic if, in addition, the treatment effect of the combination exceeds 
the products of the effects of the single treatments. More precisely, if the product of 
the medians of the combination and control group is less than the product of the 
best results (i.e. minimal T.S.I.) in each of the single treatment groups. 
RESULTS 
For reasons of feasibility and efficacy we took one RCC xenograft to study the 
effects of alpha-IFN, gamma-IFN and TNF on s.c. tumor growth in a wide range of 
single and combination tests. Also the influence of administration route was 
evaluated for this tumor. The NC-65 was chosen because pilot studies with this line 
had shown an intermediate sensitivity towards the tested cytokines. 
Effect of the IFN concentration on tumor growth inhibition. 
To determine the most effective concentrations of alpha- and gamma-IFN we 
performed a series of experiments in which the IFN concentration was varied. 
Subcutaneous (s.c.) peritumoral treatment started 24-48 hours after implantation of 
1-2 cubic mm tumor pieces. NC-65 tumor bearing animals were treated with three 
different concentrations of IFN, either alone or in combination with 50 ng/g TNF 
(i.e. 3000 U TNF-alpha). IFN concentrations used were 25, 5 and 0.5 ng/g for 
alpha-IFN and 400, 80 and 8 ng/g for gamma-IFN (i.e. 7500, 1500 and 150 U/g for 
both IFN's). 
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Figure 1: 
Effect of alpha-IFN (A) and a combination of alpha-IFN and TNF (В) on s.c. growth of the NC-65 
renal tumor. The BRM's were applied three times a week s.c. peritumoral. Treatment started 24 
hours after s.c implantation of 1-2 mm tumor cubes in the right flank. 
A: growth control (treatment 1); alpha-IFN 0.5 ng/g (p= 0.01) (treatment 2); alpha-IFN 5 ng/g (p= 
0.30) (treatment 3); alpha-IFN 25 ng/g (p= 0.21) (treatment 4). (Kruskal-Wallis: ρ < 0.06) 
В: growth control (treatment 1); alpha-IFN 0.5 ng/g, TNF 50 ng/g (p= 0.01) (treatment 2); alpha 
IFN 5 ng/g, TNF 50 ng/g (p= 0.06) (treatment 3); alpha IFN 25 ng/g, TNF 50 ng/g (p= 1.00) 
(treatment 4). (Kruskal-Wallis: ρ < 0.01). 
For the sake of clearness, ranges have not been indicated in this Figure. Minimum and maximum 
values are given in Tabic 1 with reference to the different treatments. 
Figure 1A in which the effect of the alpha-IFN concentration on s.c. growth of the 
NC-65 tumor is depicted, shows that the alpha-IFN concentrations of 25 and 5 ng/g 
have no antitumor effect. A concentration of 0.5 ng/g, however, shows a, statistically 
significant, anti-tumor effect as compared to the growth control (p= 0.01). Further 
decrease of the dose resulted in a poorer antitumor effect (data not shown). When 
TNF was combined with alpha-IFN, and the alpha-IFN concentration was varied, 
comparable bell shaped dose response curves were found. Figure 2A and В which 
give the results of similar experiments, performed with gamma-IFN, show that like 
alpha-IFN, bell shaped dose response curves were found. Both 80- and 8 ng/g doses 
resulted in statistically significant inhibition of tumor growth (p= 0.01) in which the 
lower concentration resulted in the best antitumor effect. Again in combination with 
TNF the same optimum dose for antitumor efficacy for gamma-IFN was evident. 
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Figure 2: 
Effect of gamma-IFN (A) and a combination of gamma-IFN and TNF (В) on s.c growth of the NC­
OS renal tumor. The BRM's were applied three times a week s.c. peritumoral. Treatment started 24 
hours after s.c implantation of 1-2 mm tumor cubes in the right flank. 
A: growth control (treatment 1); gamma-IFN 8.0 ng/g (p= 0.01) (treatment 2); gamma IFN 80 ng/g 
(p= 0.04) (treatment 3); gamma-IFN 400 ng/g (p= 0.21) (treatment 4). (Kmskal-Wallis: ρ < 0.01). 
В: growth control (treatment 1); gamma-IFN 8.0 ng/g, TNF 50 ng/g (p= 0.01) (treatment 2); 
gamma IFN 80 ng/g, TNF 50 ng/g (p= 0.02) (treatment 3); gamma IFN 400 ng/g, TNF 50 ng/g (p= 
0.09) (treatment 4). (Kmskal-Wallis: ρ < 0.01) 
For the sake of clearness, ranges have not been indicated in this Figure. Minimum and maximum 
values are given in Table 1 with reference to the different treatments. 
Effect of Tumor Necrosis Factor concentration and dosage scheme on tumor growth 
inhibition. 
In order to determine the concentration and dosage scheme of TNF resulting in the 
best antiproliferative effect we varied concentration and dosage schedule of TNF. 
Figure 3 shows the results of an experiment in which the antitumor effects of TNF 
(50 and 500 ng/g) in combination with optimal alpha- and gamma-IFN 
concentrations (see previous section; 0.5 and 8.0 ng/g respectively) on the NC-65 
tumor were tested. Both IFN's as well as TNF were applied three times a week s.c. 
peritumorally. Unlike the typical bell shaped dose response curves of the IFN's, the 
antitumor effect of TNF was dose dependent (Fig. 3). TNF concentrations of 250 
ng/g gave intermediate tumor growth inhibition and TNF concentrations of 25 ng/g 
gave lower tumor growth inhibition than the concentration of 50 ng/g (data not 
shown). 
Because no complete tumor growth inhibition could be effectuated with IFN/TNF 
combinations when both drugs were applied three times a week, we varied TNF 
dosage schedules. 
Figure 4 shows an example of an experiment with the NC-65 tumor in which the 
IFN's were applied three times a week and in which the TNF was administered five 
times a week. Treatment started 24-48 hours after s.c. tumor implantation and the 
first treatment always consisted of both BRM's which were applied in a single 
injection. Application of TNF five times a week resulted in significantly better 
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о 10 20 30 40 
DAYS 
Figure 3: 
Effect of TNF concentration in combination with alpha- or gamma-IFN on s.c growth of the NC-6S 
renal tumor. The BRM's were applied three times a week s.c. peritumoral. Treatment started 24 
hours after s.c implantation of 1-2 mm tumor cubes in the right flank. Growth control (treatment 
1); alpha-IFN 0.5 ng/g, TNF 50 ng/g (p= 0.01) (treatment 2); gamma-IFN 8.0 ng/g, TNF 50 ng/g 
(p= 0.01) (treatment 3); alpha-IFN 0.5 ng/g, TNF 500 ng/g (p= 0.01) (treatment 4); gamma-IFN 8.0 
ng/g, TNF 500 ng/g (p= 0.01) (treatment 5). (Kruskal-Wallis: ρ < 0.001). 
For the sake of clearness, ranges have not been indicated in this Figure. Minimum and maximum 
values are given in Table 1 with reference to the different treatments. 
antitumor effects as compared to a treatment in which the TNF was applied three 
times a week (Fig. 4). The combination of alpha-IFN 0.5 ng/g applied three times a 
week with 500 ng/g TNF applied five times a week resulted in a complete inhibition 
of tumor development. The mice were kept alive for eight months after treatment 
and no tumor growth could be detected by that time. 
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Figure 4: 
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Figure 4: Effect of TNF dosage scheme in combination with fixed alpha- and gamma-IFN doses on 
s.c. growth of the NC-65 renal tumor. The IFN's were applied three limes a week and TNF was 
applied three or five times a week. Treatment started 24 hours after implantation of 1-2 mm tumor 
cubes and the BRM's were applied s.c. peritumoral. Growth control (treatment 1); gamma-IFN 8.0 
ng/g, TNF 500 ng/g (3x/week) (p= 0.01) (treatment 2); alpha-lFN 0.5 ng/g, TNF 500 ng/g (ЗхЛ еек) 
(p= 0.01) (treatment 3); alpha-IFN 0.5 ng/g, TNF 500 ng/g (5x/week) (p= 0.01) (treatment 4); 
gamma-IFN 8.0 ng/g, TNF 500 ng/g (5x/wcck) (p= 0.01) (treatment 5). (Kruskal-Wallis: ρ < 0.0001). 
For the sake of clearness, ranges have not been indicated in this Figure. Minimum and maximum 
values are given in Tabic 1 with reference to the different treatments 
Effect of route of administration on growth inhibition by alpha-IFN. gamma-IFN. 
TNF and their combinations. 
Experiments with the NC-65 tumor in which the IFN's and TNF were applied 
intraperitoneally or intravenously showed no significant antitumor effects on the s.c. 
growing tumor. Intravenous application even resulted in a slight stimulation of tumor 
growth. 
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TABLE 1: 
Figure 
IA 
IB 
2A 
2B 
3 
4 
treatment 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
median 
2040 
1190 
1590 
1670 
2250 
850 
1410 
1950 
2040 
750 
1630 
1700 
2250 
690 
1170 
1610 
2040 
780 
760 
190 
510 
1810 
670 
590 
0 
300 
minimum 
1660 
860 
0 
0 
1510 
0 
1280 
1570 
1660 
0 
0 
1530 
1510 
0 
950 
1380 
1660 
580 
580 
0 
470 
1520 
610 
380 
0 
200 
maximum 
2560 
1390 
2450 
2140 
2650 
1200 
2150 
2690 
2560 
1200 
1980 
2260 
2650 
850 
1950 
2230 
2560 
1380 
930 
280 
740 
2030 
920 
640 
0 
350 
Table 1: 
Median and range of the fitted values on day 40 belonging to the different treatment groups in 
Figures 1-4. 
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Effects of alpha-IFN. pamma-IFN. TNF and their combinations on s.c. tumor growth 
of eight different RCC xenografts. 
From the results with the NC-65 tumor we have chosen 10 treatment regimens (i.e. 
5 mono therapies and 5 combination therapies) in order to evaluate the effects in a 
set of 8 human RCC xenografts. All experiments were performed as described in 
the previous sections. The results are summarized in Table 2. The IFN's were 
applied three times a week and TNF was applied five times a week. Treatment 
started 24-48 hours after tumor implantation. 
The growth of the NU-1 tumor, a fast growing tumor, (i.e. tumor doubling time of 4 
days) cannot be inhibited completely by any of the tested combinations. The 
combination of alpha-IFN 5 ng/g + TNF 500 ng/g results in strongest inhibition of 
tumor growth with 5% growth as compared to the control group. Unlike the NC-65 
tumor, the higher concentration of alpha-IFN is more active than the lower 
concentration both in single as in combination tests. Gamma-IFN, however, shows 
no statistically significant different anti-tumor effects between the 8.0 and 80 ng/g 
treatment groups, both in single tests as in combination with TNF. 
The NU-3 tumor appears to be one of the least sensitive tumors with maximum 
anti-tumor effects of the gamma-IFN 8.0 ng/g + TNF 500 ng/g combination 
resulting in 11% growth as compared to the control group. This tumor is most 
sensitive for gamma-IFN and although there is no difference in anti-tumor activity 
between the gamma-IFN 8.0 and 80.0 ng/g treatment groups, the combination with 
TNF results in differences in anti-tumor activity between the two gamma-IFN doses 
in which the low gamma-IFN concentration shows highest anti-tumor effects. 
Development of the NU-5 tumor is completely inhibited by a combination of 5.0 
ng/g alpha-IFN applied three times a week + 500 ng/g TNF applied five times a 
week. Percentage growth after therapy is lower after treatment with the high IFN 
doses tested. This concerns both alpha- and gamma-IFN, applied in single or in 
combination therapy with TNF, suggesting a different optimum IFN concentration 
for this tumor. 
The NU-10 tumor is very sensitive for the IFN combinations with TNF. All tested 
combinations with TNF resulted in a complete inhibition of tumor development. No 
difference in anti-tumor effect was found between the 0.5 ng/g and 5.0 ng/g alpha-
IFN test groups and also this tumor appears to be more sensitive for a gamma-IFN 
concentration of 8.0 ng/g than for the 80.0 ng/g concentration. 
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A 5.0 ng/g alpha-IFN therapy already results in a complete inhibition of NU-12 
tumor development. This tumor appears to be moderately sensitive for the TNF 500 
ng/g monotherapy but the combinations of 5.0 ng/g alpha-IFN (as expected 
according to the effect of the mono therapy with 5.0 ng/g alpha-IFN) and 80.0 ng/g 
gamma-IFN with TNF both resulted in complete inhibition of tumor development. 
As with the NU-5 tumor the highest of both tested alpha- and gamma-IFN 
combinations gave best results with regard to tumor growth inhibition. 
Like the NU-3 tumor the NU-20 tumor shows to be rather insensitive for the 
cytokines. Optimum dose for alpha-IFN will be higher than 0.5 ng/g because the 
higher dose whether or not tested in combination with TNF resulted in reduced 
tumor growth as compared to the low dose tested. Also this tumor shows to be 
more sensitive for the lower tested gamma-IFN dose. Although no difference in 
sensitivity between the tested doses in the monotherapy experiments were measured, 
the differences in the combinations with TNF were much more pronounced. 
Development of the NU-22 tumor is also inhibited more pronounced by s.c. 
peritumoral treatment with 5.0 ng/g alpha-IFN than with 0.5 ng/g. Treatment of this 
tumor with 0.5 ng/g alpha-IFN results in 31% growth as compared to the growth 
control whereas treatment with 5.0 ng/g alpha-IFN results in only 17% growth, so 
optimal alpha-IFN concentration does not lay within the very low dose range. The 
combination of 5.0 ng/g alpha-IFN + 500 ng/g TNF results in complete inhibition of 
tumor development. Gamma-IFN shows to be less active against this tumor and no 
significant difference in antiproliferative action is measured between the two gamma-
IFN doses tested neither alone nor in combination with TNF. 
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Table 2: 
treatment NC-65 NU-1 NU-3 NU-5 NU-10 NU-12 NU-20 NU-22 
% growth% growth% growth% growth% growth% growth% growth% growth 
control 
alpha-IFN 0.5 
alpha-IFN 5.0 
gamma-IFN 8.0 
gamma-IFN 80.0 
TNF 500 
alpha-IFN 0.5/gamma-IFN 8.0 
alpha-IFN 0.5/ΓΝΡ 500 
alpha-IFN 5,0/TNF 500 
gamma-IFN 8.0/TNF 500 
gamma-IFN 80.0/TNF 500 
100 
74 
96 
61 
80 
60 
45 
0 
12 
19 
21 
100 
98 
51 
61 
62 
38 
46 
30 
5 
19 
21 
100 
64 
75 
58 
57 
56 
34 
24 
31 
11 
24 
100 
98 
39 
93 
85 
28 
67 
7 
0 
13 
9 
100 
63 
63 
37 
46 
30 
21 
0 
0 
0 
0 
100 
28 
0 
34 
21 
50 
10 
5 
0 
13 
0 
100 
76 
69 
79 
81 
65 
61 
28 
16 
22 
31 
100 
31 
17 
63 
70 
23 
21 
5 
0 
11 
13 
Table 2: 
Effects of alpha-IFN, gamma-IFN, TNF and their combinations on s.c tumor growth of eight 
different RCC xenografts. The IFN's were applied three times a week and TNF was applied five 
times a week. Treatment started 24 hours after implantation of 1-2 mm tumor cubes and the BRM's 
were applied s.c. peritumoral. 
BRM concentrations are given in ng/g. Combinations were given in one single injection. Ρ values for 
the different tumors were 0.01 for all combination treatments except for the alpha/gamma-lFN 
combination on the NU-5 tumor (p= 0.14). (Kruskal-Wallis: ρ values are < 0.0001 for each 
xenograft) 
Effect of tumor volume on growth inhibition by combinations of alpha-IFN. gamma-
IFN and TNF. 
In order to establish the effects of tumor volume on efficacy of the treatment, s.c. 
growing tumors with T.S.I, values between 50 and 500 were treated with their 
optimum IFN/TNF combination. No growth inhibiting effects could be measured 
after starting treatment of tumors with T.S.I. = 500 and only reduced growth 
inhibiting effects were noticed after starting treatment of tumors with T.S.I, values 
between 50 and 100, which was tested on the NC-65, NU-1, NU-3, NU-10 and NU-
12 tumors. Treatment of tumors with their optimal combination (as indicated in 
Table 2) resulted in a five to ten-fold reduced growth inhibition when T.S.I, values 
of the tumors was 50-70. Treatment of tumors with T.S.I, values of 100 further 
reduced the growth inhibiting effects of the BRM combinations. Moreover, for the 
NC-65 tumor no antitumor effect was evident when BRM therapy was started at 
T.S.I, values of 100 (data not shown). 
DISCUSSION 
Patients with renal cell carcinoma usually present clinically at a late stage of disease 
progression, i.e. 30% have proven metastases at initial diagnosis. This fraction 
increases still further when one takes into account that follow up after nephrectomy 
of patients with clinically localized disease reveal a number of patients that 
apparently already had micrometastases at initial diagnosis. It is, therefore, evident 
that systemic therapeutic regimens are necessary for treatment of renal cell 
carcinoma patients. Whereas renal tumors are refractory to nearly all forms of 
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chemotherapy, immunotherapy has proven to be promising in the treatment of 
metastatic renal cell carcinoma. 
The use of cytokines like IFN's and TNF has been evaluated in this study. Even 
though clinical trials already established that these BRM's can be effective in the 
treatment of metastatic renal cell carcinoma, many questions remain unanswered, 
e.g. what is the optimal dosage, dosage scheme, administration route and, do these 
parameters have to be optimised for each individual patient. Qearly, such questions 
demand the use of animal model systems. 
We used human renal cell carcinoma tumors transplanted into nude mice, in which 
only the direct- and macrophage- and NK cell mediated effects of these cytokines 
can be evaluated. 
Experimental results presented in this paper show that the tumors exhibit 
differential sensitivities for the different BRM's. Depending on tumor, s.c. 
development of five tumors could be inhibited completely by different combinations 
of both IFN's with TNF. The s.c. development of only one tumor, the NU-12 tumor 
could be inhibited completely by alpha-IFN monotherapy. Subcutaneous growth of 
three of the tested tumors, however, could not be inhibited completely. 
For alpha-IFN usually the highest concentration was most effective. Five tumors 
(NU-1, -5, -12, -20 and -22) were inhibited more pronounced using 5.0 ng/g alpha-
IFN, whereas for two tumors (NC-65 and NU-3) the lower concentration was most 
effective. For the NU-10 tumor no difference in sensitivity was evident between the 
tested doses. Gamma-IFN, however, usually was effective at the lower concentration 
tested (8.0 ng/g). Growth of three tumors (NC-65, NU-10, NU-22) was inhibited 
stronger at the lower concentration whereas no significant difference was found for 
three other tumors (NU-1, NU-3 and NU-20). In combination with TNF, however, 
also the NU-3 and NU-20 tumors showed to be more sensitive for the lower 
gamma-IFN dose tested. For two tumors (NU-5 and NU-12), however, the highest 
gamma-IFN concentration whether or not in combination with TNF was most 
effective. 
The data suggest bell shaped dose response curves for gamma-IFN in the range 
tested. For alpha-IFN the same effect was seen in a minority of the cases. The 
antiproliferative effect of these drugs is clearly differential, i.e. in the eight tested 
xenograft lines the optimal doses, as determined under our experimental conditions, 
varied ten-fold. This indicates that there is an optimum IFN dose for each individual 
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tumor, which implies that parameters have to be evaluated that can be used to 
optimize treatment regimens. Perhaps serum beta2-microglobulin and neopterin are 
candidates as such2. 
The fact that lower doses of alpha- and or gamma-IFN can be more effective could 
be advantageous for clinical use, since high concentrations of Interferons can easily 
lead to immunosuppression16·42·". 
Combinations of the lowest tested doses of both Interferons showed additive effects 
on the NC-65, NU-5, NU-10, -12 and -22 tumors. Synergistic effects after treatment 
of a combination of both IFN's were never measured. Antitumor effects of 
combinations of alpha- or gamma-IFN with TNF, however, usually showed to be 
additive or synergistic (data not shown). 
The direct antiproliferative effect of TNF is dose dependent. Treatment schedule 
also affects the antiproliferative effects of TNF in which a treatment protocol of five 
times a week results in further tumor growth inhibition as compared to a protocol 
in which the TNF is applied three times a week. These effects of TNF are found in 
combination with alpha- or gamma-IFN or when TNF is used as mono-therapy, so 
these effects of TNF are not directly related to a combination with IFN. 
Tumor Necrosis Factor alpha has a dose response curve like most 
chemotherapeutical agents, i.e. the higher the dose the better the anti-tumor effect. 
Toxicity of TNF in clinical situations is a major problem and allows only low doses 
of TNF to be used in patients^5 '^*. When, taken into account the different 
area/volume ratio's , the dosage used to treat the nude mice is translated to the 
human situation, it appears that the tolerance of nude mice for human recTNF is at 
least ten-fold higher than the tolerance of humans to human recTNF. The treated 
mice did not show any signs of toxicity when the human ree. TNF was injected s.c. 
Whether the minor differences between the human and murine TNF 
molecules^40,50 can explain the dramatical reduction in toxicity without reducing 
the direct anti-tumor effects, remains speculative. The implications thereby, however, 
would be profound. 
Because combinations of TNF with the IFN's can have a synergistic antiproliferative 
effect, it is of greatest importance that the effect of TNF is enhanced by combining 
it with either alpha-IFN or gamma-IFN. Thus, complete growth inhibition could be 
provoked in most tested xenografts. Also, in the combinations the effect was 
differential for the eight xenograft lines tested. 
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The effect of tumor volume at start of therapy has been evaluated in 5 lines. It 
appeared that at higher tumor volumes, i.e. T.S.I. > 50, only partial growth 
inhibiting effects of the BRM's were evident. The clinical implication would be that 
cytokine treatment is only applicable to the group of patients with clinically localized 
disease, that have micrometastases. Patients at a relative high risk (T3) could be 
candidates for such adjuvant treatment regimens. However, to get rid of the primary 
tumor itself, radical nephrectomy remains the treatment of choice^2. 
Earlier clinical trials revealed that cytokine treatment can provoke tumor 
regression •', indicating that indirect effects, i.e. immune system mediated, can play 
a crucial role in the antitumor effect of such a treatment. Inclusion of these effects 
in animal model systems now seems to be possible by using SCID mice in which the 
human immune system can be partly reconstituted2^7. Thus, more insight could be 
gained in the complete spectrum of cytokine mediated antitumor effects and their 
usefulness can be studied to a greater extent. 
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SUMMARY 
We have investigated the antiproliferative activities of recombinant rat-gamma-
Interferon and recombinant human Tumor Necrosis Factor alpha in a rat renal cell 
carcinoma model system. The tumor was transplanted subcutaneously, the drugs were 
administered peritumorally. Gamma-Interferon treatment starting two days after tumor 
implantation resulted in a dose-dependent growth inhibiting effect. Tumor Necrosis 
Factor alpha was only effective at the highest concentration. Different combinations of 
the drugs have additive or synergistic antiproliferative effects. The combination of both 
highest doses completely inhibited tumor growth without any obvious toxic effects on 
the rats. Rechallenge of the cured rats with a tumor piece in the contralateral flank did 
not result in a tumor specific immune response. Shortening of the treatment period to 
two weeks resulted in an increased lag-period, but finally all tumors started to grow. 
Furthermore, the anti-tumor effect was dependent on tumor volume at start of therapy. 
Monotherapy could not inhibit tumor growth of an established tumor. The combination 
with both highest doses, however, inhibited tumor growth even when treatment was 
started at a tumor volume of 2-5 cm . 
Treatment with gamma-Interferon and Tumor Necrosis Factor is most effective at low 
tumor burden. These studies suggest that clinical application of these drugs is most 
effective in an adjuvant setting. 
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INTRODUCTION 
Advanced carcinoma of the kidney is refractory to nearly all forms of systemic therapy. 
Hormonal therapy can result in a small proportion (0-10%) of objective responses, but 
these are incomplete and of short duration. Single or combination chemotherapy also 
gives no clearly definable improvement in patient survival. 
Immunotherapy is a relatively new approach in cancer therapy. Biological Response 
Modifiers (BRMs) like Interferons, Tumor Necrosis Factor and Interleukins show 
promising results in experimental model systems and in Phase I and II clinical 
trials^ . The efficacy of Interferon (IFN) monotherapy in renal cell carcinoma (RCC) 
has recently been reviewed4 and is associated with clinical responses in approximately 
15% of patients. Combination therapy with Alpha- and Gamma-IFN can result in even 
higher response rates . Lymphocyte Activated Killer cells combined with Interleukin 2Ö 
and Tumor Infiltrating Lymphocytes also appear to be very promising 
immunotherapeutic options. 
Gamma-IFN is a product of activated T-lymphocytes and has pleiotropic effects*. For 
example, it can directly inhibit the growth of tumor cells in vitro, alter the expression 
of surface antigens and stimulate NK-cells and macrophages. 
Tumor Necrosis Factor alpha (TNF), originally identified as a substance produced by 
macrophages exposed to endotoxin, possesses a number of biological activities, 
particularly anti-tumor activity. TNF causes cytostasis or cytolysis of in vitro cell cultures 
from a variety of animal and human malignant tumors9. However, TNF can stimulate 
the in vitro growth of normal cells and induce procoagulant activity in endothelial cells 
and thrombus formation^ , which has been suggested as an indirect tumoricidal effect. 
In vitro studies on human renal cell xenografts showed that TNF has direct 
antiproliferative effects on RCC . Furthermore, in vivo studies using murine models, 
showed that TNF had anti-tumor effects at high d o s e s ^ 5 . 
Combinations of gamma-IFN and TNF can result in the enhancement of their 
respective anti-tumor activities^2"'5 thus providing an even more promising therapeutic 
approach, that up to now has not been tested for RCC in syngeneic model systems in 
vivo. Even though phase I and II trials indicate that TNF or gamma-IFN treatment is 
feasible , many questions regarding the mode of action (i.e. direct cytotoxic effect vs. 
indirect immune system mediated effects), the route of administration, treatment 
schedules and dosages remain hitherto unanswered. Therefore, more basic studies in 
experimental animals may provide guidelines for the optimal use of BRMs in humans. 
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In the studies described here, we tested the antiproliferative effects of gamma-IFN and 
TNF in a syngeneic tumor model system i.e. a spontaneously arisen rat renal cell 
carcinoma. Histologically and biochemically the tumor closely resembles human 
RCC16·17. 
Both the direct antiproliferative and immunomodulatory activities of gamma-IFN are 
species specific. Human gamma-IFN is active in human and not in syngeneic mouse 
systems and vice v e r s a i Therefore we have used rat-gamma-IFN in our rat renal cell 
tumor model system, this rat-gamma-IFN showed no antiviral activity with mouse or 
human cells, both sensitive to their homologous interferon, but rat cells could be 
protected against both vesicular stomatitis virus and vaccinia virus . In contrast to 
gamma-IFN, TNF shows little species specificity. Murine and human TNF are 79% 
homologous at the amino acid level and only the murine natural TNF is a 
glycoprotein20. The in vitro activities of murine and human TNF were compared, and 
only a very limited degree of species specificity was found . Also in vivo the species 
preference is not as pronounced as in the case with the interferons2^. Both murine and 
human TNF showed synergistic antiproliferative effects with murine gamma-IFN in a 
mouse model system . 
The importance of tumor volume at start of therapy was evaluated, and the 
implications of these findings for clinical use of these BRMs are discussed 
MATERIAL AND METHODS 
Animals 
Adult male Lewis rats (Charles River Wiga GmbH, Sulzfeld, FRG) were kept 3 rats 
per cage with a regimen of 12 hours light per day. The animals were allowed access 
to RMH-TM food (Hope Farms BV., Woerden, The Netherlands) and water ad 
libitum. 
Tumor Line 
The rat renal cell tumor line was kindly provided by Dr. R. Babayan, Boston, MA. The 
tumor was maintained by serial subcutaneous transplantation. For our experiments, the 
tumor was excised from a tumor-bearing animal, and after removal of normal and 
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necrotic tissue, the tumor tissue was cut into pieces of 50 mg (46-53 mg). The precise 
weight of each tumor piece was measured on preweighed sterile gauzes on a laboratory 
scale (Mettler). An 0.5 cm incision was made in the right flank of recipient animals, 
and after separating the subcutaneous tissue by blunt dissection, the tumor fragment 
was placed subcutaneously (s.c.) . The incision was closed using skin clips (7.5 χ 1.75 
mm, Aesculap, Germany). In this way a tumor take of 100% was achieved. The tumor 
did not metasta-size from this site. 
After complete removal of subcutaneous tumors of 2-3 cm·' together with overlying skin 
and subcutaneous fat, no tumors recurred. A direct rechallenge with 50 mg tumor 
pieces in the contralateral flank did not cause any changes in tumor take or growth 
rate in 14 untreated rats, suggesting that this tumor is not immunogenic. 
Drugs 
Recombinant human TNF alpha was kindly provided by Boehringer Ingelheim 
(Alkmaar, The Netherlands). The specific activity of TNF determined in the presence 
of Actinomycin D was 6 χ IO7 Units/mg protein as determined in the 1^ -929 cytotoxicity 
assay. The purity was >99% as determined by SDS Polyacrylamide gel electrophoresis 
and it contained less than 1.0 ng endotoxin per mg protein based on the limulus 
amoebocyte assay. The original TNF solution was diluted with RPMI 1640 culture 
medium (Gibco, Paisley, UK) to a final concentration of 2, 20, or 200 μg per ml, 
divided in aliquots and stored at -20° С 
Recombinant rat gamma-IFN was produced by a chinese hamster ovary (CHO) cell line 
transformed with a plasmid carrying the chromosomal gene for rat gamma-IFN and 
purified as described previously22. The cytopathic effect reduction assay was used for 
estimating gamma-IFN activity. Ratee cells (a continuous rat embryonic cell line) were 
incubated with gamma-IFN for 18 hours before they were challenged with vesicular 
stomatitis virus to determine the cytopathic effect. Because no internationally accepted 
reference standard for rat interferon is available, all titers were determined by 
comparison with a laboratory standard preparation of gamma-IFN (1 mg pure rat 
gamma-IFN corresponds with 7 χ 10o Units). After purification by monoclonal antibody 
affinity chromatography gamma-IFN was freeze-dried for longtime storage. It was 
reconstituted with Milli-Q to a final concentration of 16,000 or 160,000 Units per ml, 
divided in aliquots and stored at -80° С until use. 
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Treatments and monitoring 
Gamma-IFN and TNF were administered s.c, peritumorally, 3 and 5 times per week 
respectively, in a 0.5 ml injection volume. Phosphate buffered saline (PBS) was used 
for the control group. Treatment started two days after tumor implantation or at a 
tumor volume of 0.2-0.5, 1 or 2-5 спт* and was continued until the tumors in the 
control group reached a volume of 10 cm . However, in the experiments with shorter 
treatment periods, two weeks of treatment or a single administration was given. All 
experiments were carried out in duplicate. 
Tumor growth was followed by measurements of tumor size according to the method 
of Janik et al.2 3 by the same measurer throughout each experiment. Three times per 
week length (1), width (w) and height (h) were measured using a slide caliper. No 
correction was made for skin thickness. The tumor volume (V) was calculated from the 
formula 
V = 0.5236 χ 1 χ w χ h. 
Statistical analysis 
For each rat, the tumor volume was estimated 6 weeks after tumor implantation (i.e. 
time when control group reaches volume of 10 cm3) by loglinear regression on the 
tumor volumes throughout this period. Two-sided t-tests were used to compare the final 
volumes of the treatment versus the control groups and to test for additive effects in 
the combination treatments. Ρ < 0.05 is considered as statistically significant. 6 animals 
were included in each group. 
The effect of treatment A is defined as EA = V ^ ^ / V ^ and the effect of treatment 
В as EB = V'controifV'g, where ^, V^, and Vcon/ro/ are the estimates for the tumor 
volumes of treatment А, В or control group respectively. Additivity is defined2'' as 
EA+g = EA χ Eg (i.e. log ΕΑ+Β = log EA + log E^). A combination of two 
treatments is synergistic when the effect of the combination (Ε
Α+Β) is greater than the 
product of the effects of the separate treatments. 
RESULTS 
To study the in vivo anti-tumor effects of gamma-IFN and TNF, we used a 
spontaneously arisen, syngeneic transplantable rat renal cell tumor l i n e ^ 7 . 
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Single agent therapy. 
Pilot-studies in which we evaluated the influence of administration route on anti-tumor 
effect showed that i.p. and i.v. injected BRMs were less effective than s.c. injections. 
Similar observations were made in other rodent model systems28. Therefore, we injected 
gamma-IFN and TNF s.c, peritumorally, in the experiments described. 
Gamma-IFN monotherapy ( fig 1A) was started 2 days after tumor implantation. Under 
these conditions gamma-IFN has an antiproliferative effect whereby the highest dose 
results in the strongest growth inhibiting effect, suggesting a dose-dependent response 
(40,000 U gamma-IFN, s.c, 3 times per week gave intermediate effects, data not 
shown). 
Figure 1: 
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Figure 1: Effect of single agent therapy started 48 hours after tumor implantation. A: Gamma-IFN 
monotherapy administered s.c. peritumorally, 3 times per week. B: TNF monotherapy, s.c, peritumorally, 
S times a week. n.s. = not significant. 
When TNF was used as single agent only the highest dose (i.e. 100 μg TNF per rat per 
day) produced a significant anti-tumor effect (fig IB). 
In both series of experiments using single agent therapy it appeared that after 
termination of therapy, the tumor regained its original growth potential (i.e. same 
volume doubling time, data not shown). 
Combination therapy 
Reasoning that gamma-IFN and TNF can have additive or synergistic effects, we 
combined 8,000 or 80,000 U gamma-IFN with 10 or 100 ßg TNF (Fig. 2). The 
combination of 8,000 U gamma-IFN and 10 μg TNF had an additive growth inhibiting 
effect. A tenfold increase of the TNF dose did not improve the anti-tumor effect. 
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Figure 2: 
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Figure 2: Combination therapy with gamma-IFN and TNF, 3 times and 5 times per week respectively. 
Treatment started 48 hours after tumor implantation. IFNl = 8000 U; IFNh = 80.000 U; TNFm = 10 
Mg; TNFh = 100 μ& With the combination 80.000 U gamma-IFN and 100 /xg TNF no tumors developed 
at all. 
Combinations with the highest dose of gamma-IFN produced the best effects. In the 
group treated with the combination 80,000 U gamma-IFN and 10 /ig TNF, only 2 out 
of 6 rats developed a tumor (Table 1). 
Moreover, tumor growth started 35 days later than the control group (lag-period of 35 
days). Significantly, at this dose of 80,000 U gamma-IFN with a tenfold increase of the 
TNF concentration to 100 μ% no tumors developed at all. Both combinations have 
synergistic effects (p < 0.001). Because 200 days after tumor implantation no tumors 
were found, these rats were considered cured. 
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Table 1: 
Treatment Bodyweightc Bodyweight Increase'' Cure / 
ÏFN" TNF* day 0 day 42 
0 0 
8.000 0 
80.000 0 
0 1 
0 10 
0 100 
8.000 10 
8.000 100 
80.000 10 
80.000 100 
365 (28) 
359 (26) 
373 (20) 
375 (12) 
359 (14) 
356 (14) 
373 (27) 
352 (22) 
364 (21) 
352 (21) 
431 (33) 
414 (13) 
ND* 
431 (17) 
415 (17) 
415 (25) 
424 (34) 
420 (38) 
422 (24) 
414 (18) 
6 5 ( 8 ) 
5 5 ( 7 ) 
5 6 ( 7 ) 
5 6 ( 7 ) 
59 (15) 
5 1 ( 8 ) 
68(18) 
57 (12) 
58 (11) 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
4/6 
6/6 
Tabic I 
Effect of s.c. pcritumoral administration of recombinant rat-gamma-IFN and recombinant human Tumor 
Necrosis Factor alpha on bodyweight and number of cured male Lewis rats: data of a representative 
experiment. 
a
 units rat-gamma-IFN per rat, 3 times per week 
ь
 micrograms TNF per rat, 5 times per week 
c
 weight in grams, standard deviation in parentheses 
d
 weight increase in grams, standard deviation in parentheses 
e
 not determined 
f
 number of rats tumor free for more than 200 days/total number of rats per group 
Effect of duration of therapy 
Having found a drug combination that could prevent tumor formation completely, we 
sought to gain more insight regarding the administration scheme. Since in clinical 
trials^"* treatment is usually given intermittently for 1 or 2 weeks for reasons of toxicity, 
we tested the effectiveness on tumor growth of shorter periods of treatment. We, 
therefore, treated the animals with the optimal drug combination 80,000 U gamma-
IFN and 100 μg TNF for one day or for two weeks starting 48 hours after tumor 
implantation (fig. 3). A single administration of the combination already gave a clear 
growth inhibition. When treatment was continued for two weeks, tumors started to grow 
21-58 days later than the control group (lag-period). However, all rats developed a 
tumor. 
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Figure 3: 
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DAYS 
Figure 3: Effects of shorter duration of therapy with the optimal drug combination 80.000 U gamma-
IFN and 100 ßg TNF. Treatment started 48 hours after tumor implantation. A:= single treatment. B:= 
two weeks treatment. 
Treatment does not induce immunity 
To determine whether BRM therapy using the combination 80,000 U gamma-IFN and 
100 μg TNF can induce specific immunity, as observed by Palladino et al28, we 
rechallenged 6 cured rats with a subcutaneous tumor. 200 days after tumor implantation 
and subsequent treatment a new tumor piece of 50 mg was implanted in the 
contralateral (left) flank. All rats developed a tumor which started to grow without a 
lag-period and with a normal growth rate. 
The influence of tumor volume at start of therapy 
The first series of experiments revealed that gamma-IFN and TNF therapy can inhibit 
tumor growth completely. Whether this therapy is effective in provoking the regression 
of larger tumors was studied by starting therapy at different tumor volumes. 
Monotherapy started at a tumor volume of 0.2-0.5 cm3 had no effect on tumor growth 
(fig. 4A). 
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Figure 4: 
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Figure 4: The influence of tumor volume al start of therapy. Gamma-IFN 3 times and TNF 5 times per 
week, s.c, peritumorally. A: monotherapy started at tumor volume of 0.2-0.5 cm3. B: Combination 
therapy with combination of 80.000 U gamma-IFN and 10 μg TNF. С: Combination therapy with 
combination of 80.000 U gamma-IFN and 100 μg TNF", n.s. = not significant. (* note: treatment started 
at different tumor volumes, as indicated in the figures). 
The most effective BRM combinations as established in the low tumor load studies, 
were tested for their antiproliferative efficacy when treatment was started at higher 
tumor loads. The combination with 10 Mg TNF had no antiproliferative effects (fig. 4B). 
The combination with 100 μg TNF, however, slowed down tumor growth significantly 
(fig. 4C). Even when tumors reached a size of 2-5 cm3, growth rate could be inhibited 
almost completely. However, no regression of tumor size could be provoked. After 
completion of therapy all tumors started to grow again with the same volume doubling 
time. 
Side effects of therapy 
No obvious side effects were seen at any dose of gamma-IFN or TNF alone or in 
combination. No rats showed any signs of lethargy or wasting. At the end of the 
treatment period all rats were weighed and all groups had gained weight within the 
same range as shown in Table I. 
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DISCUSSION 
Chemotherapy and radiotherapy have limited therapeutic efficacy in advanced renal cell 
carcinoma. Therefore, new treatment modalities must be developed. Previous in vitro 
studies have shown that Biological Response Modifiers such as gamma-IFN and TNF 
have antiproliferative effects on renal cell carcinoma^. In the studies presented here, 
we investigated the antiproliferative effects of these BRMs in a non-immunogenic 
animal model system. 
Gamma-IFN monotherapy showed a better effect with increasing doses. These results 
suggest a dose-dependent relationship between gamma-IFN dose and tumor growth 
inhibition. Similar observations were made by Gressen with mouse alpha/beta-IFN in 
a syngeneic Friend Leukemia tumor model system. Talmadge^5, however, showed that 
50,000 U of mouse gamma-IFN 3 times per week was highly effective, whereas 100,000 
U of this IFN had no therapeutic effectivity, suggesting a bell-shaped dose-response 
curve, i.e. a dose-optimum. It cannot be excluded that higher doses of gamma-IFN in 
our model system will also have less efficacy on tumor growth. TNF monotherapy was 
only effective with the highest dose of 100 μg. This indicates that TNF monotherapy 
will have very limited clinical potential, which is already apparent from phase I trials-*. 
The combination of 8,000 U gamma-IFN and 10 or 100 μg TNF has additive effects, 
whereas combinations of 80,000 U gamma-IFN with 10 or 100 μg TNF have clearly 
synergistic antiproliferative effects (p<0.001). Animals in which no tumor growth was 
evident after 6 weeks of treatment, remained more than 200 days tumor free and were 
considered cured. In different rodent model systems, this combination has also been 
shown to be effective against other solid tumors, such as breast, bowel and lung 
carcinomas and melanomas72"^. 
Having found a drug combination that can prevent tumor formation completely after 
6 weeks of treatment, we shortened the treatment period in a separate experiment. A 
single administration of a combination of 80,000 U gamma-IFN and 100 ßg TNF 
resulted in a significant growth inhibition, but no lag-period was observed. Two weeks 
of treatment, however, prolonged the lag-period by at least 21 days. It is, therefore, 
conceivable that intermittent therapy, i.e. two weeks treatment, two weeks no treatment, 
can be sufficient for anti-tumor therapy. 
Palladino et al. found that TNF treatment of Meth A sarcoma bearing mice resulted 
in the establishment of a tumor specific immunity. Mice which had rejected a s.c. Meth 
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A sarcoma were immune to rechallenge with a lethal dose of this tumor 35 days after 
initial challenge. In contrast, specific immunity did not develop after alpha-IFN 
treatment of the intraperitoneally growing L1210 tumor2*. Similarly, no specific 
immunity was found in our model system. Rechallenge 200 days after initial tumor 
implantation had no influence on tumor take or growth rate. Under these experimental 
conditions no specific immune response was induced by gamma-IFN and TNF 
treatment which suggests that a direct anti-tumor mechanism and/or macrophage and 
NK cell mediated tumor cell lysis are responsible for the growth inhibition. However, 
it cannot be excluded that the cytokines can induce tumor associated antigens necessary 
for a specific immune response. Further studies are needed to elucidate the working 
mechanisms of these BRMs. 
In most clinical trials BRM treatment is started when the patient has proven 
(progressive) metastatic disease. The patient has a high tumor load even when a tumor 
nephrectomy has been performed. Therefore, we investigated the effect of gamma-IFN 
and TNF on higher tumor loads. Starting therapy 15 days after tumor implantation at 
a tumor volume of 0.2-0.5 cc, gamma-IFN or TNF monotherapies were not effective 
on even the smallest tumors. This is in good agreement with the limited efficacy of 
IFN monotherapy observed in clinical trials^4. 
The combination of 80,000 U gamma-IFN and 10 μg TNF, which was very effective 
when treatment was started 48 hours after tumor implantation did not inhibit tumor 
growth when started at higher tumor volumes, however the combination of the highest 
doses of gamma-IFN and TNF significantly slowed down tumor growth, but did not 
provoke tumor regressions. Similar observations of the influence of tumor volume at 
start of therapy were elegantly shown for experimental prostatic carcinoma . These 
experiments clearly demonstrated the need to carry out tumor debulking and adjuvant 
chemotherapy as early as possible in order to minimize the total tumor load and to 
maximize the possibility of cure. 
Pilot studies showed that peritumoral injections were more effective than i.p. or i.v. 
treatment in our model system. In clinical trials, however, treatment is usually given 
systemically unequivocally resulting in lower local drug levels. Reasoning that the 
smallest tumors were most sensitive to low BRM doses (fig. 2 compared with figs. 4A 
and 4B), we might argue that patients with RCC should be treated as early as possible, 
i.e. in the case of localized disease, starting with therapy immediately after 
nephrectomy. Due to the unpredictable clinical course of this disease a significant 
number of patients with stage I RCC would be overtreated which is clearly 
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unacceptable. In addition to this therapy it is, therefore, of major importance that new 
diagnostic tools are developed that help us to find patients with a poor prognosis (i.e. 
patients at risk). Awaiting these new diagnostic tools a randomized clinical trial could 
be started comparing surgery alone vs. surgery plus adjuvant IFN and TNF in patients 
with locally advanced RCC and/or with micrometastases in the regional lymphnodes 
(stage II and III). 
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ABSTRACT 
In this study we evaluated the usefulness of the histocompatibility leucocyte antigen 
(HLA) class-I and class-II expression on renal cell carcinoma (RCC) xenografts as 
predictive markers for response to cytokine therapy. Eight different RCC xenografts 
growing in BalbC nu/nu mice were treated with 0.5 or 5.0 ng/g recombinant human 
alpha- or gamma-Interferon (IFN), or 500 ng/g recombinant human Tumor Necrosis 
Factor (TNF). Modulation of HLA class-I, -II expression was evaluated 
immunohistochemically using the monoclonal antibodies W6.32 and B8.11.2 and at 
the mRNA level using the plasmids pDPOOl and DR alpha 120. HLA class-I 
expression in all lines was upregulated by alpha- and gamma-IFN and was highest in 
the high IFN dose treated tumors. TNF also stimulated HLA class-I expression and 
upregulated class-I expression still further when combined with IFN. Highest 
upregulation of HLA class-I in all tumors was measured in the alpha-IFN S.O/TNF 
500 ng/g treated mice although this was not necessarily the treatment regimen 
resulting in the most pronounced antitumor effect. Hence, maximum upregulation of 
class-I antigens at a given regimen was not always indicative for the highest 
achievable antitumor effect. HLA class-II expression which was present only on 
three of the untreated tumors was upregulated by both alpha- and gamma-IFN. 
TNF itself did not upregulate class-Π expression but enhanced the class-II 
expression on the alpha-IFN treated tumors but not on the gamma-IFN treated 
tumors. Class-I and class-II expression in the untreated xenografts were not related 
to sensitivity of the tumors for the direct effects of the cytokines, however, 
irrespective of the basal expression level, the inducibility of both HLA class-I and 
class-II antigens appear to be indicative for the direct sensitivity of renal tumor 
xenografts towards alpha-IFN, gamma-IFN and TNF. Since modulation of HLA 
antigens was studied in the nude mouse, no T-cell mediated effector mechanisms 
can explain the good correlation between inducibility and response. Nonetheless, our 
studies indicate that the extent of modulation of HLA class-I and -II can serve as 
predictive marker for response to cytokine therapy, which may serve as valuable 
criterium for inclusion of patients in cytokine treatment regimens. 
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INTRODUCTION 
In the management of metastatic renal cell carcinoma, cytokine therapy has proven 
to be effective in approximately 15% of the patients^"*. In the further 
implementation of this still experimental therapeutical modality, two questions are 
considered relevant i.e., how can the optimal cytokine treatment combination and 
dosage be determined and, are there markers predicting a response. Recent findings 
indicate that the optimal doses can vary for individual patients . Moreover, no 
insight in the best combination of cytokines is yet available. In the identification of 
patients that respond to immunotherapy, both host mediated effects as well as 
tumor cell characteristics should be considered. In this study special emphasis was 
given to the role of histocompatibility antigens as a predictor for response. These 
molecules play an important role in both the presentation of autologous and or 
heterologous antigens to the immune system and result in eventual binding and 
elimination. Furthermore, it has been recognized that these molecules can be 
induced by several cytokines6"*. In a previous study in which we studied the cytokine 
sensitivity of eight human RCC xenografts in a nude mouse model we found a 
variable response to the treatment with interferon-alpha, -gamma and TNF9. In the 
same model we evaluated the level of expression of HLA antigens and the 
modulation by cytokines. The nude mouse model will not permit conclusions 
regarding the functional role of these molecules in an eventual host mediated 
response induced by immunotherapy, however, the expression and inducibility of 
HLA class-I and class-II molecules can be correlated with the non-immune mediated 
anti-tumor response. 
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MATERIAL AND METHODS 
Renal Cell Carcinoma Xenografts 
The NC-65 renal tumor xenograft70 was kindly provided by Dr. J.C. Romijn from 
the Department of Urology, Erasmus University, Rotterdam, The Netherlands. All 
NU lines were established in our own laboratory^. After radical nephrectomy, 
viable tumor fragments were transplanted into nude mice and used for experiments 
between the third and thirtieth transplant generation in BalbC nu/nu mice. Tumor 
stage of the primary tumors varied between T2 and T4. 
Mice 
Six weeks old BalbC nu/nu mice (Bomholtgârd, Ry, Denmark) were used. Prior to 
the start of the experiments, the animals were adjusted to the experimental 
environment for two weeks. Groups of five male or female mice were kept in PAG 
type 2 cages covered with an iso cap (Iffa Credo, France) for sterile conditions. 
Sterilized sawdust (Iffa Credo Broekman b.v., The Netherlands) was used as bedding 
material inside the cages. The mice were fed ad libitum with gamma irradiated (0.9 
MR) SRM-A MM food (Hope Farms, Woerden, The Netherlands) and drinking 
water was acidified with 0.7 ml concentrated HC1/1. Day-night rhythm was 12 hours 
light, 12 hours dark and the temperature was 220С. Humidity in the experimental 
environment was unregulated. 
Cytokines 
Human IFN-alpha, IFN-gamma and TNF-alpha, kindly supplied by Boehringer 
Ingelheim, Alkmaar, The Netherlands, were produced in Escherichia coli by 
recombinant DNA technology. The specific activity of IFN-alpha and IFN-gamma 
was 3.2xl0E8 units/mg protein and 2xlOE7 units/mg respectively. It was measured by 
inhibition of encephalomyocarditis (EMC) virus replication in A549 cells (human 
lung myeloma cell line) with reference to the National Institute of Health (NIH) 
leucocyte IFN-alpha standard Go 23-901-527 and the NIH IFN-gamma standard Gg 
23-901-530. The purity of both IFN's was >98% as determined by SDS 
Polyacrylamide gel electrophoresis and the amount of endotoxin was less than 1.0 
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ng/mg protein for IFN-alpha and less or equal to 0.5 ng/mg protein for IFN-gamma 
as based on the limulus amoebocyte lysate assay. The specific activity of TNF-alpha 
determined in the presence of actinomycine-D was 6xlOE7 units/mg (the L-929 
cytotoxicity assay). The purity was > 99% as determined by SDS Polyacrylamide gel 
electrophoresis and it contained 1.0 ng or less endotoxin/mg protein based on the 
limulus amoebocyte assay. The cytokines were dissolved in the accessory dissolvent 
and diluted with unsupplemented RPMI medium (Gibco, Paisley, U.K.) After 
dilution, the drugs were stored in 1.2 ml aliquotes at -SO^C until use. 
Treatment of tumor bearing mice 
Each treatment group consisted of 5 mice. Both male and female mice were used 
because previous experiments showed no differences in growth characteristics. Six 
weeks old mice were subcutaneously implanted with tumor pieces of 1-2 mm in the 
right flank. After careful removal of internal necrosis, tumor pieces were cut from 
s.c. growing tumors which were passaged every 4 to 6 weeks depending on tumor. 
Treatment groups were randomized before start of therapy and treatment started 
when tumors had grown to a volume of about 65 cubic mm. (10-14 days after 
implantation), or 24-48 hours after implantation of the tumor pieces. The animals 
were treated subcutaneously peritumoral three or five times a week during six 
weeks. Each application was in a total volume of 200 μΐ. Interferons (150 or 1500 
U/g = 0.5 or 5.0 and 8.0 or 80.0 ng/g for alpha-IFN and gamma-IFN resp.) were 
applied three times a week and TNF (30,000 U/g = 500 ng/g) was applied three or 
five times a week. When the animals received both IFN's or IFN + TNF, this was 
given in a single injection. Control mice were treated with the unsupplemented 
RPMI three times a week. 
Tissue sampling 
Three to six hours after the last peritumoral injection, the mice were sacrificed by 
cervical dislocation of the spinal tract. The tumors were taken out and immediately 
snap frozen and stored in liquid nitrogen for immunohistochemical purposes or at 
-8(fC for mRNA expression studies of Northern analyses. 
135 
Immunohistochemistiy 
Four μιη thick cryostat sections of tumor tissue were stained by means of the direct 
immunopercoddase technique using 3-3'diaminobenzidine (DAB) and hydrogen 
peroxide as substrates. Monoclonal antibodies used were W.6.32 for HLA-A,B,C 
(Qass-I) expression (Barnstable et al., 1978) and B8.11.2 for HLA-DR (Qass-II) 
expression (Lemonnier et al., 1982). The direct labeled MoAb's were kindly 
provided by dr. G.N.P. van Muyen, dept. of Pathology, University Hospital of 
Nijmegen, The Netherlands. 
Evaluation of stained specimens 
The cryostat sections were evaluated by light microscopy (Zeiss Axiskop) and the 
staining of the tumor cells was graded using the following scale: - = no visible 
staining present, 1 = just visible staining, 2 = clear visible staining and 3 = strong 
staining. The percentage of tumor cells stained for HLA-A,B,C or HLA-DR was 
estimated within the following arbitrary ranges: - = 0%, 1 = 1-25%, 2 = 26-50%, 3 
= 51-75% and 4 = 76-100% positive tumor cells (Rubin et al., 1989) 
RNA isolation and Northern blot analyses. 
Total RNA from tumors was isolated using the lithium chloride/urea procedure as 
described by Auffray and Rougeon^. For Northern blot analyses ten micrograms of 
total RNA was glyoxylated, size fractioned on 1% agarose gels and transferred to 
Hybond-N+ nylon membrane (Amersham). Hybridization was carried out with the 
radioactively labelled plasmids pDPOOl and DR alpha 120 (American Type Culture 
Collection) containing the human genes for HLA-B7 (HLA Class-I) and HLA-
DRA1 (HLA-DR Class-II alpha chain) respectively75'76. 
Labelling of the probes was performed as described before77. 
Hybridization experiments were performed according to Church and Gilbert7*. 
Shortly, membranes were preincubated in hybridization buffer (7% SDS, 1% BSA, 
0.5M sodiumphosphate buffer pH= 7.4, ImM EDTA, 100 μg/ml salmon sperm 
DNA) for 1-4 hours at 650C. The radioactively labelled probe (2-5.10E8 dpm/ßg) 
was added to a maximum of 1.10E6 dpm/ml (2-5 ng probe/ml) and the membranes 
were hybridized overnight at 650C After hybridization the membranes were washed 
in buffers containing 1% SDS, ImM EDTA, and decreasing concentrations of 
sodiumphosphate buffer pH= 7.4; 0.5M, 0.25M and 0.1M. Each wash step was 
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performed at бЗ^С during 30 minutes. After autoradiography (Kodak X-omat AR 
diagnostic fílm) dehybridization of the membranes was performed as recommended 
by the manufacturer (0.1% SDS). 
Quantitation of autoradiographic data: Densitometry 
To quantitate the expression levels of HLA antigens in the different tumor lines, 
autoradiographs were scanned with an LKB Ultroscan XL enhanced laser 
densitometer connected with an Ultroscan XL 2000 integrator for integration of the 
data. Values of the untreated control groups were arbitrarily given the value 1. 
In order to make an accurate estimation of expression levels, controls are necessary 
to check both the quality as well as the quantity of the RNA sample loaded per 
lane. The first control was based on U.V. visualization. After RNA-transfer, the 
nylon membrane was examined on a UV-transilluminator (Chromato-Vue 
Transilluminator model TS-20, Ultraviolet Products Inc., San Gabriel, California). 
Without staining with ethidium bromide of neither gel nor membrane, the RNA can 
be visualized due to quenching of the intrinsic autofluorescence properties of the 
membrane (UV shadowing). When 10 ng of total RNA is loaded (based on OD260), 
the rRNA bands are clearly visible and give a good indication of the quantity and 
quality of the RNA. Furthermore, the rRNA bands were used for standardization. 
RESULTS 
The HLA class-I and class-II antigen expression of the untreated xenografts and the 
corresponding tumors after treatment with different cytokines and their combinations 
are given in Table 1A and IB respectively. Both the results of the 
immunohistochemical and the Northern analyses (shown in Figures ΙΑ,Β and 2A,B) 
are summarized in these Tables. Generally, the qualitative impression regarding 
HLA class-I and -II expression obtained by immunohistochemical studies, 
corroberated the semi-quantitative determination of the HLA class-I and -II 
expression by Northern analyses. Only in case of the immunohistochemical analyses 
of the class-II antigens, however, additional information was obtained by this 
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technique i.e. the fraction of positive cells increased. For the further interpretation 
of inducibility of these molecules we used the results of the Northern analyses which 
are graphically represented in Figure 3. 
HLA Class-I expression on untreated and cytokine treated renal tumor xenografts. 
Both the basal expression level, as well as, the extent of modulation after therapy 
varied considerably amongst the xenografts. A comparative analyses of the basal 
HLA class-I expression in the RCC xenografts revealed that two of the lines; NU-3 
and NU-20 showed a very low basal class-I expression whereas the NU-5 and NU-
22 lines show a very high basal class-I expression (Table 2). 
Upon cytokine treatment of NU-3 and NU-20 bearing mice, class-I expression was 
induced only to a minor extent (less than three fold, Figure 3, Table 1A). Highest 
modulation of class-I expression is seen in the alpha-IFN 5.0/TNF 500 ng/g treated 
groups with 2.5 and 2.7 times the expression of the untreated tumor for both tumors 
respectively (Table 1A). Except for the gamma-IFN 8.0 and 80.0 ng/g treated groups 
of the NU-20 tumor, higher class-I expression is found for the groups treated with 
the high IFN dose and, although the differences are very small, HLA class-I 
expression is higher in all groups treated with a combination of two cytokines than 
in the corresponding single cytokine treated groups. 
The NU-5 and NU-22 tumors show a remarkable high class-I expression in the 
untreated control groups (Table 2). The induction of expression upon treatment, 
however, is relatively low (Figure 3.). Densitometrie analyses show highest expression 
in the groups treated with a combination of alpha-IFN 5.0ÍTNF 500 ng/g in which 
the HLA class-I expression is 3.6 and 2.9 times the control level for both lines 
respectively (Table 1A). Upregulation is higher in the IFN/TNF treated groups than 
in the IFN treated groups and a rise in HLA class-I expression is dose dependent 
for IFN. Upregulation in the alpha-IFN 0.5/gamma-IFN 8.0 ng/g group is only a 
little higher than in the corresponding single cytokine treated groups. 
The other xenografts tested; NC-65, NU-1, NU-10 and NU-12, have an intermediate 
basal expression of HLA class-I. Inducibility of HLA class-I expression in NC-65 and 
NU-1 was absent or moderate in the single cytokine treated groups. All 
combinations of the IFN's with TNF result in a rise in class-I expression. Again, 
maximum modulation of expression in these tumors is measured in the alpha-IFN 
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S.OATNF 500 ng/g treated groups which is 3.8 and 4.7 times the control level 
respectively (Table 1A). Except for the single IFN treated groups of the NC-65 
tumor, upregulation of HLA class-I is also dependent on the IFN concentration. 
Differences in HLA class-I expression on the NU-10 and NU-12 tumor lines are 
pronounced and the Northern analyses clearly reveal the differences in class-I 
expression between the treated and the control groups of these tumors (Figure 2A). 
Highest modulation of class-I expression is again shown by the alpha-IFN S.OATNF 
500 ng/g treated groups which shows a 10-12 fold rise in the expression. All 
combination groups except for the alpha/gamma-IFN treated group of the NU-12 
tumor show higher class-I expression than the single cytokine treated groups. Also in 
these tumors, upregulation of class-I is higher in the groups treated with the high 
IFN dose than in the corresponding groups treated with the low IFN dose. 
HLA class-II expression in untreated and cytokine treated renal tumor xenografts. 
Five of the eight lines, i.e. the NC-65, NU-1, NU-3, NU-5, and NU-20 lines show no 
visible HLA Class-II expression, neither in the untreated controls nor in any of the 
cytokine treated groups (Table IB). Interestingly, in case of the NU-1 tumor, class-II 
expression appeared to be inducible to detectable levels by gamma-IFN. Since no 
expression was evident in the control group, inducibility was indicated by -+ and + 
(Table IB). 
Table 1A, IB: 
Relation between cytokine treatment and HLA class-I (Table 1A) and class-II (Table IB) expression 
on eight RCC xenografts growing subcutaneously in BalbC nu/nu mice. Cytokine concentrations are 
given in ng/g. I = immunohistochemical analyses. Staining of the tumor cells was performed with the 
MoAb's W6.32 (class-I) and B8.11.2 (class-II), and graded according to the following scale: - = no 
visible staining present, 1 = just visible staining, 2 = clear visible staining and 3 = strong staining 
(left figures). The percentage of tumor cells expressing HLA antigens (right figures) was estimated 
within the following ranges: - = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75% and 4 = 76-100% 
positive tumor cells. N = Northern analyses. Hybridization was carried out with the radioactively 
labelled plasmids pDPOOl (class-I) and DR alpha 120 (class-II). Figures of the Northern analyses 
represent the relative integrated optical densities for which the expression of the untreated control 
group was arbitrarily given the value 1. 
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TABLE IA 
NC-65 NIM NU-3 NU-5 NU-10 NU-12 NU-20 NU-22 
I N I N I N I N I N I N I N I N 
control 
alpha-IFN 0.5 
alpha-IFN 5.0 
gamma-IFN 8.0 
gamma-IFN 80.0 
alpha-IFN 0.5/gamma-IFN 8.0 
TNF 500 
alpha-IFN 0.5/TNF 500 
alpha-IFN 5.0/TNF 500 
gamma-IFN 8.0/TNF 500 
gamma-IFN 80.0/TNF 500 
i r * 
1;4 
1;4 
1;4 
1;4 
A»^ 
1;4 
2;4 
2;4 
2;4 
2;4 
1.0 
1.0 
1.0 
1.0 
1.0 
1.4 
1.1 
3.7 
3.8 
1.9 
23 
2;4 
2i4 
3;4 
2;4 
3;4 
2;4 
2;4 
3;4 
3;4 
3;4 
3;4 
1.0 
1.0 
3.5 
1.4 
3.8 
1.4 
1.8 
3.3 
4.7 
3.6 
4.2 
1;4 
1;4 
2;4 
1;4 
2;4 
2;4 
i;4 
2;4 
2;4 
2;4 
2;4 
1.0 
1.6 
1.8 
1.6 
1.7 
zo 
1.9 
2.1 
2.5 
1.6 
ZO 
2;4 
2;4 
3;4 
2;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
1.0 
1.0 
1.9 
1.0 
1.1 
1.4 
1.3 
1.1 
3.6 
1.7 
1.8 
2;4 
3;4 
3;4 
2;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
1.0 
5.3 
8.7 
2.5 
5.4 
7.2 
5.3 
7.2 
10.1 
5.4 
8.1 
2;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
3;4 
1.0 
6.8 
9.6 
3.0 
6.3 
6.6 
Z4 
7.1 
11.5 
5.6 
10.2 
1;4 
1;4 
1;4 
i;4 
i;4 
i;4 
i;4 
1;4 
2;4 
1;4 
i;4 
1.0 
1.5 
Z3 
1.4 
1.3 
1.8 
1.3 
1.8 
2.7 
1.5 
1.7 
Z4 
2;4 
Z4 
2;4 
2;4 
2;4 
2;4 
2;4 
3;4 
2;4 
Z4 
1.0 
1.2 
2.2 
1.0 
1.2 
1.6 
1.1 
1.4 
2.9 
1.1 
1.9 
TABLE IB 
control 
alpha-IFN 0.5 
alpha-IFN 5.0 
gamma-IFN 8.0 
gamma-IFN 80.0 
alpha-IFN 0.5/ganima-IFN 8.0 
TNF 500 
alpha-IFN 0.5/TNF 500 
alpha-IFN 5.0/TNF 500 
gamma-IFN 8.0ΛΤ4Ρ 500 
gamma-IFN 80.0/TNF 500 
NC-65 
I N 
. 
-
-
-
-
-
-
-
-
-
. 
NU-1 
I N 
. 
-
-
-+ 
+ 
-
-
-
-
-+ 
+ 
NU-3 
I N 
_ 
-
-
-
-
-
-
-
-
-
-
NU-5 
I N 
. 
NU-10 
I 
i;0 
i;2 
i;2 
i;2 
l;3 
2:2 
i;0 
i;3 
i;3 
i;i 
i;3 
N 
1.0 
4.0 
6.3 
1.9 
8.9 
6.4 
1.0 
7.9 
8.0 
1.8 
8.8 
NU-12 
I 
1;4 
i;4 
3;4 
1;4 
2;4 
2;4 
1;4 
l;4 
2;4 
1;4 
3;4 
N 
1.0 
1.1 
6.0 
2.2 
6.7 
Z7 
1.0 
1.5 
6.2 
zo 
6.8 
NU-20 
I N 
NU-22 
I N 
1;1 1.0 
1;1 1.0 
1;3 2.3 
Z3 Z4 
Z3 7.7 
1;1 1.5 
1;1 1.0 
1;1 1.0 
W Z8 
2;2 Z6 
Z3 7.6 
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Figure IA, IB 
Immunohistochemical analysis of HLA class-I (Fig. 1A) and HLA class-II (Fig. IB) antigens on RCC 
xenografts. Monoclonal antibodies used were W6.32 (class-I) and B8.11.2 (class-II) in a DAB 
peroxidase assay. 1) NU-10, 2) NU-12, 3) NU-20, 4) NU-22 
A = untreated control; В = alpha-IFN treated; С = gamma-IFN treated; D = TNF treated 
TABLE 2 
Tumor NC-65 NU-1 NU-3 NU-5 NU-10 NU-12 NU-20 NU-22 
R.I.O.D. 1.7 2.5 1.0 38.0 6.0 5.0 1.2 36.0 
Table 2: 
Relative integrated optical densities (R.I.O.D.) of basal HLA class-I expression of eight different 
RCC xenografts as measured on autoradiograms. For integration of the basal expression levels, the 
expression level of the NU-3 tumor (lowest basal class-I expression) was given the value 1. 
The NU-10 tumor shows a Class-II expression in the control group which can be 
strongly modulated by alpha- and gamma-IFN (Figure 3, Table IB). 
Immunohistochemical staining of the HLA Class-II antigens shows two different 
ways of modulation; 1) the percentage of positive tumor cells and 2) the intensity of 
the staining (Table IB). For this tumor the changes in the fraction of tumor cells 
positive for Class-II is most predominant. Intensity of staining increases only in the 
alpha/gamma-IFN combination treated group. TNF cannot modulate of HLA Class-
II expression on this tumor, however, for alpha-IFN the combinations with TNF 
show a more pronounced augmentation than the alpha-IFN treated groups. In 
combination with gamma-IFN, TNF does not give rise to an additional class-II 
expression. Augmentation of class-II expression is dose dependent in the range 
tested and most pronounced for the gamma-IFN treated groups (Figure 3, Table 
IB). 
Staining of HLA Class-II antigens in the untreated NU-12 tumor reveals that 
already 76-100% of the tumor cells express HLA Class-II antigens (Table IB). 
Treatment of this tumor with the different cytokines results in upregulation of Class-
II expression by all treatment modalities except for TNF and only a minor rise in 
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expression is noticed with the low alpha-IFN dose. Again, upregulation is dependent 
on the IFN dosage. Also in this tumor line, TNF has dual effects on Class-II 
expression. TNF has no effect on class-II expression whereas relative Class-II 
expression in the alpha-IFN treated groups is upregulated by TNF. No additional 
enhancement of Class-II expression by TNF, however, is found in the gamma-IFN 
combination treated groups. 
The untreated control group of the NU-22 tumor reveals a maximum of 25% of the 
tumor cells positive for HLA Class-II, and treatment results in a rise in the fraction 
of positive cells up to 75%, as well as, a rise in intensity of staining. As for the NU-
10 and NU-12 tumor lines, stimulation of Class-II is noticed for alpha-, as well as, 
for gamma-IFN and again, TNF has no effect on HLA Class-II expression on this 
line when tested as single cytokine. The alpha-IFN 5.0 ng/g treatment groups, 
however, show upregulation of HLA Class-II expression and although differences are 
small, TNF further enhances upregulation of Class-II by alpha-IFN. Also for this 
tumor, strongest modulation of Class-II expression is found in the groups treated 
with highest IFN doses. TNF has no effect on HLA Class-II expression of the 
gamma-IFN treated groups. Unless the NU-10 and NU-12 tumors, the combination 
of the low alpha- and gamma-IFN doses tested resulted in a lower HLA Class-II 
expression than in the gamma-IFN 8.0 ng/g treated group. 
Relation between the expression and inducibility of HLA antigens and sensitivity to 
cytokine therapy. 
Having found that HLA class-I and class-II antigens can be differentially modulated 
in vivo we evaluated whether basal expression levels and/or inducibility in general 
were related to cytokine sensitivity. Relative basal expression levels were quantified 
by Northern analyses (Table 2). Upon comparison with the sensitivity for cytokine 
treatment , it is evident that there is no good correlation between basal class-I 
expression and the sensitivity for cytokine treatment. Similarly, for class-II expression 
as far as present on the untreated tumors, no good relation was found between 
basal expression and sensitivity. 
We compared inducibility in general of both class-I and class-II HLA antigens with 
the sensitivity for the cytokines. On basis of qualitative (immunohistochemical) and 
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Figure 2A, 2B: 
Northern blot analyses of HLA class-I (Fig 2A) and HLA class-II (Fig 2B) expression on NU-10, 
NU-12, NU-20 and NU-22 tumors subcutaneously growing in BalbC nu/nu mice and treated with 
different combinations of cytokines. Hybridization was carried out with the radioactively labelled 
plasmids pDPOOl (class-I, Fig 2A) and DR alpha 120 (class-II, Fig 2B). Treatments were as follows: 
1= control; 2= alpha-IFN 0.5; 3= alpha-IFN 5.0; 4= gamma-IFN 8.0; 5= gamma-IFN 80.0; 6= 
alpha-IFN 0.5/gamma-IFN 8.0; 7= TNF 500; 8= alpha-IFN 0.5/TNF 500; 9= alpha-IFN 5.0/TNF 
500; 10= gamma-IFN 8.0/TNF 500; 11= gamma-IFN SO.OATiF 500. Concentrations are given in ng/g 
and the 28s rRNA bands on the same blots were used for standardization and correction. 
semi-quantitative (Northern) evaluation of HLA class-I and class-II modulation we 
defined modulation as L (low), M (moderate) and H (high) (Table 3) on basis of 
the following considerations: for the immunohistochemical level we took the 
minimum level found for that particular tumor irrespective of treatment modality 
and for the immunohistological modulation we differentiated between three different 
levels, in which L indicates no change in expression, M indicates a change and H 
indicates a pronounced change in visible expression. The relative minimum 
expression levels of the class-I Northern analyses as given in Table 2 are subdevided 
into the following categories: 1= expression of the NU-3 tumor, 2= 2-10 times this 
expression and 3= >10 times this expression. For class-II, 1= no expression; 2= no 
basal expression but inducible; 3= basal expression present. For the modulatory 
levels as revealed by Northern analyses we took the maximum inducibility level 
found and assigned three different levels of upregulation: L= < 3 times basal level; 
M= 3-6 times basal level and H= £ 6 times basal level. 
On basis of earlier studies9 we assigned three different levels of low, medium and 
high to the sensitivity of the lines for the direct effects of the cytokines, in which 
low was assigned to those lines in which none of the treatment modalities gave rise 
to less than 5% growth of the untreated control level; medium was assigned to 
those lines in which at least one of the treatments gave rise to less than 5% growth 
of control level, and high was assigned to those lines in which at least two of the 
treatments gave rise to a complete inhibition of tumor growth. Table 3 clearly 
reveals that, at least for the direct effects of the cytokines, there is a direct relation 
between sensitivity of the lines and the level of upregulation of both classes of 
antigens. Both sensitive tumors NU-10 and NU-12 show high upregulation of both 
class-I and class-II antigens whereas the insensitive tumors NU-3 and NU-20 show 
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Figure 3: 
Relative integrated optical densities on Northern blot autoradiograms of HLA class-I and class-II 
expression on eight different RCC xenografts subcutaneously growing in BalbC nu/nu mice treated 
with different combinations of cytokines. Treatments were as indicated in the legends of Figures 2A 
and 2B. 
only low upregulation of both class-I and class-II antigens. All other lines which 
show intermediate sensitivity for the cytokines also show intermediate upregulation 
of class-I and class-II antigens. Also, the NU-22 tumor shows low upregulation of 
class-I antigens but high upregulation of the class-II antigens and nevertheless, this 
tumor seems to be only intermediate sensitive for the direct effects of the cytokines. 
So, substantial upregulation of both class-I and class-II antigen is apparently 
indicative for a good response to cytokine treatment. Upregulation of either class-I 
or class-II correlates with a moderate sensitivity of that tumor line. 
DISCUSSION 
In this study we evaluated the usefulness of HLA class-I and class-II expression on 
renal cell carcinoma xenografts as predictive markers for response to cytokine 
therapy. Since expression of HLA class-I and class-II antigens is directly related to 
the functionality of CD8+ and CD4+ T-lymphocytes which play an important role 
in the defense mechanism of the body against alio- and abnormal auto-antigens, 
optimal modulation of the class-I and class-II antigens may be important in host 
reactivity against cancer cells. However, in the T-cell deficient nude mouse, T-cell 
mediated effector mechanisms cannot be studied. Hence, no functional relation 
between class-I and class-II modulation and cytokine induced antitumor effects can 
be established. Nevertheless, many authors have described HLA antigen modulation 
in \itTo7'8'19'23. Moreover, the nude mouse model is suitable to study modulation of 
HLA class-I and class-II antigens on human tumor cells by treating the mice with 
human cytokines2*'25. 
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TABLES 
tumor 
NC-65 
NU-1 
NU-3 
NU-5 
NU-10 
NU-12 
NU-20 
NU-22 
Class-I HIA expression 
immunohistology 
minimum modulation 
level 
northern 
minimum modulation 
level 
1;4 M 2 M 
2;4 M 2 M 
1;4 L 1 L 
2;4 M 3 M 
2;4 H 2 H 
2;4 H 2 H 
1;4 L I L 
2;4 L 3 L 
Class-II HLA expression 
immunohistology 
minimum modulation 
level 
northern 
minimum modulation 
level 
0;0 L I L 
0;0 L 2 M 
0;0 L I L 
0;0 L I L 
1;0 H 3 H 
1;4 H 3 H 
0;0 L I L 
1;1 H 3 H 
sensitivity 
M 
M 
L 
M 
H 
H 
L 
M 
Table 3: 
Relation between minimal HLA class-I and class-II expression levels on RCC xenografts, modulatory 
capacity of the HLA antigens by cytokines and the sensitivity of the xenografts towards these 
cytokines. The minimum immunohistological levels were scored as indicated in Table 1A and IB. In 
the immunohistological modulation, L indicates no change in expression, M indicates a change and 
H indicates a pronounced change in visible expression. The minimum expression levels for the class-I 
and class-II Northern analyses are; Class-I: 1= basal expression of the NU-3 tumor, 2= 2-10 times 
this expression and 3= > 10 times this expression. Class-II: 1= no expression; 2= no basal 
expression but inducible; 3= basal expression present. In the modulation as revealed by Northern 
analysis, L= < 3 times basal level; M= 3-6 times basal level and H= > 6 times basal level. In the 
sensitivity of the xenografts, L indicates that none of the treatment modalities gave rise to less than 
5% growth of the untreated control level, M indicates that at least one of the treatments gave rise 
to less than 5% growth of control level and H indicates that at least two of the treatment modalities 
gave rise to a complete inhibition of tumor growth. 
Figure 3 shows that all xenografts show upregulation of HLA class-I expression after 
treatment with alpha-IFN, gamma-IFN, TNF and/or their combinations. It also 
shows that considerable differences in the extent of modulation exist between the 
different tumors. In general, a dose response relation between upregulation of the 
HLA class-I antigens and IFN concentration (in the dose range tested) was evident. 
Comparing these results with the in vivo sensitivity of the tumors for the different 
cytokine treatments9 in which was found that some of the tumors showed higher 
growth inhibition when treated with the low IFN dose than with the high IFN dose, 
it becomes clear that the maximum rise in HLA class-I expression is not related to 
highest sensitivity of the xenografts at a given treatment regimen. 
Table IB shows that, as far as HLA class-II expression is detectable in the 
untreated control groups, and within the dose range tested, also HLA class-II 
upregulation is related to the alpha- and gamma-IFN concentration in a typical dose 
response relation. According to our present knowledge, this is the first time that 
upregulation of HLA class-II antigens after treatment with alpha-IFN is clearly 
demonstrated although, under certain circumstances, minor changes in net class-II 
expression after application of alpha-IFN were also found by Rosa et al. and 
Halloran et al.27 on (mouse) renal tissue. 
Induction of class-II antigens, also in a dose dependent way, was found after 
treatment with gamma-IFN in the NU-1 tumor. Induction of class-II expression by 
gamma-IFN is not uncommon and found by other authors añer treatment of 
different tumor types as /еП23,28'31. 
When we focus on the individual cytokines, it becomes clear that alpha-IFN has the 
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strongest effect on class I HLA antigen expression. Gamma-IFN and TNF also 
induce the expression of these molecules, albeit to a lesser extent. Noticeably, 
maximum induction of class I expression is always found for the combination of 
alpha-IFN 5.0Л№ 500. As mentioned before, this is not always the combination 
resulting in the highest achievable antitumor effect. Qass II expression is influenced 
most predominant by gamma-IFN. Alpha-IFN also has a clear effect on expression 
of these molecules, whereas TNF has no effect at all. In combinations of TNF with 
the interferons, however, a differential effect was observed. Whereas, TNF did not 
add to the effect when combined with gamma-IFN, it resulted in a stronger relative 
induction of class II expression when combined with alpha-IFN. Again, for the 
inducibility of class II expression, the highest achievable antitumor effect did not 
correlate with the maximum rise in expression of class II expression at a given 
treatment regimen. 
So, apparently the inducibility at a given dosage was not indicative for the 
corresponding antitumor effect. When we scored for inducibility in general, however, 
it became evident that this correlated well with cytokine therapy for a given tumor 
line. 
We, therefore, conclude that the basal expression levels of class-I and class-II 
antigens does not predict sensitivity of that particular line for these cytokines. In a 
clinical setting, Rubin et al. also found that there is no significant correlation 
between pretreatment HLA-DR expression status of a tumor and subsequent 
response to therapy. Irrespective of the basal expression level, however, our studies 
showed that the extent of augmentation of both HLA class-I and class-II antigens 
were indicative for the direct sensitivity of renal tumor xenografts towards alpha-
IFN, gamma-IFN and TNF. We here showed that in a model system in which no Τ 
cell mediated effector mechanisms are present, there is a good correlation between 
both HLA class-I and class-II antigen expression and the sensitivity of a particular 
tumor for the direct cytostatic effects of alpha-IFN, gamma-IFN and TNF. Because 
T-cell effector mechanisms cannot explain these results, modulation of the HLA 
class-I and class-II antigens here probably function as predictive markers for 
response as 'innocent bystander', indicating that mechanisms of a cytokine mediated 
induction of expression can be activated. Concomitantly with induction of the HLA 
class-I and -II antigens, other antigens not yet studied may be upregulated during 
therapy, augmenting and or inducing for instance monocyte/macrophage responses. 
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These findings indicate the potential usefulness of a short term in vitro test in which 
the modulation of the HLA antigens on (renal) tumor cells can be tested. This test 
eventually might predict sensitivity of the patients towards cytokine therapy and may 
be useful in selecting patients for clinical trials. 
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SUMMARY AND CONCLUSIONS 
Numerous clinical phase-I and -II trials using different cytokines and treatment 
protocols in the treatment of primary and metastatic RCC led to many questions 
regarding the optimal concentrations, combinations and treatment modalities to be 
used. This thesis describes experimental in vitro and in vivo cytokine therapies in 
which we tried to get some insight into the effects of alpha-IFN, gamma-IFN, TNF 
and their combinations against RCC. 
Chapter 1 gives a general description of the clinical background of the human renal 
tumors and an overview of the treatment modalities for the RCC tumors including 
the therapies with various cytokines. It also gives an overview of widely used in vitro 
and in vivo experimental models in cancer research, in which emphasis is laid on 
the experimental models used in the here described studies. 
In Chapter 2 we describe the evaluation of tumor biological changes during the 
establishment of human RCC xenografts. For our studies we established a number 
of xenografts in nude mice using fresh primary RCC tumor samples. Five of these 
tumors were characterized by various parameters, such as cytological and histological 
aspects, tumor doubling times and clonogenic potential. All characteristics were 
followed from primary tumor to the first 10 or 15 transplant passages. We found 
that, in general, there was a differentiation in some or almost all the tumor 
characteristics during the first four transplant passages. There was a change towards 
a more aggressive phenotype even though the histology remained essentially the 
same. These xenografts give a good representation of the primary renal tumors 
although we were probably dealing with the most aggressive form. 
In chapter 3, the in vitro sensitivities of seven xenografts towards the direct effects 
of alpha-IFN, gamma-IFN, TNF and their combinations are described. Single cell 
suspensions were treated with one dose of the cytokines and the antiproliferative 
effects of the treatments were followed by means of the clonogenic potential of the 
cells in a double layer soft agar clonogenic assay. These experiments learned us that 
the direct in vitro antiproliferative effects of the three cytokines were seemingly dose 
dependent. Widely different sensitivities between the different xenografts were found 
which was an indication of the heterogeneity in sensitivity between the xenografts. 
Sensitivity towards TNF, in general, was lowest of the three cytokines tested, but 
combinations of TNF with the IFN's were highly synergistic in their antiproliferative 
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efficacy. Although the single cytokines, even in the highest tested concentration 
sometimes showed no, or only minor antiproliferative effects, colony formation in 
four of the seven tumors could be inhibited completely with a combination of alpha-
or gamma-IFN + TNF. This showed that only the combinations of alpha- and/or 
gamma-IFN with TNF are effective in inhibiting the in vitro colony forming capacity 
of renal tumor cells. 
Treatment of the tumors in a nude mouse model system, however, resulted in 
antitumor effects which were not comparable to the in vitro situation. These results 
are described in chapter 4. Two main differences were found between the in vitro 
and in vivo antiproliferative effects of the cytokines. First, the in vivo antitumor 
effects of the IFN's were not dose dependent in three of eight tumors, which 
learned that at least these tumors had their own Optimum' IFN concentration. 
Second, and probably related to the first, the in vitro and in vivo sensitivities for the 
IFN's were not comparable to each other. This showed that in the in vivo model, 
factors not present in the in vitro model, were active, playing a role in the 
antitumor efficacy of the cytokines. Also in the in vivo model, antitumor effects of 
TNF were dose dependent. Tumor volume influenced efficacy of the treatment and 
only animals with very small tumors (about 2-5 mmJ) of the sensitive lines could be 
'cured' completely. Tumors of 50 mm3 showed only reduced growth inhibition and 
none of the tumors of 100 mm or more showed measurable effects on growth. 
These studies indicated that the doses at which optimal direct effects of the 
cytokines are measured are critically dependent on the tumor treated and its 
volume. Even though the direct effects are only a part of the mode of action of the 
cytokines, the results indicated that the dosages need individualization. Because the 
IFN's and TNF play important roles in the immunological cascade of effects in 
syngeneic immunocompetent systems, the nude mouse in unsuitable for studying the 
indirect immune response elicited upon treatment with cytokines. To study the 
antitumor effects of IFN and TNF in a syngeneic renal tumor model we used a rat 
renal tumor model in which the antitumor effects of rat gamma-IFN and human 
TNF were tested (chapter 6). In this model we could not find an optimum IFN 
dose, which means that within the dose range tested, the highest dose resulted in 
the most pronounced antitumor effect. We cannot exclude, however, that also in this 
syngeneic tumor model an optimum IFN dose exists, because we tested only one 
tumor line with two different gamma-IFN doses. As in the nude mouse, sensitivity 
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for TNF was low and only high doses proved to be effective. Also in this tumor 
model, the combination of IFN + TNF showed synergistic antitumor effects and 
tumor growth might be inhibited completely when treatment started at low tumor 
load, whereas treatment started at larger tumor volumes resulted in only reduced 
tumor growth, which is analogous to the findings in the immune incompetent nude 
mouse model. In the rat tumor model, however, we were able to inhibit growth of 
tumors of 2 cm0 or more with a combination of high doses of IFN + TNF, an effect 
which we could not establish in the non- syngeneic nude mouse model. 
The in vivo studies with both the non-syngeneic nude mouse model and the 
syngeneic rat renal tumor model indicated that treatment is most effective at low 
tumor load and that animals with small tumors may be 'cured' completely. The 
findings with the human renal tumor xenografts further indicated that treatment 
probably needs individualization. This means that markers with predictive value for 
the effect of the treatment on a particular tumor have to be found. 
Chapter 6 describes the relation between the HLA class-I and class-II antigen 
expression on renal tumor cells and the antitumor effect of different cytokine 
treatments on human renal tumor xenograft growth. We tested for the HLA class-I 
and -II expression as possible markers for response because in syngeneic tumor 
models these antigens play an important role in the immune response. Both class-I 
and class-II expression (if present) could be upregulated by both IFN's, and TNF 
upregulated class-I expression. Upregulation was dose dependent which means that 
highest upregulation did not always correlate with the most pronounced antitumor 
effect. HLA class-I upregulation was highest in all tumors treated with the high 
alpha-IFN/TNF combination. HLA class-II upregulation (if present) was highest 
upon treatment with the high gamma-IFNATiF combination. HLA class-I and class-
II expression on the untreated xenografts were not related to the sensitivity of the 
tumors for the direct effects of the cytokines. However, irrespective of the basal 
expression, the inducibility of both HLA class-I and class-II antigens appeared to be 
indicative for the direct sensitivity of the renal tumor xenografts towards alpha-IFN, 
gamma-IFN and TNF. This means that the extent of modulation of the HLA class-I 
and class-II antigens can serve as predictive marker for response to cytokine therapy 
which is an important finding. 
160 
These studies indicate that RCC is relative refractory towards cytokine therapy in 
the experimental tumor models. Animals with small tumors can be 'cured' 
completely by high concentrations of TNF combined with IFN. However, because 
especially TNF causes serious side effects, ways have to be found to reduce these 
effects, or to modify the treatment in such a way that only low doses will be 
needed. Numerous solutions may appear to be efficient, e.g. modifying the molecular 
structure, reducing the side effects but leaving the antitumor effects intact. Changing 
treatment modalities e.g. application schemes may eventual result in lower doses to 
be needed, which will make combination therapies with other cytokines possible. 
Interleukins which, as TNF, cause serious side effects when applied in higher doses, 
may be good candidates for such combination therapies. Another possibility is the 
treatment of the tumors with monoclonal antibodies directed against antigens on the 
tumor cells. Binding of antibodies may result in a so called antibody dependent 
cellular cytotoxicity (ADCC) and/or complement mediated cell lysis of the tumor 
cells'. As our own investigations indicated that antigens may be upregulated 
(Chapter 6), upregulation of tumor associated antigens by cytokines may occur as 
well, resulting in modulation of the binding of specific antibodies directed against 
such antigens. Especially when coupled to drug containing liposomes2 or to T-
cells^, these antibodies promise to be very active in the treatment of malignant 
diseases. 
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SAMENVATTING EN CONCLUSIES 
Talrijke klinische fase-I en -II trials met verschillende cytokines en 
behandelingsprotocollen bij de behandeling van primair en gemetastaseerd niercel 
carcinoom (NCC), resulteerden in vele vragen betreffende het gebruik van optimale 
concentraties, combinaties en behandelingsvormen. Dit proefschrift beschrijft 
experimentele in vitro en in vivo cytokine therapieën waarin getracht is meer inzicht 
te krijgen in de effecten van alpha-IFN, gamma-IFN, TNF en hun combinaties op 
het niercel-carcinoom. 
Hoofdstuk 1 geeft een algemene beschrijving van de klinische achtergrond van de 
humane niertumoren en een overzicht van de behandelingsvormen voor de niercel-
tumoren, inclusief de therapieën met verschillende cytokines. Het geeft tevens een 
overzicht van vaak toegepaste in vitro en in vivo experimentele modellen in het 
kankeronderzoek, waarbij de nadruk is gelegd op de experimentele modellen in de 
hier beschreven studies. 
In hoofdstuk 2 beschrijven we de evaluatie van tumor-biologische veranderingen 
tijdens de vestiging van humane NCC xenografts. Voor onze studies vestigden wij 
een aantal xenografts in de naakte muis, waarvoor vers primair NCC tumorweefsel 
werd gebruikt. Vijf van de tumoren werden gekarakteriseerd aan de hand van 
verschillende parameters zoals cytologische en histologische aspecten, tumor-
verdubbelingstijden en donogene activiteit. Alle kenmerken werden gevolgd vanaf de 
primaire tumor tot de eerste 10 tot 15 passages. We vonden dat er in het algemeen 
een differentiatie in sommige of in nagenoeg alle tumorkenmerken optrad 
gedurende de eerste vier passages. Er was een verandering naar een meer agressief 
phenotype alhoewel de histologie in hoofdzaak gelijk bleef. Deze xenografts geven 
een goede representatie van de primaire niertumoren, ofschoon we waarschijnlijk te 
maken hebben met de meest agressieve vorm. 
In hoofdstuk 3 wordt de in vitro gevoeligheid van zeven xenografts voor de directe 
effecten van alpha-IFN, gamma-IFN, TNF en hun combinaties beschreven. 
Celsuspensies werden behandeld met een eenmalige dosis van de cytokines en de 
antiproliferatieve effecten van de behandelingen werden gevolgd door middel van de 
donogene potentie van de cellen in een dubbellaags soft agar donogene assay. Deze 
experimenten leerden ons dat het directe in vitro antiproliferatieve effect van de 
drie cytokines naar alle waarschijnlijkheid dosis-afhankelijk is. Zeer uiteenlopende 
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gevoeligheden werden gevonden tussen de verschillende lijnen, hetgeen een indicatie 
was voor de heterogeniteit in gevoeligheid tussen de xenografts. De reactie op TNF 
was in het algemeen het laagst van de drie geteste cytokines, maar combinaties van 
TNF met de Interferonen vertoonden sterk synergisme in hun antiproliferatieve 
effectiviteit. Alhoewel de cytokines ieder op zich, zelfs in de hoogst geteste 
concentraties soms geen of slechts geringe antiproliferatieve effecten vertoonden, 
kon de kolonievorming in vier van de zeven tumoren volledig worden tegengegaan 
met een combinatie van alpha- of gamma-IFN + TNF. Dit liet zien dat slechts de 
combinaties van alpha- en/of gamma-IFN met TNF effectief zijn in het inhiberen 
van de in vitro kolonievormende capaciteit van niertumorcellen. 
Behandeling van de tumoren in een naakte muis model resulteerde in antitumor-
effecten welke niet vergelijkbaar waren met de in vitro situatie. De resultaten 
worden beschreven in hoofdstuk 4. Twee belangrijke verschillen tussen de in vitro 
en in vivo antiproliferatieve effecten van de cytokines werden gevonden. Ten eerste: 
de in vivo antitumor-effecten van de Interferonen waren niet dosis-afhankelijk in 
drie van de acht tumoren, hetgeen leerde dat tenminste déze tumoren hun eigen 
"optimum" IFN-concentratie bezaten. Ten tweede, en waarschijnlijk gerelateerd aan 
het eerste: de in vitro en in vivo gevoeligheden voor de Interferonen waren niet met 
elkaar vergelijkbaar. Dit toonde aan dat bepaalde factoren die een rol spelen in de 
antitumor-effectiviteit van de cytokines wel in het in vivo model maar niet in het in 
vitro model aanwezig waren. Ook in het in vivo model waren de antitumor-effecten 
van TNF dosis-afhankelijk. Het tumorvolume beïnvloedde de efficiëntie van de 
behandeling en alleen de dieren met zeer kleine tumoren (ongeveer 2-5 mm/) van 
de gevoelige lijnen konden volledig "genezen" worden. Tumoren van 50 mm.3 
vertoonden slechts gereduceerde groei inhibitie en geen van de tumoren van 100 
mm.
3
 of meer toonde meetbare effecten op de groei. Deze studies gaven aan dat de 
doses waarbij optimale directe effecten van de cytokines gemeten worden, kritisch 
afhankelijk zijn van de behandelde tumor en het volume daarvan. Zelfs al zijn de 
gemeten directe effecten slechts een gedeelte van het werkingsmechanisme van de 
cytokines, de resultaten maakten niettemin duidelijk dat doses moeten worden 
geïndividualiseerd. 
Omdat de Interferonen en TNF belangrijke rollen spelen in de immunologische 
cascade van effecten in syngene immunocompetente systemen is de naakte muis 
ongeschikt voor het bestuderen van de indirecte immuun-respons welke ontstaat 
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door behandeling met cytokines. Om de antitumor-effecten van IFN en TNF in een 
syngeen niertumormodel te kunnen bestuderen is gebruik gemaakt van een ratten 
niertumor model waarin de antitumor-effecten van ratte gamma-IFN en humaan 
TNF werden getest (hoofdstuk 6). In dit model kon geen optimum IFN-dosis 
worden gevonden, hetgeen betekent dat binnen de geteste dosis range, de hoogste 
dosis resulteerde in het duidelijkste antitumor-effect. We kunnen echter niet 
uitsluiten dat er ook in dit syngeen tumormodel een optimum IFN-dosis bestaat 
aangezien er slechts één tumorlijn met twee verschillende gamma-IFN doses is 
getest. Zoals in de naakte muis was de gevoeligheid voor TNF laag en slechts de 
hoge doses bleken effectief. Eveneens in dit tumormodel vertoonde de combinatie 
van IFN + TNF synergistische antitumor-effecten. De groei van de tumor kon 
volledig worden tegengegaan wanneer de behandeling werd gestart bij een klein 
volume, terwijl een behandeling die werd gestart bij grotere volumes slechts in een 
gereduceerde groei resulteerde, hetgeen analoog is aan de bevindingen in het 
immuun incompetente naakte muis model. In het ratte tumor model kon de groei 
van tumoren van 2 cm. of meer echter worden tegengaan met een combinatie van 
een hoge dosis IFN + TNF, een effect dat in het niet-syngene naakte muis model 
niet kon worden bewerkstelligd. 
De in vivo studies met zowel het niet-syngene naakte muis model als het syngene 
ratte niertumor model gaven aan dat behandeling het meest effectief is bij een klein 
tumorvolume en dat dieren met kleine tumoren geheel "genezen" kunnen worden. 
De bevindingen met de humane niertumor xenografts gaven verder aan dat 
behandeling waarschijnlijk dient te worden geïndividualiseerd. Dit betekent dat 
markers met predictieve waarde voor het effect van de behandeling op een 
bepaalde tumor moeten worden gevonden. 
Hoofdstuk 6 beschrijft de relatie tussen de HLA klasse-I en klasse-II antigen 
expressie op niertumorcellen en het antitumor-effect van verschillende cytokine 
behandelingen op de groei van humane niertumor-xenografts. Wij testten de HLA 
klasse-I en -II expressie als mogelijke markers voor respons aangezien deze 
antigenen in syngene tumormodellen een belangrijke rol spelen in de immuun 
respons. Zowel de klasse-I als de klasse-II (indien aanwezig) expressie kon worden 
versterkt door beide Interferonen. TNF versterkte de klasse-I expressie. De 
opregulatie bleek dosis-afhankelijk, hetgeen betekent dat de hoogste opregulatie niet 
altijd correleerde met het sterkste antitumor-effect. De HLA klasse-I opregulatie 
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was het sterkst in alle tumoren, die behandeld waren met de hoog alpha-IFN/TNF 
combinatie. HLA klasse-II opregulatie (indien aanwezig) was het sterkst na 
behandeling met de hoog gamma-IFN/TNF combinatie. HLA klasse-I en klasse-II 
expressie op de onbehandelde xenografts bleek niet gerelateerd aan de gevoeligheid 
van de tumoren voor de directe effecten van de cytokines. Echter, de 
induceerbaarheid van zowel de HLA klasse-I en de klasse-II antigenen was, 
onafhankelijk van het basale expressie niveau, indicatief voor de directe gevoeligheid 
van de niertumor xenografts voor alpha-IFN, gamma-IFN en TNF. Dit betekent dat 
de mate van modulatie van de HLA klasse-I en klasse-II antigenen kan fungeren als 
predictieve marker voor respons op cytokine therapie, hetgeen een belangrijke 
vinding is. 
Deze studies geven aan dat NCC in de experimentele tumonnodellen relatief 
ongevoelig is voor cytokine therapie. Dieren met kleine tumoren kunnen volledig 
"genezen" worden door hoge concentraties TNF gecombineerd met IFN. Er moeten, 
aangezien met name het TNF ernstige bijwerkingen veroorzaakt, wegen gevonden 
worden om deze effecten te reduceren, of de behandeling zodanig te wijzigen dat 
slechts lage doses nodig zullen zijn. Vele oplossingen kunnen effectief blijken te zijn, 
bijvoorbeeld het veranderen van de moleculaire structuur waardoor de bijwerkingen 
kunnen worden verminderd zonder verlies van de antitumor effecten. Het wijzigen 
van de behandelingsvormen, bv. de toedienings-schema's, kan mogelijk resulteren in 
lagere benodigde doses, hetgeen combinatie-therapieën met andere cytokines 
mogelijk zal maken. Interleukines, welke evenals TNF ernstige bijwerkingen 
vertonen wanneer in hogere doses toegediend, kunnen goede candidaten blijken te 
zijn voor combinatie-therapieën. Een andere mogelijkheid is de behandeling van 
tumoren met monoklonale antilichamen gericht tegen antigenen op de tumorcellen. 
Binding van antilichamen kan resulteren in zogenaamde antilichaam afhankelijke 
cellulaire cytotoxiciteits en/of complement gemedieerde cel-lysis van tumorcellen^. 
Aangezien de eigen onderzoekingen aangaven dat antigenen opgereguleerd kunnen 
worden (Hoofdstuk 6), kan opregulatie van tumor-geassocieerde antigenen door 
cytokines, resulterend in modulatie van de binding van specifieke antilichamen 
gericht tegen zulke antigenen, mogelijk eveneens optreden. Speciaal wanneer 
gekoppeld aan medicament bevattende liposomen2 of aan T-cellen^, beloven deze 
antilichamen zeer actief te zijn in de behandeling van maligne ziekten. 
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STELLINGEN 
behorende bij het proefschrift 
EXPERIMENTAL CYTOKINE THERAPY 
IN 
RENAL CELL CARCINOMA 
A.J.M.C. Beniers 
Nijmegen, 14 mei 1991 
1. De dubbellaags soft-agar donogene assay kan niet zinvol worden aangewend 
als in vitro model ter vervanging van de naakte muis bij het bepalen van de 
gevoeligheid van humane niertumor-xenografts voor Interferon (IFN) en 
Tumor Necrosis Factor (TNF). 
2. De heterogeniteit in de respons van humane niertumor-xenografts op 
behandeling met alpha-IFN, gamma-IFN en/of TNF is kenmerkend voor het 
individuele karakter van deze tumoren. 
3. Succesvolle transplantatie van niercarcinomen in de vorm van een xenograft 
vraagt niet alleen aanpassingsvermogen van de tumor, doch evenzeer van de 
gastheer. 
(proefschrift: H.F.M. Karthaus, Nijmegen, 1987). 
4. De bel-vormige dosis-respons curves voor het effect van alpha- of gamma-
IFN op de groei van niertumor-xenografts in het naakte muis model zijn 
een indicatie voor de noodzaak tot het vinden van predictieve markers voor 
respons. 
5. Het antiproliferatieve effect van TNF op de subcutane groei van niertumor-
xenografts in de naakte muis voldoet, binnen de tolerantie grenzen, aan de 
verwachting van vele clinische trials; hoe meer, hoe beter. 
6. De basale HLA klasse-I en -II antigen expressie van humane niertumor-
xenografts in de naakte muis is niet gerelateerd aan het effect van alpha- of 
gamma-IFN/TNF combinaties op de subcutane groei van deze tumoren. 
De mate van modulatie van de HLA klasse-I èn -II antigen expressie op 
humane niertumor-xenografts in de naakte muis t.g.v. behandeling met 
alpha- of gamma-IFWTNF combinaties, is gerelateerd aan de gevoeligheid 
van de tumoren voor behandeling met deze cytokines. 
Het meten van de in-vitro modulatie van HLA klasse-I èn -II antigen 
expressie op niertumorcellen t.g.v. behandeling met alpha- of gamma-
IFN/TNF combinaties, kan mogelijk voorspellende waarde hebben voor de 
klinische respons van de tumor. 
Waar de wiskunde tekort schiet in het verklaren van natuurverschijnselen 
kan een filosofische benadering tot nieuwe inzichten leiden. 
Het is interessant te onderzoeken of zowel het gedrag en eigenschappen der 
deeltjes en natuurconstanten, afhankelijk van de plaats in het heelal, 
afwijkingen vertonen, aangezien dit tot nieuwe inzichten en theorieën kan 
leiden. 
Naast de associatie van de vorm van een cello met het menselijk lichaam, 
kunnen de f-gaten van dit instrument worden geassocieerd met de nieren, 
één kan men missen, twee echter niet. 



